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1. Summary 
 
Mast cells are key effector cells in allergic disease triggering inflammation through mediator release. 
Allergens activate mast cells through the high-affinity receptor for IgE (FcεRI), which initiates 
signalling pathways that regulate the release of inflammatory mediators from secretory granules and 
the production of lipid mediators and cytokines. Receptor aggregation is coupled to the activation 
of protein tyrosine kinases (PTK) that coordinate Ca2+ mobilisation and protein kinase C (PKC) 
activation. Also essential is the activation of phosphoinositide 3-kinase (PI3K), as mast cell 
degranulation is blocked by pan PI3K inhibition in cells or genetic inactivation of class IB PI3Kγ in 
mice. Analysis of bone marrow-derived mast cells (BMMCs) showed that PI3Kγ regulates mast cell 
hyperactivaton by boosting PIP3 production via autocrine-paracrine adenosine/G protein-coupled 
receptor (GPCR) signalling.  
Here we demonstrate a direct pathway from the FcεRI to PI3Kγ. Degranulation triggered by 
IgE/antigen or stimulators of Ca2+ mobilisation such as Thapsigargin is blocked in PI3Kγ–/– 
BMMCs. FcεRI- and Thapsigargin-induced PI3Kγ activation depends on a high threshold 
concentration of intracellular Ca2+ and subsequent PKCβ activation. Thapsigargin to PI3Kγ 
signalling occurs completely in an adenosine- and GPCR-independent manner. Active PKCβ 
interacts with and phosphorylates PI3Kγ in vitro and in vivo on Ser582. This residue sits at the 
beginning of the helical domain, a region that has attracted attention in PI3Kα as mutation hot-spot 
in cancer. Analyses of phosphorylation-mimicking mutants indicate that Ser582 functions as switch-
site for PI3Kγ activation. Furthermore, we show that PKCβ-regulated PI3Kγ operates free of the 
adaptor protein p84. By biochemical and structural approaches we mapped the p84 binding 
interphase on PI3Kγ to the region around S582 and demonstrate that PI3Kγ-bound p84 blocks 
S582 phosphorylation. 
This study is the first to unravel a pathway and mechanism by which a protein tyrosine kinase 
(PTK)-coupled receptor engages PI3Kγ. Contemporaneously we defined the role of PKC in mast 
cell degranulation. The results of this work change our view on PI3-kinase regulation, opening 
fascinating new insights into mechanisms of isoform-specific PI3K activation.  
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2. Introduction 
 
2.1 Phosphoinositide 3-kinases (PI3Ks) 
Phosphoinositide 3-kinases are lipid kinases that phosphorylate the inositol head group of 
phosphoinositides (PIs) (Vanhaesebroeck B, Annu Rev Biochem, 2001). The inositol ring of PIs is 
linked via a phosphate group to a diacylglycerol tail that anchors the lipid to membranes. PI3Ks 
catalyse the transfere of the γ-phosphate of adenosine 5’-triphosphate (ATP) to the hydroxyl group 
at the 3’ position of the inositol moiety. PIs include phosphatidylinositol (PtdIns) and its 
phosphorylated derivatives, of which PI3Ks phosphorylate PtdIns, PtdIns(4)P, and PtdIns(4,5)P2. 
Class I isoenzymes for example modulate intracellular signalling through the generation of 
PtdIns(3,4,5)P3 from PtdIns(4,5)P2 (Fig. a). 
 
 
 
Fig. a: PI3Ks phosphorylate the 3’-OH-group of phosphoinositides 
 
The 3-phosphorylated PIs function as docking sites for proteins containing a phosphoinositide 
binding domain leading to their recruitment to a specific membrane compartment. Examples of PI-
binding domains are the pleckstrin homology (PH) domain which preferentially binds PI(3,4,5)P3 or 
the FYVE and Phox homology (PX) domains which prefer PI(3)P.  
The PI3K family has been subdivided into three classes (Fig. b) – class I, II, and III – based on 
sequence homology, protein domain organisation, substrate specificity, and mode of regulation. 
Class I PI3Ks signal downstream of cell surface receptors to control fundamental cellular functions 
like survival, growth, and proliferation, but also regulate more cell specific tasks such as insulin 
signalling, immune cell activation, and motility. The class II enzymes have been discovered based 
on sequence homology to class I and III PI3Ks (MacDougall LK, Curr Biol, 1995; Molz L, J Biol 
Chem, 1996), but their function and substrate specificity in vivo are poorly defined. Experimental 
data for example implicate roles in clathrin-mediated endocytosis and insulin signalling (Gaidarov I, 
Mol Cell, 2001; Falasca M and Maffucci T, Biochem Soc Trans, 2007). The only class III member 
vacuolar sorting protein 34 (Vsp34) is the prototype PI3K and the only member found in all 
eukaryots. Vsp34 is involved in endosomal vesicle trafficking, protein synthesis, and autophagy 
(Backer JM, Biochem J, 2008).  
All members of the PI3K family contain a conserved central core composed of a C2, a helical, and a 
lipid kinase domain. The lipid kinase domain shows homology to protein kinase domains, having a 
P- (phosphate binding loop), catalytic, and activation loop. Basic residues in the activation loop 
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influence substrate specificity and their exchange in PI3Kα by the corresponding segments in class 
II or III enzymes switches inositol lipid specificity in vitro (Pirola L, J Biol Chem, 2001). Class I 
PI3Ks use PIP2 as substrate in vivo, but also phosphorylate PtdIns(4)P and PI in vitro. They are the 
only enzymes that generate PI(3,4,5)P3. Class II PI3Ks phosphorylate PI and PI(4)P in vitro, but the 
preferred in vivo substrate is unclear, while class III PI3K Vsp34 exclusively phosphorylates PI. In 
contrast to protein kinases, PI3Ks are not regulated by activation loop phosphorylation. In addition 
to lipid kinase activity, the PI3K catalytic subunit also possesses an intrinsic protein kinase activity. 
Whether this is of any physiological significance is not known. The C2 domain is supposed to be 
involved in phospholipid membrane binding (Walker EH, Nature, 1999), while the function of the 
helical domain is unknown. Class I and III PI3Ks associate with a regulatory subunit (Fig. b), but 
not class II enzymes, which instead contain N- and C-terminal extensions. Vsp34 activity depends 
on its regulatory subunit, which is the Ser/Thr kinase p150. 
 
 
 
 
 
Fig. b: Domain organisation of PI3K catalytic and regulatory proteins. p85B: adaptor binding 
domain (ABD); RasB: Ras binding domain (RBD); C2: C2 domain; PI3Ka: helical domain; PI3Kc: 
catalytic domain; SH3: Src homology 3 domain; P: proline-rich region; BH: Bcr homology domain; 
SH2: Src homology 2 domain; iSH2: inter-SH2 domain (adapted from (Marone R, Biochim Biophys 
Acta, 2008)). 
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2.2 Class I PI3Ks 
Class I PI3-kinases have been subdivided into the subclasses IA and IB and contain four members. 
PI3Kα, PI3Kβ, and PI3Kδ belong to the class IA group, while PI3Kγ is the only class IB family 
member. Class I PI3Ks contain, additional to the C2, helical, and kinase domain, an N-terminal 
domain (ABD) followed by a Ras-binding domain (RBD). The N-terminal domain of class IA 
PI3Ks functions as adaptor binding domain (ABD) and tightly interacts with a p85 regulatory 
subunit family member. In contrast to all other domains, the ABD of class IA PI3Ks shows no 
similarity the corresponding region in class IB PI3Kγ. Consistantly PI3Kγ does not bind to p85s. 
The RBDs of PI3Kα and PI3Kγ bind to Ras in vitro and fold into a similar structure as the 
unrelated RBDs of Raf and RalGDS (Rodriguez-Viciana P, Nature, 1994; Rubio I, Biochem J, 1997; 
Pacold ME, Cell, 2000; Huang CH, Science, 2007). While studies of engineered PI3K RBD mutants 
demonstrate physiological importance of this domain, its precise mechanism of action in vivo is 
obscure (Suire S, Nat Cell Biol, 2006; Kang S, Proc Natl Acad Sci U S A, 2006; Kurig B, Proc Natl 
Acad Sci U S A, 2009; Gupta S, Cell, 2007).  
 
2.2.1 Class IA PI3Ks 
Class IA PI3Ks exist in cells in tight complex with a p85/p55 regulatory protein. These are encoded 
by three genes, Pik3r1, Pik3r2, and Pik3r3, giving rise to p85α, p55α, and p50α, p85β, and p55γ, 
respectively. All class IA PI3Ks can bind to any of the p85-related subunits. Knowledge about 
adaptor preferences and isoform-specificities is scarce. They are required for the stability of the 
catalytic subunits, regulate membrane localization, PI3K activation, and restrict catalytic activity in 
quiescent cells. All p85-related subunits contain two Src homology 2 (SH2) domains separated by 
an intervening coiled-coil domain (iSH2). Full-length p85 additionally possess an N-terminal Src 
homology 3 (SH3) domain followed by a BCR (breakpoint cluster region) domain (BH domain) 
that is flanked by two proline-rich regions (Kapeller R, J Biol Chem, 1994). The iSH2 domain binds 
tightly to the ABD of the catalytic PI3K subunit (Holt KH, Mol Cell Biol, 1994). The SH2 domains 
bind phosphorylated tyrosine residues (pY) in the tails of activated receptor tyrosine kinases, 
protein tyrosine kinases, or adaptor proteins (Klippel A, Mol Cell Biol, 1992). The phosphorylated 
tyrosine has to be part of an immunoreceptor tyrosine-based activation motif (ITAM) of the 
sequence pYXXM (X any amino acid), but there exist exceptions (HGFR, pYVSV) (Songyang Z, 
Cell, 1993; Ponzetto C, Mol Cell Biol, 1993). Binding to phosphotyrosine motifs releases inhibitory 
contacts between p85 and PI3K leading to increased lipid turnover in vitro (Carpenter CL, J Biol 
Chem, 1993; Miled N, Science, 2007). The precise roles of the p85 SH3 or BH domain are unclear. 
The SH3 domain mediates binding to proline-rich sequences and has been shown to associate with 
the adaptor proteins Shc or Cbl (Harrison-Findik D, Oncogene, 1995; Soltoff SP and Cantley LC, J 
Biol Chem, 1996; Dombrosky-Ferlan PM and Corey SJ, Oncogene, 1997; Hunter S, Mol 
Endocrinol, 1997). These interactions might regulate membrane localisation and/or activation. The 
BH domain is highly homologous to the GTPase activation protein (GAP) domain of the 
breakpoint cluster region (Bcr) protein, but does not have GTPase activity. It has been proposed to 
interact with the Rho family proteins Cdc42 and Rac (Zheng Y, J Biol Chem, 1994; Tolias KF, J 
Biol Chem, 1995). Analysis of p85 truncations showed that p85 contains a GTPase-responsive and 
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inhibitory region (Chan TO, Cancer Cell, 2002). The GTPase-responsive domain is located within 
the iSH2 domain and stimulates protein kinase B (PKB) activation by active H-Ras or Rac1, which 
however depends on prior release of PI3K inhibition by the p85 C-terminus (LED(52 amino acids)-
cSH2, LED lays over the regulatory square). Interestingly, the PI3K activating influenza virus non-
structural protein (NS)1 interacts with p85β at a similar region in the iSH2, including the LED and 
precedent sequences (Hale BG, Proc Natl Acad Sci U S A, 2010). 
 
2.2.2 Class IB PI3K 
The class IB member PI3Kγ can associate with a p101 (Pik3r5) or p84 (Pik3r6) adaptor protein 
(Sugimoto Y, Proc Natl Acad Sci U S A, 1984; Suire S, Curr Biol, 2005). Their genes are located 
next to each other on the same chromosome. p101 and p84 share 30% amino acid sequence 
identity and 37% sequence similarity. Both adaptors have no sequence similarity with any known 
protein or protein domain, and are completely different from the p85 adaptors of class IA PI3Ks. 
Sequence homologies of p101 and p84 are highest in the N- and C-terminal regions, which are also 
most highly conserved. The middle parts of the two protein sequences vary greatly and may regulate 
isoform-specific protein interactions and functions. Whereas p101 contains a nuclear localisation 
signal (NLS) and is localised to nucleus in the absence of PI3Kγ, p84 lacks such a sequence (Brock 
C, J Cell Biol, 2003; Voigt P, J Biol Chem, 2006). Adaptor protein coexpression is not required for 
PI3Kγ stability, but enhances PI3Kγ expression levels (Voigt P, J Biol Chem, 2006). On the other 
hand, p101 is instable in the absence of PI3Kγ, while p84 can be expressed alone.  
 
Discovery of PI3Kγ and p101 
PI3Kγ has been discovered by attempts to find the enzyme that catalyzes the fast and large 
accumulation of PtdIns(3,4,5)P3 in response to stimulation of neutrophils and myeloid-derived cells 
(U937) with chemotactic ligands (Stephens L, J Biol Chem, 1993; Stephens L, Cell, 1994; Sugimoto 
Y, Proc Natl Acad Sci U S A, 1984). These stimuli signal through a subfamily of G protein-coupled 
receptors (GPCRs) whose activation and chemotactic effects are blocked by B. Pertussis Toxin 
(PTx). As PTx also blocked PIP3 production indicated to the existence of a G-protein regulated 
PI3K activity. In support of this, Gβγ-dimers but not heterotrimeric Gα·GDP-Gβγ, presented on 
artifical lipid vesicles, stimulated PIP3 production in neutrophil lysates. In contrast to other known 
G-protein regulated enzymes like phospholipase C (PLC)β, this PI3K activity could only be 
activated by Gβγ dimers, but not by active GTP-loaded Gα subunits. Moreover, this PI3K activity 
had to be distinct from the previously identified protein tyrosine kinase (PTK)-sensitive PI3K 
isoforms, since activity was neither sensitive to phospho-Tyr peptides nor affected by depletion of 
p85 subunits from neutrophil cytosol. Purification of this PI3K activity from myeloid-derived cells 
or platelet cytosol yielded a protein complex of 210-220 kDa (Stephens LR, Cell, 1997; Tang X and 
Downes CP, J Biol Chem, 1997), that was composed of two subunits of ~110 and 101 kDa. This 
protein fraction was chromatographically and immunologically distinct from known PI3-kinases 
and was potently activated by Gβγ dimers in vitro. The coding DNA sequences were obtained by 
PCR-based approaches with degenerate oligonucleotide primers that have either been derived from 
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conserved regions of PI3Kα or have been deduced from peptide sequences of purified PI3K. The 
protein was called PI3Kγ (recommended by UniProt) or p110γ (alternative name). The coding 
sequence of the 101 kDa adaptor subunit was cloned by the peptide sequencing approach. 
 
Regulation of PI3Kγ by Gβγ subunits and p101 
Both recombinant PI3Kγ and PI3Kγ/p101 phosphorylate PI(4,5)P2, PI(4)P, and PI on the 3’ 
position of the inositol ring in vitro and are inhibited by Wortmannin (Stoyanov B, Science, 1995; 
Tang X and Downes CP, J Biol Chem, 1997). However, free and adaptor-associated PI3Kγ show 
differential preferences for phosphoinositides as well as differential sensitivities towards Gβγs in 
vitro. In association with p101, PI3Kγ prefers PIP2 over PI as substrate and is more sensitive to 
stimulation by Gβγ subunits. While PI3Kγ alone is not, 2-4-, or 20-40-fold activated by 
recombinant Gβγ subunits in the presence of PIP2 as substrate (Sugimoto Y, Proc Natl Acad Sci U 
S A, 1984; Krugmann S, J Biol Chem, 1999; Tang X and Downes CP, J Biol Chem, 1997; Maier U, 
J Biol Chem, 1999), enzymatic activity is increased 6-7-, 20-40-, or 60-fold by using PI as substrate 
(Krugmann S, J Biol Chem, 1999; Maier U, J Biol Chem, 1999; Leopoldt D, J Biol Chem, 1998). 
Differences between these studies likely depend on experimental conditions such as the presence of 
detergents, kind and location of the protein tag, use of human or porcine PI3Kγ, etc. PI3Kγ 
complexed to p101 is more sensitive to activation by Gβγ subunits in presence of PIP2 as substrate 
as PI3Kγ alone (20-150-fold activation), but only poorly likes PI (3-25-fold stimulation) (Maier U, J 
Biol Chem, 1999; Krugmann S, J Biol Chem, 1999; Stephens LR, Cell, 1997). Gβγs do not affect 
the affinity (Km) of PI3Kγ/p101 for ATP, but increase maximal PIP2 turnover (Vmax) (Tang X and 
Downes CP, J Biol Chem, 1997). In consistence with increased Gβγ-sensitivity in the presence of 
p101, this adaptor has a much higher affinity for Gβγ subunits than PI3Kγ, as it binds 5 times more 
Gβγs per mole input protein in binding assays (Stephens LR, Cell, 1997). This better binding 
efficiency is even more evident following coexpression of Gβγ with p101 or PI3Kγ in HEK293 
cells, as Gβγs only promote efficient translocation of GFP-tagged p101 but not PI3Kγ to the 
plasma membrane (Brock C, J Cell Biol, 2003). Gβγ dimers having a geranylgeranylated Gγ subunit 
(Gγ2, 10, 12, 13) activate PI3Kγ/p101 much more efficiently (26-fold) than those having a farnesyl 
isoprenoid moiety (0, 5-6-fold) (Gγ1, 11, Gγt (transducin)) (Kerchner KR, J Biol Chem, 2004; Maier U, J 
Biol Chem, 2000; Stoyanov B, Science, 1995). Farnesylated Gβγs associate equally well with 
PI3Kγ/p101, but are not able to stimulate enzymatic activity, maybe being compromised in 
inducing the required conformational changes. Switching of the CAAX-box of Gγ2 to get a 
farnesylated instead of geranylgeranylated subunit does not affect maximal PI3Kγ/p101 activation, 
however slightly decreases efficiency (higher EC50). On the other hand exchange of the farnesyl 
with a geranylgeranyl isoprenoid moiety of Gγ1 or Gγ11 creates gain of function mutants that fully 
activate PI3Kγ/p101, but again with reduced efficiency. Gβγ subunits not only function, through 
p101, as PI3Kγ membrane translocators, but also allosterically stimulate lipid kinase activity of 
membrane-targeted PI3Kγ (Brock C, J Cell Biol, 2003). The relative importance of these two 
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mechanisms on endogenous PI3Kγ activation has not yet been investigated. Many Gβγ effectors 
such as phospholipase Cβ (PLCβ) are membrane-associated proteins and therefore modulated by 
allosteric activation. A third activating input into PI3Kγ may further derive from receptor 
interaction. In contrast to other heterotrimeric G protein regulated proteins, neither free nor 
dimeric PI3Kγ is substantially (max 1.5x) activated by active Gα subunits from different subfamilies 
like Gαi1-3, Gαs, Gαo, and Gαq (Ramkumar V, J Biol Chem, 1993; Sugimoto Y, Proc Natl Acad Sci 
U S A, 1984; Tang X and Downes CP, J Biol Chem, 1997; Kerchner KR, J Biol Chem, 2004).  
Characterisation of p101 truncation mutants indicates that the N-terminal region of p101 mediates 
PI3Kγ binding, while the C-terminus interacts with Gβγ subunits of heterotrimeric G-proteins 
(Voigt P, J Biol Chem, 2005). As the N- and C-terminus are highly conserved in p101, they may 
constitute new protein-binding domains. However, as the structure of p101 is completely unknown, 
it can not be excluded that truncations disturb proper protein folding influencing protein 
interactions indirectly. PI3Kγ is a globular protein with extensive interdomain interactions (Walker 
EH, Nature, 1999). Here already small deletions interfere with the functional integrity the enzyme. 
Increasing N-terminal truncations decrease basal activity of PI3Kγ and removal of more than the 
first 169 amino acids shuts off catalytic activity (Krugmann S, J Biol Chem, 1999). PI3Kγ is 
therefore not suitable for interaction site mapping by generation of deletion mutants. Since 
controversial results have been obtained by this method, the interaction site of p101 on PI3Kγ is 
undefined (Krugmann S, J Biol Chem, 1999; Maier U, J Biol Chem, 1999). 
Most studies analysed p101 functions biochemically in vitro or with heterologous expression 
systems. The physiological importance of p101 could be demonstrated following generation of 
p101 knock-out mice (Suire S, Nat Cell Biol, 2006). p101 is required for neutrophil migration 
towards the GPCR-ligands C5a and fMLP. Moreover, neutrophil recruitment in vivo to the 
inflamed peritoneum also depends on p101 in a model of thioglycollate-triggered aseptic peritonitis.  
 
Regulation of PI3Kγ by Gβγ subunits and p84 
Mast cells were found to lack p101 expression, which prompted search for an alternative but 
homologous adaptor (Calvez R, Diss, 2004, University of Fribourg, Switzerland). p84 was 
discovered and comparative analysis showed that this adaptor shares several characteristics with 
p101. Both adaptors associate with PI3Kγ in coimmunoprecipitation assays following coexpression, 
and are required for fMLP- or Gβγ-induced PIP3 production in heterologous expression systems 
(HEK293) (Brock C, J Cell Biol, 2003; Voigt P, J Biol Chem, 2006). However, whereas p101 
potentiates PI3Kγ activation by Gβγ subunits in vitro and is translocated by them to the plasma 
membrane in cells (Stephens LR, Cell, 1997; Brock C, J Cell Biol, 2003), p84 does not share these 
characteristics (Kurig B, Proc Natl Acad Sci U S A, 2009). In the presence of p84 instead, Gβγ-
dependent PI3Kγ activation is sensitive to inhibition of basal Ras activation (Kurig B, Proc Natl 
Acad Sci U S A, 2009) as well as cholesterol depletion (Bohnacker T, Sci Signal, 2009). Interestingly, 
cholesterol removal also blocks lysophosphatidic acid (LPA, GPCR ligand) induced PI3K activation 
in Vero cells, where it regulates PI3K/p85 compartmentalisation (Peres C, FEBS Lett, 2003). 
Mechanistic basics of p84 action are incompletely understood and require further investigations. 
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2.3 Transmembrane signal transduction by protein tyrosine kinase- and G 
protein-coupled receptors 
PI3K class I family members couple to cell surface receptors and therefore regulate the conversion 
of external information into a cellular response. Class IA PI3Ks are canonically activated 
downstream of protein tyrosine kinase (PTK)-coupled receptors, while class IB member PI3Kγ is 
regulated by G protein-coupled receptors (GPCRs) (Fig. c). 
 
 
 
Fig. c: Activation of class I PI3Ks by cell surface receptors 
 
2.3.1 Protein tyrosine kinase (PTK)-coupled receptors 
Protein tyrosine kinase (PTK)-coupled receptors are either regulated by an intrinsic protein kinase 
activity contained in the cytoplasmic receptor tail or by association with an intracellular tyrosine 
kinase. While most PTK-coupled receptors are monomers, the insulin and insulin-like growth 
factor receptors are heterotetramers, being composed of two disulfide-linked membrane-spanning 
β-subunits and two extracellular α-subunits. Ligand binding generally triggers receptor dimerisation 
leading to kinase-mediated transphosphorylation of receptor tails or associated adaptor proteins. 
Phosphorylation sites lay in so-called immunoreceptor tyrosine-based activation motifs (ITAMs), 
which provide docking sites for the activation of downstream signalling proteins. The regulatory 
subunits of class IA PI3Ks, the “p85”s, specifically bind to phosphorylated YXXM motifs via their 
SH2 domains (Songyang Z, Cell, 1993). This brings the catalytic subunit in close proximity to the 
plasma membrane and its lipid substrate. Other domains of the regulatory and catalytic subunits 
govern further control of PI3K activation. Exact mechanisms regulating lipid kinase activation in 
vivo are poorly characterised. Examples of receptors that couple to class IA PI3Ks are the platelet-
derived growth factor receptor (PDGF), the endothelial growth factor receptor (EGF), and the 
insulin receptor (IR). While p85 binds directly to the PDGF receptor tails, mechanisms of EGF-
mediated PI3K activation are obscure. The IR phosphoryates the adaptor protein IRS1 (insulin 
receptor substrate 1), which subsequently recruits p85/PI3K. 
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2.3.2 G protein-coupled receptors (GPCRs) 
G protein-coupled receptors (GPCRs) comprise the largest group of cell surface receptors. GPCRs 
are composed of a seven transmembrane domain and transmit signals through activation of 
receptor-associated heterotrimeric GTP-binding proteins (Pierce KL, Nat Rev Mol Cell Biol, 2002). 
Ligand binding triggers conformational changes that stimulate the release of GDP from the Gα 
subunit, which results in the exchange of the GDP with an abundantly available GTP molecule and 
the release of the Gα-associated Gβγ subunits. Both the active GTP-loaded Gα subunit as well as 
the Gβγ dimer are involved in the activation of downstream effector proteins. Some GPCRs 
stimulate adenylyl cyclase, while others activate phospholipase Cβ (PLCβ) and/or PI3K. Signalling 
specificity is achieved through the diversity of the Gα, Gβ, and Gγ subunits. All Gγ subunits are 
posttranslationally modified at the C-terminal CAAX motif by attachement of a 15-carbon farnesyl 
or 20-carbon geranylgeranyl group, which anchors the Gβγ dimer to membranes. PI3Kγ activation 
is sensitive to B. Pertussis toxin from the bacterium Bordetella pertussis (Davies SP, Biochem J, 2000; 
Sugimoto Y, Proc Natl Acad Sci U S A, 1984), which specifically blocks activation of heterotrimeric 
G-proteins of the Gi/o family through ADP-ribosylation of the alpha subunit (Mangmool S and 
Kurose H, Toxins (Basel), 2011). Examples of Gi- and PI3Kγ-coupled GPCRs are the N-formyl 
peptide receptor (FPR) or the C5a complement receptor (C5aR). The FRP can be stimulated 
experimentally with the synthetic peptide N-formyl-methionyl-leucyl-phenylalanin (f-Met-Leu-Phe, 
fMLP), and is believed to be physiologically activated by N-formylated peptides derived from 
bacterial protein degradation or mitochondrial proteins upon tissue damage. fMLP and C5a trigger 
chemotaxis and oxidative burst in neutrophils in a PI3Kγ-dependent manner (Hirsch E, Science, 
2000; Suire S, Nat Cell Biol, 2006).  
 
2.4 Mast cells 
2.4.1 Introduction to mast cells 
Mast cells are tissue-resident immune cells of hematopoietic origin. They locate to all organs 
throughout the body such as skin, gut, and respiratory tract. They are particularly abundant around 
blood vessels and lymphatic microvessels. They have been discovered based on the unique staining 
of their secretory granules by different dyes. The mast cell is a phylogenetically old cell type and 
exists in all species with blood circulation. It develops from multipotent stem cells in the bone 
marrow (Kirshenbaum AS, J Immunol, 1991). Precursors leave the bone and enter the blood 
stream, from where they colonise the whole body and differentiate into mature cells under the 
influence of locally generated factors. Under homeostatic conditions, mast cell tissue homing and 
maintenance exclusively depends on the activation of the mast cell stem cell factor (SCF) receptor 
Kit by its ligand SCF, expressed as membrane-bound form on stromal cells (Galli SJ, Am J Pathol, 
1993). Mice devoid of a functional Kit receptor or defective in SCF expression lack mast cells. 
Under inflammatory conditions, mast cells are directed to sites of tissue damage or infection via 
stromal and immune cell released cytokines in a Kit-independent manner. Mast cells are long-lived 
cells and can proliferate in the tissue. As mast cell maturation depends on the local micro-
environment, they are a highly heterogeneous population. Differences occur in number, 
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morphology, mediator content, and responsiveness to various stimuli (variability of receptor 
expression). Based on histochemical and morphological properties, rodent mast cells have been 
classified into two major groups (Gurish MF and Boyce JA, J Allergy Clin Immunol, 2006). 
Connective tissue mast cells (CTMC) possess safranin-positive granules and reside in the 
submucosal connective tissue of the skin, peritoneal cavity, and respiratory tract. Mucosal mast cells 
(MMCs) are safranin-negative and are found the mucosal epithelium of the gastrointestinal tract. In 
contrast to CMTCs, MMCs develop in a T cell dependent manner, as this mast cell population is 
absent in athymic mice (Ruitenberg EJ and Elgersma A, Nature, 1976). MMCs expand rapidly upon 
T cell dependent immune responses to certain intestinal parasites. Further phenotypical differences 
are found for example in protease expression, serotonin and proteoglycan content, and stimulated 
eicosanoid release. Evidence of two principle mast cell populations has also been obtained in 
humans (Metcalfe DD, Physiol Rev, 1997). Here, classification has mainly been based on different 
protease contents of the secretory granules. While human MCTCs contain tryptase and chymase, 
human MCTs only produce tryptase. In terms of tissue localisation and T cell dependence, MCTCs 
mostly resemble rodent CTMCs, while MCTs are most similar to rodent MMCs. 
 
Rodent and human mast cell characteristics (mod. from (Metcalfe DD, Physiol Rev, 1997)):  
RODENTS Connective tissue mast cells (CTMC): Mucosal mast cells (MMC): 
Location submucosal connective tissues 
(skin, peritoneal cavity, 
respiratory tract) 
mucosal epithelial surfaces 
(gastrointestinal tract (lamina 
propria)), mucosal surfaces) 
Size 10-20 µm 5-10 µm 
Staining Safranin Alcian blue 
T cell dependence no yes 
Protease content Chymase (RMCP I, rat mast cell  
                                  protease I) 
Chymase (RMCP II, rat mast cell 
                                  protease II) 
Proteoglycans Heparin Chondroitin sulfate 
Eicosanoids PDG2 PDG2, LTC4 
HUMANS MCTC MCT 
Location skin, small intestine 
(submucosa), lymph nodes 
alveolar tissue, small intestine 
(mucosa) 
T cell dependence no yes 
Protease content Tryptase, Chymase, 
Carboxypeptidase, Cathepsin G 
Tryptase 
 
2.4.2 Mast cells are key players in allergy 
Under normal physiological conditions, mast cells are thought to regulate tissue repair and 
remodelling, host defence, and neuroimmunoendocrine processes (Maurer M, Exp Dermatol, 
2003). However, mast cells are more famous for their disease promoting roles in allergic and 
inflammatory diseases. They are key players in allergic rhinitis (hay fever), food allergy, contact 
dermatitis (eczema), allergic conjunctivitis, and anaphylactic shock and contribute to inflammation 
Introduction  13 
 
in multiple sclerosis and rheumatoid arthritis (Maruotti N, Clin Rheumatol, 2007). Mast cells are 
activated in an immunoglobulin E (IgE)-dependent manner through the high-affinity receptor for 
IgE (FcεRI) or independently of IgE by complement receptors and Toll-like receptors. They mainly 
act through the plethora of inflammatory mediators and cytokines they can synthesize and secrete. 
Mast cells thereby modulate the function of blood vessels, smooth muscle, mucus glands, and 
immune cells (Fig. d). 
 
 
 
Fig. d: Targets of mast cells 
 
 
Allergies develop after an inappropriate immune response to a normally harmless environmental 
agent, leading to the continuous production of IgE by B cells. The IgE binds to its receptor, FcεRI, 
on the mast cell surface and stimulates the production cytokines that promote mast cell recruitment 
and proliferation. The allergic response initiates open a second contact with the same allergen, 
which crosslinks the mast cell bound IgE molecules. This leads to receptor aggregation, triggering 
activation of intracellular signalling pathways that control the release of preformed proinflammatory 
mediators from secretory granules and the production of lipid mediators. These immediately 
released factors set up an inflammatory response, which is characterized by tissue swelling, heat, 
and redness. Histamine is the most potent granule associated mediator, acting on the endothelium 
to increase blood vessel diameter and permeability. The immediate reaction is followed by a late 
phase reaction that depends on the release of newly synthesized cytokines and chemokines. These 
chemotactic and cell-activating factors coordinate the recruitment of neutrophils and eosinophiles 
from the blood into the allergen-activated tissue (Fig. e). 
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Fig. e: Mast cell activation in allergy.  
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3. Aims 
 
3.1 Background  
3.1.1 PI3K is essential to mast cell degranulation 
Allergy is triggered by mast cell activation via the high-affinity IgE receptor (FcεRI). In order to 
develop new strategies to combat allergic disease, it is of interest to understand how receptor 
activation is coupled to granule exocytosis. Studies with the natural pan phosphoinositide 3-kinase 
(PI3K) inhibitor Wortmannin have identified PI3K as central regulator of mast cell degranulation 
(Marquardt DL, J Immunol, 1996). That the PI3K lipid product PIP3 is a potent modulator of mast 
cell degranulation is further reflected by the hyperresponsive phenotype of inositol 5’-phosphatase 
(SHIP) knock-out mast cells, which degranulate in response to suboptimal antigen concentrations 
due to the continues, unrestricted accumulation of PIP3. (Huber M, Proc Natl Acad Sci U S A, 
1998). Due to the key role of PI3K in IgE/antigen-triggered signal transduction, it is of interest to 
understand how this lipid kinase is activated and regulates degranulation. First attempts to this goal 
delivered information on PI3K isoform-specificity, which became examinable after establishment 
of techniques to generate transgenic mice. 
Analysis of PI3Kγ–/– mice showed that PI3Kγ regulates mast cell activation, immune cell migration, 
and respiratory burst (Hirsch E, Science, 2000; Sasaki T, Science, 2000; Li Z, Science, 2000; 
Laffargue M, Immunity, 2002; Del Prete A, EMBO J, 2004). Our group has demonstrated the 
essentiality of the PI3Kγ PI3K-isoform in mast cell degranulation in vivo in a model of passive 
systemic anaphylaxis (Laffargue M, Immunity, 2002). This acute life-threatening allergic disease 
depends on the body-wide activation of mast cells and the release of histamine. Experimentally this 
can be simulated in wild type mice by intravenous injection of IgE and antigen and the dye Evans 
blue as marker of endothelial barrier integrity. Whereas wild type mice react with a dramatic 
increase in vascular permeability, as visualised by leakage of Evans blue into the surrounding tissue, 
PI3Kγ–/– mice are protected. In order to study the molecular basis of PI3Kγ activation, mast cell 
degranulation was analysed at the cellular level using bone marrow-derived mast cells (BMMC) 
developed from wild type and PI3Kγ–/– mice. 
 
3.1.2 PI3Kγ regulates mast cell hyperdegranulation via an autocrine activation loop 
Consistent with defective mast cell activation in vivo, PI3Kγ–/– BMMCs also show an impaired 
degranulation response. As PI3Kγ has been shown to be activated by G protein-coupled receptors 
(GPCRs) (Stephens LR, Cell, 1997) and as the FcεRI is a protein tyrosine kinase (PTK)-coupled 
receptor, it has been investigated whether autocrine-paracrine pathways regulate mast cell 
degranulation. A good candidate GPCR-ligand was adenosine as this agent was known to be 
released by activated mast cells and tissue, is found at increased levels at inflamed sites of asthmatic 
people, and stimulates vascular leakage in a mast cell dependent manner after administration to 
mice (Marquardt DL, Proc Natl Acad Sci U S A, 1984; Forsythe P and Ennis M, Inflamm Res, 
1999; Tilley SL, J Clin Invest, 2000). In accordance with these thoughts, PI3Kγ was found to 
enhance degranulation through adenosine/GPCR-triggered PIP3 production. PI3Kγ thereby 
Aims  16 
 
functions as a mast cell hyperactivator boosting degranulation triggered by IgE/antigen (Laffargue 
M, Immunity, 2002) (Fig. f).  
 
 
 
Fig. f: Model of mast cell hyperactivation by adenosine 
 
Based on this and as pan PI3K inhibition completely blocks mast cell degranulation, it has been 
proposed a model, in which the FcεRI first engages class IA PI3K to trigger a weak degranulation 
response which is subsequently amplified by class IB PI3Kγ leading to full-scale mediator release. 
In analogy to B cell receptor signalling (Okkenhaug K, Science, 2002; Clayton E, J Exp Med, 2002; 
Koyasu S, Biochem Soc Trans, 2004), class IA PI3K has been expected to regulate Ca2+ 
mobilisation downstream of the FcεRI. Whereas inositol 5’-phosphatase SHIP was expected to 
counterregulate class IA PI3K signalling, PI3Kγ has been thought to escape receptor-proximal PIP3 
inactivation by SHIP (Fig. g) (Wymann MP, Biochem Soc Trans, 2003). 
 
 
 
Fig. g: Model of SHIP action in mast cells 
 
3.1.3 PI3Kγ relays more that adenosine/GPCR signalling 
Despite PI3Kγ was identified to potentiate mast cell degranulation via adenosine/GPCR pathways, 
this mechanism does not completely explain the phenotype of PI3Kγ–/– BMMCs. In the study of 
Laffargue et al. (Laffargue M, Immunity, 2002), an observation remained unexplained: Blockade of 
GPCR or adenosine signalling interfered only partially with degranulation of wild type BMMCs, 
resulting in an inhibition that was much less severe than the phenotype of PI3Kγ–/– BMMCs. To 
take this into account, it must to be thought about other ways of PI3Kγ regulation. Consistently, 
PI3Kγ is required to relay much more that adenosine signalling, as this nucleoside is not needed for 
mast degranulation in vivo and in vitro. Whereas A3 adenosine receptor (A3AR)–/– knock-mice are 
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resistant to vascular changes after intradermal adenosine injection, they are still sensitive to passive 
systemic anaphylaxis (Tilley SL, J Clin Invest, 2000). As well, A3AR–/– BMMCs respond normally to 
IgE/antigen but not adenosine stimulation. These observations could either be explained by the 
involvement of other GPCR-ligands than adenosine or the existence of an unknown PI3Kγ 
activation pathway.  
 
3.2 Starting point 
3.2.1 Thapsigargin is a non-canonical PI3Kγ activator 
Experiments with Thapsigargin opened the door to the discovery of a novel PI3Kγ activation 
mechanism. FcεRI aggregation culminates in the mobilisation of intra- and extracellular Ca2+ and 
degranulation. Ca2+ mobilising agents like Thapsigargin trigger mast cell degranulation at this 
receptor-distal step in wild type BMMCs (Fig. h). In contrast, PI3Kγ–/– BMMCs completely fail to 
degranulate following Thapsigargin stimulation. This was of surprise, as Ca2+ mobilisation triggered 
by the FcεRI was thought to be regulated by class IA PI3K and therefore to occur downstream of 
PI3K activation. Instead, these results showed essentiality of PI3K at a later/parallel step to Ca2+ 
mobilisation, and that this involves class IB PI3Kγ. Actually, it has already been observed that pan 
PI3K inhibition blocks degranulation induced by Ca2+ mobilising agents (Marquardt DL, J 
Immunol, 1996), but the significance of this has been inadvertently ignored. Importantly, whereas 
Thapsigargin triggers PI3K activation, as measured by PKB phosphorylation, in wild type BMMCs, 
this is also blocked in the absence of PI3Kγ. Thapsigargin therefore turned out to be a convenient 
tool to address non-canonical PI3Kγ activation in mast cells. Signalling mechanisms can thereby be 
analysed in a simplified cellular environment decoupled from upstream and other receptor-
regulated events.  
 
 
 
Fig. h:  Thapsigargin triggers mast cell degranulation at the step of Ca2+ mobilisation 
(SOCE: store-operated Ca2+ entry; ER: endoplasmic reticulum; IP3R: inositol(1,4,5)-trisphosphate 
receptor; SERCA: sarco/endoplasmic reticulum Ca2+ ATPase; Orai: calcium release-activated 
calcium channel protein 1) 
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3.2.2 Objective 
The goal of this study was to unravel GPCR-independent mechanisms of PI3Kγ activation 
downstream of the FcεRI. This has been started by the characterisation of Thapsigargin-triggerd 
PI3Kγ activation in BMMCs by former lab members. Some experimental data thereof are included 
in the manuscript figure section and are described there. Of most importance, analysis of protein 
kinase C (PKC)β–\– BMMCs showed that PI3K activation is blocked in the absence of this kinase. 
It was therefore of prior interest to unravel how PKCβ mechanistically connects to PI3Kγ, starting 
with the analysis whether this involves a direct or indirect mechanism. Contemporaneously, 
Thapsigargin-based results had to be incorporated into the analysis of FcεRI-mediated signal 
transduction. Additionally, it was necessary to think about alternative PI3Kγ activation models and 
to check compatibility with current literature. 
To study mast cell signal transduction and exocytosis, bone marrow-derived mast cells (BMMCs) 
were preferred as model system. As we wanted to analyse PI3K signalling, it was of importance to 
work with primary cells and not cell lines that harbor mutations that promote constitutive PI3K 
activation. Activation mechanisms were studied with recombinant proteins in vitro or by exogenous 
protein expression in cultured cells. Signalling and degranulation were analysed in wild type,  
PI3Kγ–/–, and PKCβ–/– BMMCs. 
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4. Results 
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4.1 Abstract 
Allergy depends on mast cell mediator release and stimulation of the high-affinity IgE receptor 
(FcεRI). Receptor clustering activates protein tyrosine kinases that coordinate Ca2+ mobilisation and 
protein kinase C (PKC) activation. Mast cell degranulation is blocked by pan phosphoinositide 3-
kinase (PI3K) inhibition or genetic inactivation of class IB PI3Kγ. Adenosine amplifies receptor-
triggered degranulation in an autocrine-paracrine manner via G protein-coupled receptor-coupled 
PI3Kγ. Here we demonstrate direct activation of PI3Kγ by the FcεRI and Ca2+ mobilising agents. 
PI3Kγ activation depends on high Ca2+ levels and PKCβ, which phosphorylates PI3Kγ on Ser582 
in the helical domain. This is an interesting region as it constitutes a hot-spot of oncogenic PI3Kα 
mutations. Analysis of phosphorylation-mimicking mutants indicates that Ser582 acts as switch-site 
for PI3Kγ activation. We determined the PI3Kγ-p84 binding interphase and show that PI3Kγ is 
active in an adaptor subunit-free manner. Our data provide unexpected new insights into PI3-
kinase regulation and underpin PI3Kγ’s central role in allergy regulation. 
 
4.2 Introduction 
Allergic inflammation is driven by mediator release from mast cells. These immune cells of 
hematopoietic origin reside in vascularized tissue throughout the body. Allergies develop after an 
inappropriate immune response to a harmless environmental agent, leading to the production of 
allergen-specific immunoglobulin E (IgE) by B cells at sites of allergen exposure (Gould HJ and 
Sutton BJ, Nat Rev Immunol, 2008). Allergens activate mast cells by triggering aggregation of the 
high-affinity receptor for IgE (FcεRI) through crosslinking of receptor-bound IgE molecules. 
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FcεRI activation is coupled to the release of preformed pro-inflammatory mediators from secretory 
granules, the synthesis of lipid mediators, and the translationally or transcriptionally controlled 
generation of cytokines and chemokines. Mast cell activation in vivo promotes an immediate 
increase in vascular permeability leading to tissue swelling, which depends on activation of the 
endothelium by granule-released histamine (Nagai H, Biol Pharm Bull, 1995). Hours later, cytokines 
and chemokines orchestrate the recruitment of neutrophils and eosinophils from the blood to the 
affected tissue.  
In order to find targets to treat allergic disease it is important to understand how receptor activation 
is coupled to granule release. The FcεRI is a tetrameric complex composed of the IgE-binding α 
chain, a β-chain, and two disulfide linked γ-chains (Ravetch JV and Kinet JP, Annu Rev Immunol, 
1991). Receptor aggregation is coupled to the activation of membrane-anchored protein tyrosine 
kinase (PTK) Lyn (Nishizumi H and Yamamoto T, J Immunol, 1997). Lyn phosphorylates tyrosines 
in immunoreceptor tyrosine-based activation motifs (ITAMs) in the β- and γ-chains and thereby 
initiates both positive and negative signalling events (Kawakami Y, J Immunol, 2000; Hernandez-
Hansen V, J Immunol, 2004; Xiao W, J Immunol, 2005). Phosphorylated ITAMs serve as docking 
sites for the Src homology 2 (SH2) domains of the tyrosine kinase Syk as well as the inositol-5'-
phosphatase SHIP1 (Kimura T, J Biol Chem, 1996; Osborne MA, J Biol Chem, 1996). Syk 
functions as the master activator of mast cell degranulation, promoting Ca2+ mobilisation through 
coordination of phospholipase Cγ (PLCγ) activation. Syk phosphorylates the adaptor proteins LAT 
and SLP-76 as well as PLCγ (Costello PS, Oncogene, 1996; Scharenberg AM and Kinet JP, J Allergy 
Clin Immunol, 1994). Phosphorylated LAT recruits SLP-76, which indirectly binds to LAT via its 
Grb2/Gads-binding domain (Saitoh S, J Exp Med, 2003; Kambayashi T, Mol Cell Biol, 2010; Zhu 
M, J Exp Med, 2004). Both of these adaptors, alone and in cooperation, promote the recruitment of 
phospholipase C (PLC)γ1 and PLCγ2 to the plasma membrane, where PLCγ gets fully activated by 
phosphorylation (Pivniouk VI, J Clin Invest, 1999; Kettner A, Mol Cell Biol, 2003; Wang D, 
Immunity, 2000; Wen R, J Immunol, 2002; Saitoh S, Immunity, 2000). PLCγ hydrolyses 
phosphatidylinositiol(4,5)bisphospate (PI(4,5)P2) to generate inositol(1,4,5)trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 promotes Ca2+ release from the endoplasmatic reticulum (ER), while 
DAG and Ca2+ regulate protein kinase C (PKC) activation. ER-store depletion is coupled by store-
operated Ca2+ entry (SOCE) to the influx of extracellular Ca2+. STIM1 thereby serves as luminal 
Ca2+ sensor and triggers assembly of Orai1 into functional plasma membrane Ca2+ channels (Baba 
Y, Nat Immunol, 2008; Vig M, Nat Immunol, 2008). Both Ca2+ mobilisation and PKC activation 
are recognized as central steps in mast cell degranulation. Likewise essential is activation of 
phosphoinositide 3-kinase (PI3K), which generates the lipid second messenger PI(3,4,5)P3 (PIP3). 
While blockade of PIP3 production by Wortmannin completely inhibits degranulation (Marquardt 
DL, J Immunol, 1996; Pendl GG, Int Arch Allergy Immunol, 1997), blockade of PIP3 degradation 
promotes hypersensitivity to suboptimal antigen concentrations as well as degranulation by the non-
secretagogue stem cell factor (SCF) (Huber M, Proc Natl Acad Sci U S A, 1998). PIP3 positively 
modulates mast cell degranulation by enhancing Ca2+ mobilisation by recruiting PLCγ and Brutons 
tyrosine kinase (Btk) to the plasma membrane (Kawakami Y, J Immunol, 2000; Kitaura J, J Exp 
Med, 2000; Iwaki S, J Biol Chem, 2005). Mast cell degranulation is counterregulated at the step of 
Results  21 
 
PI3K activation by the inositol phosphatase SHIP1, which dephosphorylates PIP3 to PI(3,4)P2 
(Huber M, Proc Natl Acad Sci U S A, 1998). SHIP1 functions a signal terminator, but also as a 
“gate-keeper” to prevent degranulation at sub- and supraoptimal antigen concentrations (Gimborn 
K, J Immunol, 2005). Mast cell degranulation finishes by the docking and fusion of granules to the 
plasma membrane (Deng Z, Biophys J, 2009). While early signalling events are well characterized, it 
is not much known about how Ca2+, PKC, and PI3K connect to granule release. 
Protein kinases C (PKCs) are serine/threonine kinases that are composed of an N-terminal 
regulatory and a C-terminal catalytic domain. In quiescent cells they are located in the cytosol in an 
inactive state, but translocate to plasma membrane upon cell surface receptor stimulation. The 
family has been grouped into three classes. PKCα, PKCβ, and PKCγ belong to the conventional 
PKCs (cPKCs) and are activated by Ca2+, DAG, and phospholipid-binding. Of these cofactors, 
novel PKCs (nPKC; PKCδ, ε, η, θ) do not require Ca2+ for activation, while atypical PKCs (aPKC; 
PKCζ, ι/λ) do not depend on Ca2+ nor DAG. 
FcεRI activation is followed by translocation of several PKC isoforms (Ozawa K, J Biol Chem, 
1993). Despite this, analysis of PKC knock-out mast cells showed so far only a requirement of 
PKCβ for mast cell degranulation (Nechushtan H, Blood, 2000), while PKCα, PKCδ, or PKCε are 
dispensable (Fehrenbach K, J Immunol, 2009; Leitges M, Mol Cell Biol, 2002; Lessmann E, Int 
Immunol, 2006). Although PKCβ is an essential degranulation regulator, its substrates remained 
obscure. In rat basophilic leukemia (RBL-2H3) cells, antigen or calcium ionophore stimulate the 
phosphorylation of myosin heavy and light chains at sites, that are found to be targeted by PKC in 
vitro kinase assays (Ludowyke RI, J Biol Chem, 1989; Ludowyke RI, J Immunol, 1996; Ludowyke 
RI, J Immunol, 2006). Apart from regulation of cytoskeletal changes, PKC has been speculated to 
regulate granule-membrane fusion. With respect to this, IgE/antigen was found to trigger SNAP-23 
phosphorylation at two residues in rodent mast cells, of which one site is conserved (Hepp R, J Biol 
Chem, 2005). Despite phosphorylation is sensitive to PKC inhibition, IκB kinase (IKK)β is rather 
the direct kinase (Suzuki K and Verma IM, Cell, 2008). Consistently, SNAP-23 is a poor substrate 
for PKC in vitro (Foster LJ, Biochemistry, 1998) in contrast to IKKβ (Suzuki K and Verma IM, 
Cell, 2008). By now nothing is known about the role of the mentioned sites nor their relevance for 
degranulation (Bresnick AR, Curr Opin Cell Biol, 1999; Morgan A, Biochem Soc Trans, 2005; 
Snyder DA, Cell Biochem Biophys, 2006).  
Phosphoinositide 3-kinase (PI3K) activation is triggered by diverse cell surface receptors to regulate 
both homeostatic as well as transient cellular functions. Basal growth factor-induced PI3K 
signalling regulates cell survival and proliferation, whereas acute PI3K activation is essential to 
specific cellular tasks, like regulated secretion, adhesion, and chemotaxis (Foukas LC, Proc Natl 
Acad Sci U S A, 2010; Hirsch E, Science, 2000; Del Prete A, EMBO J, 2004). Through regulation 
of these processes, PI3K confers a risk to cancer development or chronic inflammation once 
regulatory mechanisms become inoperative (Samuels Y, Science, 2004; Jaiswal BS, Cancer Cell, 
2009; Rudd ML, Clin Cancer Res, 2011; Rommel C, Nat Rev Immunol, 2007). 
Receptor-coupled PI3Ks belong to the class I family, being composed of the subgroups IA and IB. 
The class IA PI3Ks - PI3Kα, β, and δ - are canonically activated by protein tyrosine kinase (PTK)-
coupled receptors and associate with a p85/p55 regulatory protein (p85α, p50α, p55α; p85β; p55γ). 
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The only class IB member PI3Kγ is activated downstream of heterotrimeric G protein-coupled 
receptors (GPCRs) and interacts with the adaptors p101 or p84 (also known as p87PIKAP) (Stephens 
LR, Cell, 1997; Suire S, Curr Biol, 2005).  
PI3Ks are lipid kinases that transfere a phosphate group from ATP to the 3’ hydroxyl group of the 
inositol ring of phosphoinositides. These lipid molecules then serve as docking sites for the 
recruitment of downstream effectors. Class I PI3Ks catalyse the formation PIP3, and thus transduce 
downstream signalling through the recruitment of pleckstrin homology (PH) domain containing 
proteins to the plasma membrane. The best-known downstream effector of PI3K is protein kinase 
B (PKB), which after its recruitment to the plasma membrane, gets activated by phosphorylation on 
Thr308 and Ser473. Detection of PKB phosphorylation serves as convenient readout to measure 
PI3K activation. 
PI3Kγ has been discovered to exist in a tight complex with p101 in myeloid-derived cells (Stephens 
LR, Cell, 1997). p101 sensitises PI3Kγ for activation by Gβγ subunits of trimeric G proteins in 
vitro and heterologous expression systems, and is essential for chemotaxis of neutrophils towards 
GPCR-ligands (Stephens LR, Cell, 1997; Brock C, J Cell Biol, 2003; Suire S, Nat Cell Biol, 2006). As 
mast cells were found to lack p101 expression, a homologous PI3Kγ adaptor, that shared 30% 
sequence identity with p101, was identified and called p84 (Suire S, Curr Biol, 2005; Bohnacker T, 
Sci Signal, 2009). Ectopically expressed p84 coimmunoprecipitates with PI3Kγ and supports Gβγ-
dependent PtdIns(3,4,5)P3 production in HEK293 cells (Brock C, J Cell Biol, 2003; Voigt P, J Biol 
Chem, 2006). However, in contrast to p101, p84 does not potentiate PI3Kγ activation by Gβγ 
subunits in vitro nor is it translocated by them to the plasma membrane (Kurig B, Proc Natl Acad 
Sci U S A, 2009). p84 action is incompletely understood, but sensitive to overexpression of the 
GTPase activating domain of neurofibromin or cholesterol depletion (Kurig B, Proc Natl Acad Sci 
U S A, 2009; Bohnacker T, Sci Signal, 2009).  
While inhibitor based studies identified PI3K to be central to mast cell degranulation, insights into 
PI3K-isoform specificities awaited availability of isoform-targeted transgenic mice. We have shown 
that deletion of PI3Kγ in mice blocks FcεRI-dependent mast cell degranulation in vivo (Laffargue 
M, Immunity, 2002). Analysis of bone marrow-derived mast cells (BMMCs) has shown that PI3Kγ 
functions as an amplifier of mast cell degranulation in an autocrine-paracrine manner via adenosine 
signalling through G protein-coupled receptors (GPCRs). However, as this pathway only partially 
contributes to degranulation, it does not explain the strong degranulation defect of PI3Kγ–/– 
BMMCs (Saito H, J Immunol, 1987; Laffargue M, Immunity, 2002; Endo D, Int Arch Allergy 
Immunol, 2009). Furthermore, despite PI3Kγ is activated by adenosine via the A3 adenosine 
receptor, A3AR knockout mice and BMMCs are still sensitive to passive systemic anaphylaxis and 
antigen-induced degranulation, respectively (Tilley SL, J Clin Invest, 2000; Gao Z, Mol Pharmacol, 
2001).  
As it must exist another pathway to PI3Kγ in BMMCs, we explored novel activation mechanisms. 
A convenient tool to that goal turned out to be Thapsigargin, since degranulation induced by this 
Ca2+ mobilising agent was blocked in PI3Kγ–/– BMMCs. By pharmacological and genetic targeting 
strategies, we identified that PI3Kγ activation depends on store-operated Ca2+ entry and subsequent 
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PKCβ activation. PKCβ activates PI3Kγ by phosphorylation of Ser582 in an adaptor-independent 
manner. Coincidentally we determined the p84 binding interphase on PI3Kγ. Our results change 
our view on PI3K regulation and show for the first time how a PTK-coupled receptor connects to 
class IB PI3Kγ.  
 
4.3 Results 
4.3.1 Thapsigargin-induced mast cell degranulation depends on PI3Kγ, but not Gβγ 
subunits of heterotrimeric G proteins 
Activation of the high-affinity receptor for IgE (FcεRI) on mast cells by IgE and antigen triggers 
granule exocytosis and the release of proinflammatory mediators. PI3Kγ is essential to mast cell 
degranulation in mice in a model of passive systemic anaphylaxis as well as in bone marrow-derived 
mast cells (BMMCs) in vitro (Laffargue M, Immunity, 2002). A central step in signalling to mast cell 
degranulation is the mobilisation of extracellular Ca2+ by store-operated Ca2+ entry (SOCE) (Beaven 
MA, J Biol Chem, 1984; Ma HT and Beaven MA, Crit Rev Immunol, 2009). As Ca2+ mobilising 
agents like Thapsigargin and ionophores trigger degranulation at this step, they are of valuable help 
to dissect receptor proximal from distal signalling events. In order to delineate PI3Kγ activation in 
BMMCs, we compared degranulation of wild type and PI3Kγ–/– BMMCs in response to receptor 
activation and Ca2+ influx. Following loading with anti-dinitrophenyl (DNP) specific IgE overnight, 
FcεRI receptors of wild type and PI3Kγ–/– BMMCs were activated through crosslinking of the 
bound IgEs with multivalent antigen (DNP30-40-human serum albumin). In the same experiment, 
BMMCs were also directly stimulated with the plant compound Thapsigargin to trigger SOCE-
induced degranulation. Thapsigargin, an inhibitor of the Ca2+ influx pumps of the 
sarco/endoplasmatic reticulum, activates the plasma membrane Ca2+ channels indirectly by 
promoting passive depletion of the intracellular Ca2+ stores (Thastrup O, Proc Natl Acad Sci U S A, 
1990). Degranulation, as measured by the release of β-hexosaminidase into the cell supernatant, was 
impaired in PI3Kγ–/– BMMCs both following stimulation with IgE/DNP or Thapsigargin (Figure 
1A). Further, PI3Kγ deficiency caused a similar blockade in degranulation as the treatment of wild 
type BMMCs with the pan PI3K inhibitor Wortmannin (Figure 1A). These observations imply that 
mast cell degranulation mainly depends on the PI3Kγ PI3K-isoform and that PI3Kγ is activated at 
a step downstream of Ca2+ mobilisation. These results were surprising to us, as PI3Kγ so far has 
only been reported to be activated downstream of G protein-coupled receptors (GPCRs) (Stephens 
L, Cell, 1994; Stephens LR, Cell, 1997). How Thapsigargin engages PI3Kγ? Since impaired FcεRI-
induced degranulation of PI3Kγ–/– BMMCs has been related to defective PI3Kγ activation by the 
autocrine released GPCR ligand adenosine (Laffargue M, Immunity, 2002), we analysed whether 
Thapsigargin-induced degranulation is also potentiated by autocrine-regulated mechanisms. To test 
this hypothesis we preincubated wild type and PI3Kγ–/– BMMCs with adenosine deaminase (ADA), 
which inactivates adenosine by converting it to inosine, before stimulation. While IgE/DNP 
stimulated degranulation was partially reduced in wild type BMMCs in the presence of ADA, 
Thapsigargin-induced degranulation was insensitive to ADA treatment (Figure 1B). Consistently, 
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Thapsigargin-induced PI3K activation, as measured by activation of its downstream target protein 
kinase B (PKB), was also not affected by ADA treatment (Figure 1C, right). In contrast, ADA 
efficiently blocked PKB phosphorylation following stimulation with adenosine (Figure 1C, left). 
PI3Kγ activation by GPCRs is blocked by B. Pertussis Toxin (PTx) (Stephens L, J Biol Chem, 1993; 
Laffargue M, Immunity, 2002) that inhibits activation heterotrimeric G-protein of the Gi/o family by 
ADP-ribosylation of the Gα subunit (Mangmool S and Kurose H, Toxins (Basel), 2011). In order to 
exclude the possibility that Thapsigargin activates PI3Kγ through release of other GPCR-ligands 
than adenosine, we blocked GPCR signalling by preincubation with PTx. While Thapsigargin-
induced PKB activation was insensitive to PTx, adenosine-mediated PI3Kγ activation was 
abrogated (Figure 1D). Blocked PKB phosphorylation in PI3Kγ–/– BMMCs shows again that 
Thapsigargin engages exclusively the PI3Kγ PI3K isoform (Figure 1C/D). All in all, these data 
show that Thapsigargin-induced PI3Kγ activation and degranulation does not depend on 
GPCR/Gβγ-coupled PI3Kγ. Conclusively it must exist a non-canonical route to PI3Kγ in BMMCs. 
 
4.3.2 Thapsigargin-induced PI3Kγ activation depends on an influx of extracellular Ca2+ 
To ensure that Thapsigargin-induced PI3Kγ activation depends on its property to trigger Ca2+ 
mobilisation, we performed stimulations under Ca2+ free conditions. To capture the calcium ions in 
the medium, wild type BMMCs were preincubated for 5 min with the Ca2+ chelating compound 
EDTA prior to stimulation. Thapsigargin-induced PKB phosphorylation was blocked the presence 
of EDTA (Figure 2A, left). As well, PKB phosphorylation triggered by another Ca2+ mobilising 
agent, the calcium ionophore ionomycin, was blocked following Ca2+ chelation with EDTA (Figure 
2A, right). To evaluate that not only extracellular Ca2+, but also its influx into the cell is required for 
PI3Kγ activation, BMMCs were incubated with the membrane permeable Ca2+ chelator 
BAPTA/AM to capture mobilised Ca2+ intracellularly. Again, PKB activation was blocked by 
Thapsigargin, but not by interleukin 3 (IL-3) or adenosine (Ade), which activate PI3K by distinct 
pathways that do not require Ca2+ mobilisation (Figure 2B).  
Next we determined the intracellular Ca2+ concentrations required to trigger PI3Kγ activation. To 
this end, BMMCs, loaded with the fluorescent Ca2+ sensing dye Fura-4F, were stimulated in the 
presence of different extracellular Ca2+ concentrations to modulate maximal stimulus-triggered Ca2+ 
uptake. After stimulation with Thapsigargin, the increase in Fura fluoresence was measured with a 
photospectrometer, and concomitantly (at 2 min) some cells were removed out of the cuvette and 
processed for quantification of PKB activation by immunoblotting. PKB phosphorylation was 
plotted as function of the calculated intracellular Ca2+ concentrations [Ca2+]i. Graphical illustration 
of the data shows, that Thapsigargin-induced PKB activation follows a switch-on kinetic 
mechanism (Figure 2C). As long as the intracellular Ca2+ levels are below ~630 nM PI3Kγ is off, 
but otherwise on. Panel 2D shows that PI3Kγ activation is blocked at extracellular Ca2+ 
concentrations below physiological levels, and represents a Western blot used to generate the data 
shown in Fig 2C. While Thapsigargin and IgE/DNP trigger store-operated Ca2+ entry (SOCE), 
GPCR-coupled receptors mobilise Ca2+ only from internal stores (Ramkumar V, J Biol Chem, 
1993), and therefore do not activate Ca2+-sensitive PI3Kγ. While Thapsigargin triggers an 
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intracellular Ca2+ rise to more than 1 µM, IB-MECA, an A3 adenosine receptor (A3AR) agonist, 
reaches maximal levels of only about 160 nM (Figure 2E). GPCR-triggered Ca2+ mobilisation is 
sensitive to B. Pertussis toxin (PTx), as it depends on inositoltriphosphate (IP3) production by Gβγ-
sensitive phospholipase C β (PLCβ). As expected, Thapsigargin-induced Ca2+ mobilisation is not 
affected by this G protein inhibitor (Figure 2E). 
 
4.3.3 PKCβ relays Ca2+ mobilisation to PI3Kγ activation 
Next we looked for candidates that may couple Ca2+ mobilisation to PI3Kγ activation. One 
candidate was the protein kinase C (PKC) family, which has been subdivided into three groups 
based on cofactor requirements for activation. Only conventional PKCs (cPKCs) require Ca2+ for 
activation, but not novel PKCs (nPKCs) or atypical PKCs (aPKCs), which only depend on DAG or 
neither Ca2+ nor DAG, respectively. A further hint for an involvement of PKC in PI3Kγ activation 
came from our observation that the PKC activator phorbol 12-myristate 13-acetate (PMA) triggers 
PKB phosphorylation in BMMCs. We tested a panel of PKC-inhibitors for inhibition of PI3K 
activation in wild type BMMCs. After a 20 min preincubation time with the inhibitors, BMMCs 
were stimulated with Thapsigargin, PMA, or adenosine, and PI3K activation was analysed by 
phospho-PKB immunoblotting. Broad-spectrum PKC-inhibitors (Ro318425, Gö6983), a 
conventional/atypical PKC-inhibitor (Gö6976), and a conventional PKC-inhibitor (PKC412) 
substantially blocked PKB phosphorylation both in response to stimulation with Thapsigargin or 
PMA (Figure 3A, Figure S1A). Rottlerin, which selectivity for PKC has been questioned (Davies 
SP, Biochem J, 2000; Soltoff SP, Trends Pharmacol Sci, 2007) since being published to be a PKCδ-
specific inhibitor (Gschwendt M, Biochem Biophys Res Commun, 1994), had no effect on PKB 
activation. On the other hand, GPCR-dependent PI3Kγ activation by adenosine was resistant to 
inhibition of PKC (Figure S1B). The reduction in PKB activation in the presence of increasing 
concentrations of PKC412 correlated well with an inhibition of Thapsigargin- or IgE/DNP-
induced mast cell degranulation (Figure 3B). 
In order to determine which isotype of conventional PKC is involved in PI3Kγ activation, we 
analysed BMMCs developed from the bone marrow of PKCα, PKCβ, and PKCγ knock-out mice. 
Whereas PKB activation was blocked in PKCβ–/– BMMCs in response to stimulation with PMA or 
Thapsigargin (Figure 3C), this defect was not observed in PKCα–/– or PKCγ–/– BMMCs (Figure 
S1C). Interestingly phosphorylation of T308 of PKB was completely blocked after PI3K-inhibition 
with Wortmannin, but not phosphorylation of S473, which was only partially affected (Figure 3C, 
lane 6 and 9). PKB activation requires phosphorylation at both positions, which is mediated by two 
different kinases. Phosphorylation of T308 in the activation loop is strictly mediated by 
phosphoinositide-dependent kinase 1 (PDK1) and depends on its PH-domain that mediates 
recruitment to PI3K-produced PIP3. Mechanisms of S473 phosphorylation are less clearly defined, 
but depend on distinct kinases in different cell types and signalling pathways. In in vitro assays and 
partially in mast cells, it has been shown that PKCβ2 can function as a S473 kinase (Kawakami Y, J 
Biol Chem, 2004). Since only T308 phosphorylation is strictly dependent on PIP3 production, we 
favoured to use this site as readout for PI3K activation hereinafter. Whereas PMA and 
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Thapsigargin depend on PKCβ for PI3K activation (Figure 3C), PKB phosphorylation is not 
impaird in PKCβ–/– BMMCs in response to adenosine which signals through GPCR-coupled PI3Kγ 
nor the cytokines interleukin-3 (IL-3) or stem cell factor (SCF) which activate class IA PI3K (Figure 
3D). FcεRI-triggered degranulation is reported to be impaired both in PI3Kγ–/– and PKCβ–/– 
BMMCs (Laffargue M, Immunity, 2002; Nechushtan H, Blood, 2000). We herein confirm these 
findings and additionally show that degranulation is blocked to a similar extent upon knock-out of 
either protein, both following stimulation with IgE/DNP (Figure 3E) or Thapsigargin (Figure 
S1D). Since the direct result of PI3Kγ activation is PtdIns(3,4,5)P3 production, we measured 
formation of this membrane lipid in PKCβ–/– and PKC-inhibitor treated BMMCs. BMMCs were 
labelled metabolically with [32P]-orthophosphate for 4 hours, followed by stimulation with 
adenosine, Thapsigargin, or PMA. Cellular lipids were extracted, deacylated, and analysed by high 
performance liquid chromatography (HPLC). Both genetic and pharmacological targeting of PKCβ 
completely blocks PIP3 production in BMMCs by Thapsigargin or PMA, but not adenosine (Figures 
3F, G). Panel 3F shows PIP3 peaks of representative HPLC chromatograms, and quantifications of 
PIP3 production are displayed in graphical form in panel 3G. PIP3 production in response to PMA 
occurs very fast and follows transient kinetics, producing a peak of PIP3 at ~30 seconds after 
stimulation (Figure 3H).  
 
4.3.4 PKCβ interacts with and phosphorylates PI3Kγ 
PKCβ-dependent PIP3 production occurred quickly and efficiently and was sensitive to long-term 
genetic and short-term small molecule-based PKC inactivation. As a next step, we examined 
whether PKCβ functions mechanistically as direct PI3Kγ activatior. To check this hypothesis, we 
first analysed whether PKCβ and PI3Kγ are interaction partners, which we tested by the means of 
coimmunoprecipitation assays. We coexpressed PI3Kγ with different PKCβ2 constructs (Figure 
4A) in HEK293 cells and immunoprecipitated either PI3Kγ or HA-tagged PKCβ. Upon capturing 
of PI3Kγ, only the catalytic domain (cat) and the pseudosubstrate deletion mutant (∆ps) of PKCβ2 
copurified with PI3Kγ, but not the wild type full-length enzyme (Figure 4B, left). Similarly, upon 
immunoprecipitation of PKCβ2, only the PKCβ2 cat fragment and the ∆ps deletion mutant 
copurified PI3Kγ (Figure 4B, right). PKCs are found in an inactive closed conformation in 
quiescent cells, which is mechanistically mediated through an intraprotein interaction between the 
pseudosubstrate (ps) domain and the kinase domain (KD). Since PKCβ interacts with PI3Kγ only 
in its open conformation, indicates that PKCβ has first to be activated by cofactor binding in cells. 
Since PKCβ is a protein kinase and PI3Kγ an interaction partner, we wanted to know whether 
PI3Kγ is a PKC substrate. Recombinant GST-tagged wild type (PI3Kγ wt) and kinase-inactive 
PI3Kγ (PI3Kγ KR) were incubated in an in vitro kinase assay with recombinant PKCβ2 in the 
presence of 10 µM ATP and [γ32P]-ATP. After 30 min of incubation, the two proteins were 
separated by SDS-PAGE and phosphate incorporation into PI3Kγ was quantified by 
phosphorimager technology. PKCβ phosphorylates both wild type and kinase-dead PI3Kγ (Figure 
4C, lanes 5-8). Wild type PI3Kγ autophosphorylates on its C-terminal tail on Ser1101 (Czupalla C, 
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Rapid Commun Mass Spectrom, 2003), and this activity is seen in lane 1 and 3 of figure 4C. Since 
PKCβ-mediated phosphorylation was about twice as intense as PI3Kγ autophosphorylation, PI3Kγ 
is a reasonable substrate for PKCβ. 
In order to determine the PKCβ-specific phosphorylation sites, in vitro phosphorylated and 
trypsin-digested kinase-inactive PI3Kγ was analysed by liquid chromatography tandem mass 
spectrometry (LC-MSMS). A peptide with the sequence YES(582)LKHPK could be identified both 
phosphorylated on Ser582 as well as non-phosphorylated. Representative spectra of both peptides 
are shown in Figure S2A/B. Using a MRM (multiple reaction monitoring) method (Figure S2C) we 
could clearly show that phosphorylation was not present in the assay without PKCβ or when a 
PKC-inhibitor was used (Figure 4D, upper half). Furthermore the phosphorylation could also be 
detected with MRM in vivo after stimulation of BMMCs with PMA or IgE/DNP but not without 
stimulation (Figure 4D, lower half). Although the stimulation time for IgE/DNP was not optimal 
(see Figure S3G), the phosphopeptide could be clearly detected. 
Inspection of the amino acid residues surrounding S582 shows that this region assorts quite well 
with a published optimal substrate motif for PKCβ determined by peptide library screening (Figure 
4E) (Nishikawa K, J Biol Chem, 1997). Furthermore, S582 is conserved in higher vertebrates such 
as mammals and birds (Figure 4F). Mast cells have been found in all classes of vertebrates including 
as well amphibians and fish (Mulero I, Proc Natl Acad Sci U S A, 2007). Interestingly, only mast 
cells from an evolutionarily advanced phylogenetic order of fish, the Perciformes, store histamine in 
their granules und use it as inflammatory mediator (Mulero I, Proc Natl Acad Sci U S A, 2007). 
Other fish species and also amphibians lack histamine (or serotonin) and do not respond to 
histamine administration. The PKC-PI3Kγ pathway might therefore have evolved at about the 
same time as histamine started to regulate immunity. Sequence comparison of class I PI3Ks shows 
that S582 is an isoform-specific regulatory site, as only PI3Kγ contains a phosphorylatable amino 
acid residue at this position (Figure S2D). 
 
4.3.5 PI3Kγ phosphorylation depends on Ca2+ and PKCβ and S582 positively regulates 
PI3Kγ's lipid kinase activity 
To be able to monitor PI3Kγ phosphorylation in vivo, we requested the production of phospho-
Ser582 specific polyclonal antibodies by commercial ways. To validate specificity of the antibodies, 
we mutated Ser582 of PI3Kγ to alanine and analysed whether epitop recognition was lost. GFP-
tagged PI3Kγ wt and a S582A mutant were transfected into wild type BMMCs and the cells were 
stimulated with PMA. PI3Kγ was immunoprecipitated from cell lysates with an anti-PI3Kγ 
antibody and phosphorylation of S582 was detected by immunoblotting. Only GFP-PI3Kγ wt (and 
endogenous PI3Kγ), but not the S582A mutant was specifically phosphorylated upon PMA 
stimulation (Figure S3A). Next we analysed whether PI3Kγ phosphorylation is regulated in a 
stimulus-specific manner. PMA, Thapsigargin, and IgE/DNP all triggered PI3Kγ S582 
phosphorylation in BMMCs, but not adenosine, in agreement with its different mode of PI3Kγ 
activation (Figure 5A). Consistent with impaired PKB activation in the absence of Ca2+ 
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mobilisation, phosphorylation of PI3Kγ on S582 by IgE/DNP was also blocked by EDTA, EGTA, 
and BAPTA/AM (Figure 5B). Phosphorylation of PI3Kγ is mainly mediated by PKCβ, as this was 
greatly impaired in PKCβ–/– BMMCs in response to PMA or IgE/DNP stimulation (Figure 5C).  
Serine 582 is located at the beginning of the helical domain of PI3Kγ. The helical domain (also 
called PIK domain or accessory domain) is conserved in PI3- and PI4-kinases, but its function is 
unknown. Certainly it is important for the structural integrity of these kinases, as being involved in 
extensive interdomain interactions (Walker EH, Nature, 1999). Interestingly, the beginning of the 
helical domain constitutes a hot-spot region of activating PI3Kα mutation found in various types of 
tumours (Samuels Y, Science, 2004). PI3Kα helical domain mutants have increased activity in vitro, 
promote PKB activation and oncogenic transformation in cell culture models, and induce tumour 
growth of xenograft transplants in vivo (Zhao JJ, Proc Natl Acad Sci U S A, 2005; Kang S, Proc 
Natl Acad Sci U S A, 2005; Ikenoue T, Cancer Res, 2005; Isakoff SJ, Cancer Res, 2005; Pang H, 
Cancer Res, 2009). To check whether the activity of PI3Kγ is regulated at the level of the helical 
domain, we compared the activity of recombinant wild type PI3Kγ, a Ser582 to Ala and a 
phosphorylation mimicking Ser582 to Glu mutant of PI3Kγ in an in vitro lipid kinase assay. 
Recombinant proteins were purified from baculovirus infected Sf9 cells by the means of a C-
terminal His6-tag, and the enzymes activities were assessed in the presence of PIP2-containing 
mixed lipid vesicles. The lipid kinase activity of the PI3Kγ S582E mutant was enhanced two-fold 
(Figure 5D), which is an increase in activity similar to that reported for PI3Kα mutants (Miled N, 
Science, 2007; Carson JD, Biochem J, 2008; Gymnopoulos M, Proc Natl Acad Sci U S A, 2007). 
Moreover, PI3Kγ S582E also showed higher activity when phosphatidylinositol (PI) was added as 
substrate (Figure 5E). Besides lipid kinase activity, PI3Kγ also possesses autophosphorylation 
activity, which was also increased 2-fold by mutation of Ser582 to Glu (Figure S3B). 
In order to analyse signalling of PI3Kγ S582 mutants in a physiologically relevant environment, we 
exogenously expressed them in PI3Kγ–/– BMMCs. Surprisingly, while PI3Kγ wild type and PI3Kγ 
S582A were efficiently expressed, expression of the phosphorylation mimicking mutants, S582E 
and S582D, was strongly downregulated early after transfection (Figure 5F). A similar 
downregulation was also observed for the GFP-tagged S582E/D mutants (not shown). While 
instability hampered further analysis of these mutants in vivo, this characteristic on the other hand 
might be an indirect sign of increased activity. Oncogenic PI3Kα mutants for example are poorly 
expressed in Sf9 cells, but this can be overcome by addition of a PI3K inhibitor (Mandelker D, 
Proc Natl Acad Sci U S A, 2009) or expression as kinase inactive form (Hon WC, Oncogene, 2012). 
In contrast to BMMCs, expression of PI3Kγ S582E/D was not affected in HEK293, which are 
devoid of endogenous PI3Kγ, but expression was also reduced in Sf9 cells (4-5-fold) compared to 
wild type PI3Kγ (not shown). 
Activation of class I PI3Ks inside cells is regulated by modulation of catalytic activity as well as 
membrane and substrate binding. Regulation occurs through adaptor subunits but also through the 
catalytic subunit itself either in cooperation with the adaptor or not. Furthermore, PI3K activation 
can depend only, partially, or not on adaptor-mediated or artificial plasma membrane-targeting, 
which has been shown for example by analysis of artificially membrane-anchored PI3K, deletion of 
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the adaptor-binding domain, or analysis of gain-of-function mutations (Costa C, Proc Natl Acad Sci 
U S A, 2007; Aoki M, J Biol Chem, 2000; Zhao JJ, Proc Natl Acad Sci U S A, 2005; Zhao L and 
Vogt PK, Proc Natl Acad Sci U S A, 2008; Zhao L and Vogt PK, Cell Cycle, 2010). While GPCR-
activated PI3Kγ is regulated by binding of the adaptor p101 to Gβγ subunits (Stephens LR, Cell, 
1997), FcεRI couples to p101-free PI3Kγ as this adaptor is not expressed in mast cells (Bohnacker 
T, Sci Signal, 2009). In neutrophils, both p101-dependent and -independent PI3Kγ effector 
functions strictly depend on a functional Ras binding domain (RBD), as genetic manipulation 
thereof causes a PI3Kγ–/– phenotype (Suire S, Nat Cell Biol, 2006). Results presented here and 
published data show that PI3Ks can be regulated at the level of the helical as well as the RBD 
domain (Samuels Y, Science, 2004; Ikenoue T, Cancer Res, 2005; Suire S, Nat Cell Biol, 2006; Zhao 
L and Vogt PK, Cell Cycle, 2010). Interestingly, we found that PKCβ not only phosphorylates 
PI3Kγ on S582 but simultaneously also on S257 in the Ras binding domain (RBD). Mass 
spectrometric analysis of in vitro phosphorylated trypsin-digested human PI3Kγ revealed a second 
phosphopeptide with the sequence KKSP(257)LMDIPESQSEQDFVLR and two non-modified 
peptides with the sequences KSLMDIPESQSEQDFVLR and SLMDIPESQSEQDFVLR. 
Representative spectra of the first two peptides are shown in Figure S3C/D. As for S582, S257 
phosphorylation was detected in vitro and in vivo by MRM (Figure S3E/F) and site-specific 
antibodies (Figure S3G and data not shown). Phosphorylation of S257 is triggered in response to 
IgE/DNP, PMA and Thapsigargin stimulation (Figure S3G and data not shown). It therefore may 
be possible that in cells both phosphorylations are required to promote PI3Kγ activation. We did 
not observe increased activation of S257 phosphorylation mimicking mutants (S257E, S257D) of 
recombinant PI3Kγ in vitro nor additional activation of a double S257E, S582E mutant (Figure 
S3H). Still it should be kept in mind that detection of PI3K activation is limited by the already high 
activity state of this enzyme in vitro. As for S582, the sequence around S257 matches well with a 
PKCβ specific substrate motif (Figure S3I), and S257 is well conserved (Figure S3J). Comparison of 
the primary and secondary structure around S257 and published RBD inactivating mutations (Suire 
S, Nat Cell Biol, 2006; Kang S, Proc Natl Acad Sci U S A, 2006) with the corresponding region of 
the other class I PI3Ks, shows a stretch of very low homology and different conformation (Figure 
S3K). Isoform-specific regulation of PI3Ks may therefore be regulated, beyond other mechanisms, 
at the level of the RBD. Depending on the PI3K isoform and signalling pathway this may involve 
interaction with a Ras-like protein, a lipid molecule and/or phosphorylation thereby regulating 
allosteric activation of catalytic elements (Pacold ME, Cell, 2000) or membrane binding. Of note, 
FcεRI-triggered degranulation does not depend on Ras activation (Graham TE, J Immunol, 1998; 
Fujimoto M, Eur J Pharmacol, 2009; Mor A, Inflammation, 2011), and Thapsigargin does not 
activate Ras in BMMCs (Figure S3L). Whether S257 regulates PI3Kγ functions in mast cells is 
unknown and needs further investigation. 
 
4.3.6 Activation of PI3Kγ by phosphorylation requires p84-free PI3Kγ 
We found that mast cells are devoid of the PI3Kγ adaptor p101, but express a homologous adaptor 
protein, called p84 or p87PIKAP (Gen Bank entry AY753194, (Bohnacker T, Sci Signal, 2009)). 
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Unexpectedly, phosphorylation of exogenously expressed PI3Kγ by PMA stimulation was gradually 
blocked by coexpression of increasing concentrations of p84 in PI3Kγ–/– BMMCs (Figure 6A, lanes 
4-6). As p84 efficiently coimmunoprecipitated with exogenously expressed PI3Kγ, access to S582 is 
likely sterically blocked by p84. To further investigate whether S582 lies in the PI3Kγ-p84 
interphase, we analysed binding of p84 to PI3Kγ S582 point mutants by coimmunoprecipitation. 
We coexpressed wild type and mutated PI3Kγ with p84 in PI3Kγ–/– BMMCs und immuno-
precipitated PI3Kγ from cell lysates. Whereas p84 efficiently bound to PI3Kγ wild type and the 
S582A mutant, the affinities of p84 for the phosphorylation-micking mutants, S582E and S582D, 
were much lower (Figure 6B). Similarly, when we coexpressed the same proteins in HEK293 cells, 
we found weaker association of p84 with PI3Kγ S582E and S582D than with PI3Kγ wild type or 
S582A, both upon immunoprecipitation of either p84 or PI3Kγ (Figure 6C). These experiments 
therefore revealed the helical domain of PI3Kγ to be part of the p84 binding site. 
Whereas wild type and S582A PI3Kγ could be expressed in PI3Kγ–/– BMMCs very efficiently in the 
presence (Figure 6B) and absence of p84 (Figure 5F), expression of the phosphorylation-mimicking 
mutants was only possible by cotransfection of p84. Despite association strength of p84 is greatly 
reduced for the S582E and S582D mutants (Figure 6B), continual low affinity on and off binding of 
p84 in side cells probably prevents degradation through inhibition of these activated mutants. 
Since endogenous PI3Kγ is phosphorylated very efficiently in wild type BMMCs by PMA 
stimulation, endogenous p84 does not block activation of endogenous PI3Kγ (Figure 6A, lane 1). 
Consistently endogenous PI3Kγ coimmunoprecipitates only low amounts of endogenous p84 
(Figure 6A, lane 1). Despite low association by coimmunoprecipitation, endogenous p84 expression 
depends partially on PI3Kγ in mast cells, neutrophils, and splenocytes, as expression of this adaptor 
is reduced in corresponding PI3Kγ–/– cells (Bohnacker T, Sci Signal, 2009). We performed 
additional coimmunoprecipitation experiments to more deeply characterise the interaction 
behaviour of endogenous and plasmid-expressed PI3Kγ and p84. Whereas exogenously expressed 
PI3Kγ coimmunoprecipitates both transfected p84 and the low amount of endogenous p84 found 
in PI3Kγ–/– BMMCs, endogenous PI3Kγ pulls endogenous p84 very inefficiently down (Figure 6D). 
Furthermore, whereas exogenously expressed GFP-PI3Kγ binds to endogenous p84 from wild type 
BMMCs, endogenous PI3Kγ fails to do so (Figure 6E). p84-PI3Kγ binding not only varies between 
endogenous and exogenous proteins, but also in mast cell lines. While endogenous p84 and PI3Kγ 
form a stable complex in the human mast cell line HMC-1, they do this poorly in rat basophilic 
leukaemia cells (RBL-2H3) (not shown). Currently, the reasons for these disparate interaction 
affinities are unclear. 
 
4.3.7 PI3Kγ interacts with p84 mainly through the beginning of the helical domain 
To understand the structural reasons by which p84 blocks PI3Kγ S582 phosphorylation, we 
performed deuterium exchange mass spectrometry (DXMS) to map the PI3Kγ-p84 binding 
interface. DXMS has become a powerful method for examining protein folding, protein-protein 
contacts, protein-ligand binding, and conformational changes (Engen JR, Anal Chem, 2009). We 
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have previously applied this methodology to map the interface of the catalytic subunit of class IA 
PI3Kδ with its p85 regulatory subunit and lipids (Burke JE, Structure, 2011). This technique relies 
on the fact that amide hydrogens exchange with solvent at a rate dependent on their conformation 
and solvent accessibility. Location and extent of deuterium uptake are analysed by peptide mass 
determination following proteolysis. We first optimized protein digestion conditions and were able 
to identify 202 peptide fragments from the PI3Kγ catalytic subunit that covered >90% of the 
primary sequence (Figure S4, Table S1). Deuterium incorporation into free and p84-complexed 
PI3Kγ was analysed at seven time points from 3 to 3000 seconds. The presence of p84 caused 
decreases in deuterium exchange greater than 0.5 Da in peptides that spanned the N-terminal, C2, 
and helical domain of PI3Kγ (Figure 7B, Figure S5). Greatest exchange changes in the presence of 
p84 were mapped onto the crystal structure of PI3Kγ lacking the N-terminal domain (PDB ID: 
2CHX, residues 144-1093) to visualize the p84 binding area (Figure 7A, Figure S5). The peptides 
that showed the greatest decrease in deuterium incorporation (>1.0 Da) clustered to three specific 
regions, the RBD-C2 linker, C2-helical domain linker, and the helical domain. To visualize the areas 
that have the largest changes in deuterium incorporation in the presence of p84, we integrated the 
average differences in exchange at all seven time points (Figure 7C). This analysis showed that 
PI3Kγ interacts with p84 predominantly with the helical domain, and that p84 protection clusters 
around S582. We did not map the interacting surface on p84, due to difficulties in expressing and 
purifying free p84 in a sufficient quantity for these studies. 
We were surprised to find that p84 interacts with PI3Kγ predominantly through the helical domain, 
as it has been postulated that this adaptor binds to the N-terminus of PI3Kγ, in analogy to p85 
binding to class IA PI3K. However, this assumption has never been analysed experimentally by 
means of N-terminal PI3Kγ truncation mutants. We generated a deletion mutant of PI3Kγ lacking 
the first 130 amino acids. Coimmunoprecipitation experiments using either HA-p84 (Figure 7D, 
left) or PI3Kγ (right) show that wild type GST-tagged PI3Kγ and GST-tagged truncated (∆130) 
PI3Kγ interact equally well with p84. The N-terminus is therefore not directly involved in p84 
binding. We do find a slight decrease in deuterium incorporation for two peptides in the N-terminal 
domain of PI3Kγ (59-70 and 107-113) in the presence of p84, this interaction however seems to be 
dispensable for p84 binding. Untagged truncated (∆130) PI3Kγ, in contrast to GST-∆130-PI3Kγ, 
interacts only weakly with p84, and also much less efficiently than untagged full-length PI3Kγ. The 
N-terminus of PI3Kγ is therefore required for the structural integrity of PI3Kγ and the p84 binding 
region. GST-tag attachment can complements this function, rescuing p84 binding.  
 
4.4 Discussion 
PI3Kγ is a key regulator of allergy controlling IgE/antigen-dependent mast cell degranulation 
(Laffargue M, Immunity, 2002). In order to develop new strategies to treat allergic disease it is of 
interest to understand how this lipid kinase is regulated. PI3Kγ has been shown to regulate mast cell 
hyperactivation by boosting PIP3 production by autocrine and paracrine released adenosine 
(Laffargue M, Immunity, 2002). Because the PI3Kγ–/– phenotype is not recapitulated by genetic and 
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pharmacological inhibition of adenosine and GPCR signalling in mice and cells (Saito H, J 
Immunol, 1987; Endo D, Int Arch Allergy Immunol, 2009; Laffargue M, Immunity, 2002), PI3Kγ 
activation by the FcεRI is incompletely understood. We found that Thapsigargin triggers 
degranulation in a PI3Kγ-dependent but GPCR-independent manner. We thereby run across a 
convenient tool to address non-canonical PI3Kγ activation in BMMCs. FcεRI-triggered granule 
exocytosis depends on store-operated Ca2+ entry and Thapsigargin directly triggers degranulation at 
this receptor-distal step. We show that PI3Kγ activation occurs downstream of Ca2+ mobilisation 
and that PKCβ relays Ca2+ signalling to PI3Kγ activation. We thereby unravelled for the first time a 
mechanism by which a protein tyrosine kinase (PTK)-coupled receptor activates PI3Kγ.  
That PI3K activation occurs downstream of Ca2+ mobilisation is reflected by several lines of 
evidence. First, studies with the PI3K-inhibitor Wortmannin have shown that initial PLCγ 
activation, inositol trisphosphate (IP3) production, and Ca2+ mobilisation are not affected by this 
drug (Tkaczyk C, J Biol Chem, 2003). Second, in the absence of Ca2+, FcεRI crosslinking fails to 
promote protein kinase B (PKB) phosphorylation (T308), which is strictly controlled by PI3K-
derived PIP3. Third, PI3K activation absolutely depends on PKCβ2, which requires Ca2+ for its 
activation. Fourth, if PI3K activation would occur upstream of Ca2+ mobilisation, Thapsigargin or 
ionophores would be expected trigger degranulation in a PI3K-independent manner (this study and 
(Marquardt DL, J Immunol, 1996)). In disagreement with this study, we initially observed defective 
Ca2+ mobilisation in PI3Kγ–/– BMMCs in response to IgE/DNP (Laffargue M, Immunity, 2002) or 
Thapsigargin (not shown) stimulation. This however, we found to be caused by Fura-2 release into 
the medium due to its property to partition into granules, leading to artificial Ca2+ signals in wild 
type BMMCs (Almers W and Neher E, FEBS Lett, 1985; Di Virgilio F, Cell Calcium, 1990; 
Vorndran C, Biophys J, 1995). In later experiments with other fluorescent Ca2+ chelators like Fura-
4F or Fura-FF no differences between wild type and PI3Kγ–/– BMMCs were observed (not shown).  
When mast cell degranulation was discovered to be Wortmannin-sensitive, it has been anticipiated 
that PTK-coupled FcεRI couples to class IA PI3K. By now PI3Kγ turned out to be the key PI3K, 
and also many other observations disfavour involvement of class IA PI3K. The most ubiquitously 
expressed class IA PI3K regulatory subunit p85α is not required for IgE-dependent mast activation 
in vivo in a model of passive systemic anaphylaxis and in BMMCs (Fukao T, Nat Immunol, 2002; 
Tkaczyk C, J Biol Chem, 2003). Moreover, p85α-p55α-p50α–/– fetal liver-derived mast cells 
(FLMCs) and p85β–/– BMMCs degranulate normally (Lu-Kuo JM, J Biol Chem, 2000; Tan BL, 
Blood, 2003; Tkaczyk C, J Biol Chem, 2003). Consistently, FcεRI regulatory chains do not contain 
consensus p85 binding motifs (YXXM) (Songyang Z, Cell, 1993). Despite the Gab2 adaptor protein 
was suggested to function as alternative p85 anchor in mast cell exocytosis (Gu H, Nature, 2001), 
other studies do not support this finding and connect Gab2 with other functions. FcεRI-triggered 
Gab2 tyrosine phosphoryation is only evident in serum-starved BMMCs, and the presence of serum 
is sufficient to fully trigger Gab2 tyrosine phosphorylation (compare (Gu H, Nature, 2001; Yu M, J 
Immunol, 2006) with (Hernandez-Hansen V, J Immunol, 2004)). Gab2 controls chemokine mRNA 
induction both at suboptimal and optimal antigen concentrations or FcεRI occupancy (Gonzalez-
Espinosa C, J Exp Med, 2003). Furthermore, degranulation is not affected by siRNA-mediated 
Results  33 
 
downregulation of Gab2 in BMMCs (Barbu EA, J Biol Chem, 2010). Analysis of PI3Kδ kinase 
dead BMMCs (D910A/ D910A) showed that PKB is readily activated following stimulation of the 
FcεRI in contrast to PI3Kγ–/– BMMCs (Ali K, Nature, 2004). Moreover, Thapsigargin or PMA 
trigger normal PKB phosphorylation in PI3KδD910A/D910A BMMCs (not shown). In vivo, decreased 
mast cell degranulation in the ear of PI3Kδ D910A/D910A mice correlates with the reduction in mast cell 
numbers at this location (Ali K, Nature, 2004). 
Despite protein kinase C (PKC) activation is known to be a key event to mast cell degranulation, its 
function and substrates remained obscure. By analysis of BMMCs derived from isoform-specific 
knock-out mice, PKCβ was identified to be essential for FcεRI- and ionomycin-triggered mast cell 
degranulation (Nechushtan H, Blood, 2000). We herein unravelled that PKCβ functions as PI3Kγ 
regulator in this process. We additionally show that direct activation of PKCβ by phorbol ester is 
sufficient trigger PI3K and PKB activation in mast cells. PMA by itself however does not trigger 
granule exocytosis, as membrane fusion in mast cells is additionally controlled by Ca2+-regulated 
steps. Interestingly, PKCβ-dependent PI3K activation depends on relatively high Ca2+ 
concentrations lying in the low micromolar range. With respect to this, in vitro studies have 
identified a special high Ca2+ requirement for the activation of PKCβ2 compared with PKCβ1 or 
PKCα (Keranen LM and Newton AC, J Biol Chem, 1997). Whereas PKCβ2 required a 40-fold 
greater Ca2+ concentration for half-maximal activation than membrane binding, this difference was 
only 10- and 2-fold for PKCβ1 and PKCα, respectively. Apart from PKCβ2, BMMCs also express 
high amounts of PKCα. Despite these two PKCs share high homology and substrate sequence 
specificity, PKCα can not complement for PKCβ. Of the two splice variants of PKCβ, mast cells 
express much more PKCβ2 than PKCβ1 (own observations, (Kawakami Y, J Immunol, 2000)). 
PKCβ1 and PKCβ2 differ only in their last 50-52 amino acids, but the specific role of the C-termini 
is unknown. As diacylglycerol (DAG) analogs enhance granule exocytosis or directly stimulate 
release in some exocytotic cell types, PKC has been proposed to regulate granule-membrane fusion 
(Morgan A, Biochem Soc Trans, 2005). However by now, other phorbol ester sensitive membrane 
fusion regulators have been identified, like e.g. the Munc-13 proteins (Kazanietz MG, Mol 
Pharmacol, 2002). FcεRI triggers phosphorylation of synaptosomal-associated protein 23 (SNAP-
23) in mast cells. Despite sensitive to PKC-inhibitors and PKCβ deficiency ((Hepp R, J Biol Chem, 
2005), own observations), inhibitor of NF-κB kinase β (IKKβ) is rather the direct kinase (Suzuki K 
and Verma IM, Cell, 2008). As only one of the two identified sites is conserved in humans, and 
SNAP-23 phosphorylation is only reported in this cell type, the relevance of this finding is currently 
unclear. Of note, the exocytotic machinery seems to be intact in PKCβ–/– BMMCs, as costimulation 
of the FcεRI with Kit rescues defective antigen-induced degranulation (Fehrenbach K, J Immunol, 
2009).  
Characterisation of recombinant PI3Kγ phosphorylation site mutants identified S582 as a switch 
site for PI3K activation. Unfortunately, we could not directly address increased PI3K signalling in 
vivo in a physiological environment, as it was impossible to express the phosphorylation-mimicking 
mutants at adequate levels in BMMCs. However, the strong expression defect of these mutants 
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likely results from a gain of function trait, as oncogenic PI3K mutants also showed impaired 
expression in several instances. Since nucleofection of BMMCs is not a gentle method for 
exogenous protein expression, we also tried lentivirus-based approaches. This unfortunately was 
hampered by the fast loss of transgene expression as well as toxicity problems with high viral titers. 
While exogenous expression of PI3Kγ activating mutants was severely and moderately impaired in 
BMMCs and Sf9 cells, respectively, expression was normal HEK293 cells. PI3K activation 
therefore depends on a second input that is provided by the cellular environment. To take account 
of cell type specific protein regulation, functional studies should therefore be preferentially done in 
physiologically relevant cell types. The most frequently occurring mutations in PI3Kα in cancer 
cluster to three hotspots, E542 and E545 in the helical and H1047 in the kinase domain (Samuels 
Y, Science, 2004). These mutations have been reported to promote PKB activation only in certain 
cell types like mammary epithelial cells (Zhao JJ, Cancer Cell, 2003; Zhao JJ, Proc Natl Acad Sci U 
S A, 2005; Isakoff SJ, Cancer Res, 2005; Pang H, Cancer Res, 2009) or some fibroblasts (Kang S, 
Proc Natl Acad Sci U S A, 2005; Zhao L and Vogt PK, Proc Natl Acad Sci U S A, 2008; Ikenoue T, 
Cancer Res, 2005), but not in HEK293 cells. 
S582 of PI3Kγ lays at the beginning of the helical domain, and is therefore located in the same 
domain region as most oncogenic helical domain-associated mutations found in PI3Kα (P539, 
Glu542, Glu545, and Q546) (Samuels Y, Science, 2004; Samuels Y and Velculescu VE, Cell Cycle, 
2004). These sites and other oncogenic PI3Kα mutations lie near or within the last four helices of 
the catalytic domain (Zhang X, Mol Cell, 2011). These helices form a square that surrounds the 
activation and catalytic loops. Reported mutations might therefore affect catalysis or lipid binding 
by allosteric mechanisms. The PI3Kγ helical domain folds into a stack of five A/B pairs of 
antiparallel helices (Walker EH, Nature, 1999). S582 sits in the B helix of the first helical pair. As 
the intrahelical loop of this helix pair contacts the regulatory helices of the catalytic domain, it might 
forward conformational changes resulting from S582 phosphoryation. Despite located at slightly 
distinct positions than S582, helical domain mutations of PI3Kα might affect lipid kinase activation 
by a similar mechanism. Whether these mutations induce structural changes, has not yet been 
investigated by X-ray crystallography.  
As S582 points inward of the crystal structure of PI3Kγ ∆143, the helical domain beginning, at least 
in the phosphorylated state, must adopt a different conformation. Since we found that untagged N-
terminally truncated PI3Kγ (∆130) is structurally impaired with respect to p84 binding compared to 
full-length PI3Kγ, it might be that PI3Kγ ∆143 folds improperly. Additionally, PI3Kγ ∆143 has a 
ten fold lower in vitro Ras binding affinity and probably also less basal activity, as it is expressed at 
highly elevated levels in BMMCs and Sf9 cells ((Pacold ME, Cell, 2000), and own observations). 
Whereas the catalytic loop of crystallised PI3Kγ ∆143 is locked in an inactive conformation (Walker 
EH, Nature, 1999; Pacold ME, Cell, 2000), active site loop residues of PI3Kδ (∆ABD) and Vsp34 
(∆C2) are oriented in a catalytically competent manner (Berndt A, Nat Chem Biol, 2010; Miller S, 
Science, 2010). Further, it is also feasible that PKCβ binding induces a conformational change that 
exposes S582. As endogenous PI3Kγ does not interact with p84 in BMMCs, it might be possible 
that PI3Kγ adopts different conformations in distinct cell types. 
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In vitro data show that PI3Kα helical domain mutations relieve inhibitory contacts between the N-
terminal SH2 domain (nSH2) of p85 and PI3Kα. This has been derived from investigation of 
charge-reversal mutations of PI3Kα and p85α and analysis of the crystal structure of the PI3Kα 
H1047R/p85α-niSH2 complex (Miled N, Science, 2007; Mandelker D, Proc Natl Acad Sci U S A, 
2009). Whereas the niSH2 fragment of p85 blocks the activity of monomeric wild type PI3Kα 2-
fold, PI3Kα helical domain hot spot mutants are not inhibited by p85 nor further activated by 
phosphopeptides (Miled N, Science, 2007; Carson JD, Biochem J, 2008). The relative importance of 
the release of p85-inhibition for net PI3Kα activation is not yet clear, as monomeric helical domain 
mutants are more active that monomeric wild type PI3Kα. Recombinant PI3Kα is less active that 
the helical domain mutants in vitro, and N-terminally truncated p85 binding defective PI3Kα is less 
oncogenic than the mutants in vivo, despite absence of p85-inhibition (Ikenoue T, Cancer Res, 
2005; Gymnopoulos M, Proc Natl Acad Sci U S A, 2007; Miled N, Science, 2007; Zhao L and Vogt 
PK, Proc Natl Acad Sci U S A, 2008). These mutations therefore not only relieve p85-binding but 
also inherently modulate PI3K activity. 
Apart from S582, PI3Kγ concomitantly also phosphorylates S257 in the Ras binding domain 
(RBD). The RBD is important for PI3Kγ regulation, as artificially engineered PI3Kγ RBD mutants 
are functionally dead in vivo (Suire S, Nat Cell Biol, 2006; Kang S, Proc Natl Acad Sci U S A, 2006; 
Kurig B, Proc Natl Acad Sci U S A, 2009). As the RBD around S257 is divergent in all class I 
PI3Ks, it is likely that this region modulates isoform-specificities. Consistently, also RBD mutants 
of PI3Kα and PI3Kβ as well as Dictyostelium or Drosophila PI3K show functional defects under 
certain conditions (Zhao L and Vogt PK, Proc Natl Acad Sci U S A, 2008; Zhao L and Vogt PK, 
Cell Cycle, 2010; Kang S, Proc Natl Acad Sci U S A, 2006; Sasaki AT, J Cell Biol, 2004; Orme MH, 
Nat Cell Biol, 2006). Whether S257 coregulates PI3Kγ activation in mast cells is unclear at the 
moment and needs further investigation. 
As PI3Kγ complexed to p84 could not be phosphorylated on S582, we unexpectedly obtained 
information on the p84 interaction site. We show that p84 binds to PI3Kγ through the helical 
domain beginning and not the N-terminal region, as has been anticipated in analogy to adaptor 
interaction in class IA PI3K. Despite the N-terminus of PI3Kγ is not involved in p84 binding, it is 
required for the structural integrity of the p84 binding site. Addition of a GST-tag compensates this 
function. It is possible that p101 also interacts with the helical domain of PI3Kγ, because our 
results are in consent with previous publications analysing the interaction of PI3Kγ with p101. 
Krugmann et al. showed reduced binding of p101 to different long (∆122-∆369) N-terminal 
deletion mutants of Myc- or His-tagged PI3Kγ, but they did not analyse mutants with a bulky GST-
tag (Krugmann S, J Biol Chem, 1999). This however was done by Maier et al., who efficiently 
copurified p101 with both full-length and truncated (∆97) GST-PI3Kγ from baculovirus-infected 
Sf9 cells (Maier U, J Biol Chem, 1999). 
PI3Kγ has been discovered by attempts to find the enzyme that makes the PIP3 downstream of G 
protein-coupled receptors (GPCRs) in myeloid cells (Stephens L, Cell, 1994; Stephens LR, Cell, 
1997; Stephens LR, Cell, 1997). It was found there to coexist in tight association with the adaptor 
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p101, which functions as PI3Kγ’s Gβγ-sensor (Stephens LR, Cell, 1997; Brock C, J Cell Biol, 2003; 
Suire S, Nat Cell Biol, 2006). Mast cells were the first cells discovered to express PI3Kγ but not 
p101 (Bohnacker T, Sci Signal, 2009), and therefore have to engage PI3Kγ differently – for example 
through the adaptor p84 or PKCβ. Besides mast cells, endothelial cells also express PI3Kγ but not 
p101 (Hsieh SN, Diss, 2003, Friedrich Schiller University, Jena, Germany), and therefore might also 
rely on PKC. Of note, PI3Kγ can also be regulated in a p101-independent manner in cells 
expressing p101. In neutrophils, p101 is required for migration towards fMLP or C5a, but is 
dispensable for reactive oxygen species (ROS) production (Suire S, Nat Cell Biol, 2006). PKC 
activation by phorbol ester also promotes PI3K/PKB activation in cell types other than mast cells, 
like 3T3-L1 adipocytes or primary human blood-derived B cells (Nave BT, Biochem J, 1996; 
Barragan M, J Leukoc Biol, 2006). These examples illustrate that PKC-PI3K pathways will likely be 
discovered to regulate more functions in more cells. 
 
4.5 Experimental procedures 
Cell Culture 
Bone marrow-derived mast cells (BMMCs) were developed from femoral bone marrow of 8-12 
week old C57BL/6J (Jackson Laboratories), PKCβ–/– (Leitges M, Science, 1996; Standaert ML, 
Endocrinology, 1999), and PI3Kγ–/– mice (Hirsch E, Science, 2000) (both on a C57BL/6J genetic 
background). Cells were cultured in IMDM supplemented with 10% heat-inactivated FCS, 2 mM L-
glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 50 µM β-mercaptoethanol, and 2 
ng/ml recombinant murine IL-3 (Peprotech). SCF (5 ng/ml) was added once after starting bone 
marrow culture, while IL-3 was readded every 2nd to 3rd day. BMMCs were used after 4 weeks of 
culture until generally 8 or maximally 16 weeks. c-Kit and FcεRI expression was followed by flow 
cytometry. HEK293 cells were cultured in DMEM supplemented with 10% FCS, Pen/Strep, and L-
Gln. 
 
Transfections 
HEK293 cells were seeded into 6 cm dishes and were transfected with JetPEITM (Polyplus-
transfection) using 2.5 µg of total plasmid DNA. BMMCs were transfected by nucleofection 
(Amaxa) using solution T and PI3Kγ (1-3 µg) and p84 (0.2-2 µg) expression plasmids where 
indicated. Total DNA concentrations were adjusted to 10 µg with pcDNA3 vector. 
 
Stimulation of BMMCs 
For stimulation of the FcεRI, BMMCs were passively sensitized with 100 ng/ml anti-dinitrophenyl 
(DNP)-specific immunoglobulin E (SPE-7, Sigma) overnight in complete growth medium. 
Degranulation was triggered by the addition of DNP coupled to human serum albumin (DNP30-40-
HSA) at concentrations between 5 and 100 ng/ml. For analysis of PKB phosphorylation, BMMCs 
were IL-3 starved in growth medium containing 2% or 10% FCS, and stimulations were stopped on 
ice, the cells immediately collected by centrifugation for 1 min at 2000 g, and lysed in 1x Laemmli 
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sample buffer. Other stimuli used were Thapsigargin (0.03125-1 µM, Sigma), phorbol 12-myristate 
13-actetate (PMA) (50-200 ng/ml, Alexis), adenosine (1 µM, Sigma), stem cell factor (SCF) (10 
ng/ml, Peprotech), and interleukin-3 (IL-3) (10 ng/ml, Peprotech). Stimulations were done at 37°C 
for the indicated times. 
 
(Co-)Immunoprecipitation 
Transfected HEK293 cells were washed with phosphate buffered saline (PBS) and lysed with NP-
40 lysis buffer [50 mM Tris/HCl pH 7.4, 138 mM NaCl, 2.7 mM KCl, 5% glycerol, 1% NP-40] 
supplemented with protease inhibitors [20 µM leupeptin, 18 µM pepstatin, 5 µg/ml aprotinin, 
phenylmethylsulfonylfluorid (PMSF)], phosphatase inhibitors [40 mM NaF, 2 mM Na3VO4], 0.5 
mM EDTA, and 0.5 mM EGTA for 15 min on ice. Insoluble material was pelleted by 
centrifugation and one-tenth of clarified lysate was mixed with Laemmli sample buffer for overall 
protein expression examination. The remainder of lysate was incubated with anti-PI3Kγ (ascites 
fluid, 641, corresponds to Jena Bioscience ABD-027) or anti-HA.11 (Covance) antibodies for 1 
hour at 4°C on a rotating wheel, followed by incubation with 25 µl of a 50% slurry of GammaBind 
Plus Sepharose (Amersham Biosciences) or protein G agarose (Millipore) for additional 2 hours. 
Immune complexes were washed 3x with NP-40 lysis buffer, 1x with 0.1 M Tris/HCl pH 7.4, 0.5 M 
LiCl2, 0.2% NP-40, 1x again with NP-40 lysis buffer, and eluted by the addition of Laemmli sample 
buffer. 
BMMCs were collected by centrifugation and lysed in NP-40 lysis buffer supplemented with 
protease inhibitors, phosphatase inhibitors [40 mM NaF, 10 mM β-glycerophosphate, 5 mM 
sodium pyrophosphate], 2 mM EDTA, and 2 mM EGTA for 15 min on ice. Cell debris was 
removed by centrifugation and endogenous or transfected PI3Kγ was immunoprecipitated from the 
cleared lysate with anti-PI3Kγ (ascites fluid, 641) antibodies (1-2 hours) and protein A or G agarose 
beads (2-5 hours). Immune complexes were washed as describe above before resuspension in 1x 
Laemmli sample buffer. Lysates and immunoprecipitations were analysed by Western blotting. 
 
Western blotting and quantification 
Protein samples were heated to 95°C, centrifuged, separated by SDS-PAGE, and transferred to 
polyvinylidene fluorid (PVDF)-membranes (Millipore) by semi-dry transfer. Membranes were 
blocked with 5% (w/v) milk powder (Migros) in TBS-T buffer [20 mM Tris/HCl, pH 7.6, 137 mM 
NaCl, 0.1% (v/v) Tween 20 (Fluka)]. Blots were incubated overnight at 4°C with the primary 
antibody, followed by incubation with horseradish peroxidase (HRP)-coupled secondary goat anti-
mouse or anti-rabbit antibodies (Sigma). Protein bands were visualized by enhanced 
chemiluminescence (Millipore). Developed X-ray films (Fuji) were scanned on an Epson Perfection 
scanner (4990 Photo) as 16-bit grayscale images without adjustments and inverted band intensities 
quantified with ImageJ 1.42q software (NIH) using the rectangle tool. Band pixel values were 
background corrected using an area above or below the selected band. Levels of protein 
phosphorylation were normalised to relative total protein levels and expressed in correlation to a 
freely chosen stimulated sample that was set to 1. 
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β-Hexosaminidase release  
Mast cell degranulation was assessed by measuring the release of β-hexosaminidase into cell 
supernatants (Schwartz LB, J Immunol, 1979; Ozawa K, J Biol Chem, 1993). Stimulations were 
done for 20 min in PIPES-buffered solution [25 mM PIPES pH 7.4, 119 mM NaCl, 5 mM KCl, 5.6 
mM glucose, 1 mM CaCl2, 0.4 mM MgCl2, 0.1 % fatty-acid free, low endotoxin bovine serum 
albumin (LE-BSA, Sigma)] in 24 well plates having 0.5 Mio cells in a volume of 500 µl. Plates were 
centrifuged at 4°C for 5 min and 100 µl aliquots (triplicate) of supernatant were transferred to 96 
well plates. Samples for measurement of total β-hexosaminidase were obtained by lysis of cells in 
unstimulated wells with PIPES-buffered solution/0.1% Triton X-100, and 100 µl aliquots were 
transferred to the 96 well plate. β-hexosaminidase activity was assessed by incubation with 100 µl of 
substrate solution [100 mM p-nitrophenyl-N-acetyl-β-D-glucosaminidine (p-NAG) in 0.1 M 
sodium acetate pH 4] for 1 h at 37°C. The reaction was stopped with 100 µl of 0.15 M 
Na2CO3/NaHCO3 and generated p-nitrophenol was quantified by measurement of absorbance at 
410 nm on a spectrophotometer (Spectramax 340). Background values were derived from lysed 
unstimulated cell pellets incubated without p-NAG. β-hexosamidinase release was calculated by the 
formula: Release (R) [%] = (AStimulated – AUnst.)/(ATotal unst. – ATotal background)*100. 
 
Cytosolic Ca2+ concentrations 
BMMCs were washed with and resuspended in HEPES buffer [10 mM HEPES/NaOH pH 7.5, 
137 mM NaCl, 2.7 mM KCl, 5 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 0.1 % fatty acid free BSA]. 
Cells were loaded with 4 µM Fura-4F/AM for 10 min, washed twice, and resuspended in HEPES 
buffer containing different Ca2+ concentrations ([Ca2+]e (extracellular) = 0 - 1 mM). Cells were stimulated 
in a continuously stirred cuvette at 37° in a fluorescence spectrometer (Perkin Elmer LS50B). The 
excitation wavelength was alternated between 340 and 380 nm and fluorescence emission was 
measured at 510 nm. Calibration and calculation of intracellular Ca2+ concentrations were done as 
described in the supplements. 
 
Cellular PdtIns(3,4,5)P3 measurements 
Cellular PtdIns(3,4,5)P3 levels have been measured as described (Arcaro A and Wymann MP, 
Biochem J, 1993) with some modifications. BMMCs were cultured for 2 hours in phosphate-free 
RPMI medium/2% FCS, and labelled metabolically with 1 mCi/ml [32P]-orthophosphate for 4 h. 
Cells were washed, stimulated, and lysed by the addition of chloroform/methanol (1:2, v/v, with 
butylated hydroxytoluene and carrier phosphoinositides). Lipids were extracted, deacylated, and 
separated by high performance liquid chromatography (HPLC). 
 
Production of recombinant PI3Kγ 
Recombinant human PI3Kγ was expressed as N-terminal GST- or C-terminal His6-tagged-fusion 
protein in Sf9 cells by infection with recombinant baculoviruses. Plasmid (pAcG2T-PI3Kγ, codons 
38-1102) and baculovirus for GST-PI3Kγ have been described (Stoyanov B, Science, 1995). Coding 
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sequences for full-length PI3Kγ-His6 and point mutants were inserted into pVL1393 (BD 
Biosciences), and recombinant baculoviruses were obtained by cotransfection of Sf9 cells with 
BaculoGold DNA (BD Biosciences). Baculovirus-infected Sf9 cells were harvested 2-2.5 days 
postinfection, were washed with PBS, und lysed with either GST- or His-lysis buffer [GST: 50 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM NaF, 1 mM DTT, 1% Triton-X100; His: 50 
mM NaH2PO4·2H2O/NaOH, pH 8, 300 mM NaCl, 20 mM imidazol, 5% glycerol, 1% NP-40] 
containing protease inhibitors. GST-PI3Kγ was purified on glutathione sepharose 4B (Amersham 
Biosciences) and eluted with 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 
5% glycerol, 20 mM glutathione after extensive washing. PI3Kγ-His6 was purified over Ni2+-NTA 
agarose (Qiagen) and eluted with 50 mM NaH2PO4·2H2O/NaOH, pH 8, 300 mM NaCl, 250 mM 
imidazol. Proteins were mixed 1:1 with 2x storage buffer [80 mM HEPES/NaOH pH 7.4, 4 mM 
EDTA, 2 mM DTT, 20 mM benzamidine, ~90% ethylenglycol] and kept at -20°C. Protein 
concentrations were quantified by Coomassie-staining in SDS-PAGE gels using the Odyssey 
infrared imaging system (LI-COR Biosciences). Bovine serum albumin served as standard.  
 
In vitro protein kinase assay 
Recombinant wild type (wt) and kinase inactive (K833R) GST-PI3Kγ was incubated at an equal 
molar ratio with recombinant PKCβ2 (40 ng) (Invitrogen) in 1x kinase buffer (KB) [50 mM 
HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 1 mM DTT, 0.03% Triton X-100] in the presence of 
10 µM ATP and 5 µCi of [γ32P]-ATP (Perkin Elmer) for 30 min at 30°C. Some samples included 
phosphatidylserine (PS, Sigma) lipid vesicles (0.1 mg/ml) containing 1-oleoyl-2-acetyl-sn-glycerol 
(OAG, 0.01 mg/ml, Cayman Chemical). Reactions were terminated by the addition of Laemmeli 
sample buffer, and proteins were resolved by SDS-PAGE, and stained with Coomassie dye (Serva 
blue G). Gels were dried on a Whatmann paper, exposed to X-ray films and storage phosphor 
screen, and 32P-incorporation quantified with ImageQuant TL Software (Amersham Biosciences). 
As standard served a dilution series of the radioactive ATP-mix spotted onto the Whatmann paper. 
 
In vitro lipid kinase assay 
PI3Kγ-His6 (200 ng) was incubated with PtdIns(4.5)P2-containing lipid vesicles, 10 µM ATP, and 4 
µCi of [γ32P]-ATP in buffer (LKB) [40 mM HEPES pH 7.4, 150 mM NaCl, 4 mM MgCl2, 1 mM 
DTT, 0.1 mg/ml fatty-acid free BSA] for 10 min at 30°C. Composition of the lipid vesicles has 
been chosen to mimic relative mole ratios found in the inner leaflet of the plasma membrane 
(PE/PS/PC/SM/PIP2 = 30/20/10/4.5/1.2). Lipids dissolved in CHCl3/MeOH (2:1) were 
combined in a glass tube, dried under a steam of nitrogen gas, and resuspended in 1x LKB without 
BSA by tip sonication (f. c. in assay: 130 µM PE, 87 µM PS, 43 µM PC, 20 µM SM, 5 µM PIP2). 
Alternatively PtdIns/PS vesicles (~200 µM each) were used. Reactions were terminated by addition 
of 1 M HCl and CHCl3/MeOH. Lipids were isolated by chloroform extraction, separated by TLC, 
and quantified with phosphoimager technology. 
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Mass spectrometry 
Coomassie-stained PI3Kγ was excised from the SDS-PAGE gel and digested with trypsin. 
Resultant peptides were analyzed by LC-MSMS. To identify phosphosites, peptide MS-MS spectra 
were analysed with Mascot searching the protein sequence database UNIPROT_15.6. Selective 
detection of the S582 and S257 phospho- and non-phosphopeptides was done later on with 
multiple reaction monitoring (MRM) analysing the transitions shown in Figure S2C and S3F. 
 
Deuterium exchange measurement 
Recombinant PI3Kγ alone or copurified with p84 was diluted into a D2O solution. Amide 
hydrogen/deuterium exchange was allowed to proceed for 7 time periods. Samples were injected 
into the pepsin-column and resulting peptides separated by HPLC and analysed by mass 
spectrometry and DXMS software (Sierra Analytics). 
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4.6 Figures 
 
Figure 1  Walser et al. 
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Figure 2  Walser et al. 
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Figure 3  Walser et al. 
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Figure 4 Walser et al. 
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Figure 5  Walser et al. 
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Figure 6 Walser et al. 
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Figure 7 Walser et al. 
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4.7 Figure legends 
 
Figure 1. PI3Kγ controls Thapsigargin-induced mast cell degranulation in a GPCR-independent 
manner. 
(A) Granule release of PI3Kγ–/– BMMCs was compared with wild type BMMCs by measuring the 
release of β-hexosaminidase into cell supernatants. BMMCs were resuspended in PIPES-buffered 
solution and pretreated for 15 min with 100 nM Wortmannin where indicated. Degranulation was 
triggered by crosslinking of IgE (100 ng/ml, overnight) occupied FcεRIs with DNP (10 ng/ml) or 
the addition of Thapsigargin (1 µM). Data are the mean ± SEM of three experiments (n = 3). 
(B) Granule release was assessed following 1 min preincubation with 10 units/ml adenosine 
deaminase (ADA). Stimulations and statistics were done as in (A). 
(C) Wild type or PI3Kγ–/– BMMCs were stimulated with adenosine (1 µM) or Thapsigargin (1 µM) 
for 2 min, and PKB S473 phosphorylation was analysed by Western blotting. Before stimulation, 
BMMCs were IL-3 starved in medium/2% FCS for 3 hours, and pretreated with ADA for 1 min 
where indicated. 
(D) Heterotrimeric G proteins were inactivated by preincubation with 100 ng/ml B. Pertussis toxin 
(PTx) for 4 hours. Wild type or PI3Kγ–/– BMMCs were stimulated and analysed as in (C). 
 
Figure 2. Thapsigargin-triggered PI3Kγ activation depends on an influx of extracellular Ca2+ and 
follows a switch-on kinetic mechanism. 
(A) BMMCs were IL-3 starved in medium/2% FCS for 3 hours and preincubated for 5 min where 
indicated with 5 mM EDTA before stimulation with 1 µM Thapsigargin or 1 µM ionomycin. PKB 
S473 phosphorylation was analysed by Western blotting.  
(B) BMMCs cultured as in (A) were pretreated for 10 min with the cell-permeable Ca2+ chelator 
BAPTA/AM (10 µM) and stimulated either with 10 ng/ml IL-3, 1 µM adenosine, or 1 µM 
Thapsigargin. PKB activation was analysed as in (A). 
(C) BMMCs were loaded with 4 µM Fura-4F/AM for 10 min in HEPES buffer containing 1 mM 
Ca2+. Washed cells were resuspended in the same buffer but in the presence of different Ca2+ 
concentrations (extracellular Ca2+, [Ca2+]e) to modulate maximal stimulation-induced intracellular 
Ca2+ levels ([Ca2+]i). Cells were stimulated with 0.5 µM Thapsigargin and intracellular Ca2+ increase 
and PKB activation were measured by Fura fluoresence or Western blotting, respectively. pPKB 
S473 levels are displayed as a function of [Ca2+]i. Data points come from two independently 
performed experiments. 
(D) Representative Western blot that was used to quantify phospho-PKB levels in panel (C).  
(E) Intracellular Ca2+ concentrations were measured in wild type BMMCs following stimulation 
with the A3 adenosine receptor agonist IB-MECA or Thapsigargin. B. Pertussis Toxin (100 ng/ml) 
was added 4 hours before stimulation where indicated. 
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Figure 3. PKCβ relays Thapsigargin-induced PI3Kγ activation. 
(A) Effect of different protein kinase C (PKC)-inhibitors on Thapsigargin-induced PKB 
phosphorylation (S473) was analysed by Western blotting and quantified with Image J software. 
Wild type BMMCs were starved in IL-3 free medium/2%FCS and preincubated with the inhibitors 
for 20 min before stimulation. pan-PKC inh.: Ro318425, Gö9683. cPKC-inh.: PKC412 
(CPG41251). c/aPKC-inh.: Gö6976. Rottlerin: broad acting inhibitor, not PKC-specific. 
(B) Granule release and PKB activation (S473) in response to Thapsigargin (1 µM) or IgE/DNP 
(100 ng/ml IgE overnight, 10 ng/ml DNP) was measured in the presence of increasing 
concentrations of the cPKC inhibitor PKC412. Starved cells as in (A) were stimulated and analysed 
for PKB phosphorylation by Western blotting or were resuspended in PIPES-buffered solution and 
used in a β-hexosaminidase release assay. Data are averages of three independent experiments (n = 
3) with different BMMC batches (error bars indicate SEM). 
(C) PKB activation in response to 100 nM PMA or 1 µM Thapsigargin (2 min) was analysed in wild 
type and PKCβ–/– BMMCs. Cells were starved as in (A) and were pretreated where indicated with 
100 nM Wortmannin (Wm) for 15 min before stimulation. Cell lysates were analysed by Western 
blotting for phoshorylation of PKB (T308 and S473) and MAPK (Thr183/Tyr185). 
(D) Wild type and PKCβ–/– BMMCs were stimulated with 1 µM adenosine, 10 ng/ml IL-3, or 10 
ng/ml SCF under conditions as described in (C). 
(E) FcεRI-triggered degranulation of wild type, PKCβ–/–, and PI3Kγ–/– BMMCs (cultured for 4-7 
weeks) was compared following stimulation with different DNP concentrations. BMMCs were 
saturated with IgE overnight (100 ng/ml) in complete growth medium, and were stimulated in 
PIPES-buffered solution in 24 well plates at a concentration of 1 Mio cells/ml. Data are the average 
of five independent experiments (error bars indicate SEM). 
(F/G) Intracellular PtdIns(3,4,5)P3 levels were measured in untreated (Ctrl) and cPKC-inhibitor 
(PKC412) treated wild type BMMCs as well as PKCβ–/– BMMCs after stimulation with 0.5 µM 
Thapsigargin, 200 ng/ml PMA, or 5 µM adenosine for 30 seconds. BMMCs were cultured for 2 
hours in phosphate-free medium/2%FCS and then metabolically labelled with 1 mCi/ml [32P]-
orthophosphate for 4 h. Cell stimulations were stopped by the addition of CHCl3/MeOH and lipids 
were extracted, deacylated, and separated by HPLC. Panel (F) shows representative elution peaks of 
PIP3 of the HPLC chromatograms. (G) Relative levels of PIP3 production were quantified by 
integration of the peak areas of PIP3 and PIP2 and expressed as ratio of PIP3/PIP2 (data show mean 
± SEM, n = 4-6).  
(H) Intracellular PIP3 production was measured over time in wild type BMMCs the presence or 
absence of the cPKC inhibitor PKC412 in response to PMA (200 nM) stimulation. Data are 
averages of three independent experiments ± SEM. 
 
Figure 4. PKCβ interacts with and phosphorylates PI3Kγ. 
(A) Schematic representation of the PKCβ2 constructs used for transfection into HEK293 cells 
(displayed without N-terminal HA-tag). Wild type full-length PKCβ2: amino acids (aa) 1-673, 
catalytic domain (cat): aa 302-673, pseudosubstrate deletion mutant (∆ps): deletion of aa 19-31. 
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Intramolecular inhibition of wild type PKCβ by the pseudosubstrate domain (ps) is relieved in cells 
upon cofactor binding (Ca2+, phosphatidylserine (PS), diacylglycerol (DAG)). The two deletion 
mutants are in an open conformation as they lack the ps domain. 
(B) HEK293 cells were cotransfected with plasmids encoding full-length PI3Kγ and HA-tagged 
PKCβ2 constructs (illustrated in (A)). Cells were lysed and a sample thereof was removed to control 
for proper protein expression (lower part). PI3Kγ or HA-PKCβ2 was immunoprecipitated with 
anti-PI3Kγ or anti-HA antibodies, respectively, from the rest of the lysate (upper part). 
Immuncomplexes were captured on protein G beads, washed, separated by SDS-PAGE, and 
analysed by Western blotting with antibodies against PI3Kγ, HA-tag, and β-tubulin. Ig: 
Immunoglobulin heavy chain of mouse anti-PI3Kγ or anti-HA antibody. 
(C) Recombinant GST-PI3Kγ wild type (wt) or kinase inactive mutant (KR, Lys 833 mutated to 
Arg) were incubated with recombinant PKCβ2, 10 µM ATP, and 5 µCi of [γ32P]-ATP in kinase 
buffer for 30 min. The reaction was stopped by the addition of Laemmeli sample buffer and the 
proteins were separated by SDS-PAGE. The dried gel was stained with Coomassie dye and exposed 
to X-ray films and storage phosphor screen. Shown are an autoradiograph and quantifications done 
with phosphorimager technology. Data represent the mean ± SEM of three experiments (n = 3). 
For optimal PKC activation, reaction mixtures contained 1 mM Ca2+. Where indicated, samples also 
contained phosphatidylserine (PS) vesicles containing the DAG analog 1-oleoyl-2-acetyl-sn-glycerol 
(OAG). Their presence did not further increase PKCβ autophosphorylation or trans-
phosphorylation. Addition of Triton X-100 was sufficient (own observation) to fully potentiate 
kinase activity of recombinant PKCβ, which already has a high inherent basal activity. 
(D) In vitro and in vivo phosphorylation of PI3Kγ on S582 as analysed by LC-MRM. S582 non-
phospho- and phospho-peptides were detected in the multiple reaction monitoring mode (MRM), 
quantifying the transition 501.1 to 709.3 for the non-modified peptide (blue) and 541.3 to 492.1 for 
the phospho-peptide (red). Data were normalised to the transition of the non-modified peptide, 
which was set to 1. Upper part: Recombinant human kinase dead GST-PI3Kγ (2 µg) was incubated 
alone, together with PKCβ2, or PKCβ2 and PKC-inhibitor (Ro318425, 2 µM) in the presence of 
100 µM ATP and PS/OAG vesicles in kinase buffer for 30 min. After SDS-PAGE and Coomassie 
staining, PI3Kγ was excised from the gel and prepared for LC-MRM. Lower part: Wild type mouse 
BMMCs (300 Mio/stimulation) were starved for 4 hours in IL-3 free medium/2% FCS and were 
left unstimulated or were treated for 2 min with 50 nM PMA or for 4 min with 10 ng/ml DNP 
(preloaded with 100 ng/ml IgE overnight). Endogenous PI3Kγ was immunoprecipitated from cell 
lysates, resolved by SDS-PAGE, and analysed with LC-MRM. 
(E) Comparison of the sequence around S582 with a PKCβ substrate motif determined by 
screening of a peptide library (Nishikawa K, J Biol Chem, 1997). Values in parentheses indicate 
relative selectivities for the amino acids (1 corresponds to no selectivity). 
(F) Alignment of the sequences adjacent to S582 of PI3Kγ from different species (obtained by 
protein blast). 
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Figure 5. Phosphorylation of PI3Kγ is Ca2+/PKCβ-dependent and regulates enzymatic activity. 
(A) Phosphorylation of endogenous PI3Kγ was analysed in wild type BMMCs in response to 
stimulation with 100 nM PMA, 1 µM Thapsigargin, 1 µM adenosine, or 20 ng/ml DNP for 2 min. 
If necessary, BMMCs were loaded with IgE (100 ng/ml) overnight (lanes 5, 6). Before stimulation, 
BMMCs were resuspended in IL-3 free growth medium. PI3Kγ was immunoprecipitated from 
lysates with an anti-PI3Kγ antibody and protein A agarose beads. Lysate samples and immuno-
precipitations were analysed by Western blotting with the indicated antibodies. PI3Kγ 
phosphorylation was quantified with ImageJ software, normalised to total PI3Kγ levels, and 
expressed as fold of the signal obtained by PMA. Data are the mean of three experiments (n = 3) ± 
SEM. 
(B) IgE (100 ng/ml, overnight) loaded BMMCs were resuspended in growth medium without IL-3. 
Cells were pretreated for 5 min with 0.5 mM EDTA or EGTA, or for 10 min with 10 µM 
BAPTA/AM to capture either extracellular or intracellular Ca2+, respectively. Cells were stimulated 
for 30 s with DNP (100 ng/ml) and PI3Kγ phosphorylation and PKB activation were analysed as in 
(A) (n = 3, error bars indicate SEM). 
(C) Phosphorylation of PI3Kγ was compared between wild type and PKCβ–/– BMMCs. PI3Kγ–/– 
BMMCs were included into the experiment as negative control. Experimental settings were as in 
(A) and stimulations were done with 50 nM PMA or 20 ng/ml DNP. Western blots of one 
experiment are shown on the left. Bar graphs on the right show the quantification of PI3Kγ 
phosphorylation in PKCβ–/– BMMCs relative to wild type BMMCs (PMA n = 4, DNP n = 3, error 
bars indicate SEM). 
(D) Lipid kinase activities of recombinant PI3Kγ wild type (wt) and phosphorylation site mutants 
(S582A, S582E) were analysed in the presence of mixed phospholipid vesicles containing 
PtdIns(4,5)P2 as substrate (PE/PS/PC/SM/PIP2 = 30/20/10/4.5/1.2). PIP3 production was 
detected by autoradiography after extraction of the lipids and separation by thin layer 
chromatography. Shown are autoradiographs, quantifications done with phosphoimager system, 
and Coomassie stained SDS-PAGE gels of samples where no lipids but Laemmeli sample buffer 
was added instead. Data shown are the mean ± SEM of three experiments (n = 3) each done in 
triplicate.  
(E) Lipid kinase activity of recombinant PI3Kγ wt, S582A, and S582E towards phosphatidylinositol 
(PI) was measured using PI-phosphatidylserine (PS) vesicles. PI3P production was quantified and 
data represented as described in (D). Data are the mean of a triplicate experiment. 
(F) Expression plasmids of PI3Kγ wild type (wt) and S582 point mutants were transfected into 
PI3Kγ–/– BMMCs by nucleofection (Amaxa). Next day (2x) or after 8 hours (1x) cell lysates were 
prepared and protein expression analysed by SDS-PAGE and immunoblotting. PI3Kγ expression 
levels were quantified with ImageJ software, normalised to α-tubulin, and expressed as fold of wild 
type (wt) PI3Kγ (mean ± SEM, n = 3). 
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Figure 6. S582 phosphorylation requires adaptor-free PI3Kγ. 
(A) PI3Kγ and increasing amounts of p84 plasmids were transfected into PI3Kγ–/– BMMCs by 
nucleofection (Amaxa). Wild type and transfected PI3Kγ–/– BMMCs were stimulated with 200 nM 
PMA for 30 s. PI3Kγ was immunoprecipitated from cell lysates with an anti-PI3Kγ antibody and 
protein G beads. p84 binding and S582 phosphorylation were detected by Western blotting, 
quantified with ImageJ software, normalised to PI3Kγ protein levels, and plotted as fold of maximal 
values, which were set to 1. Proper exogenous protein expression was analysed by Western blotting 
of cell lysates (bottom). Data show mean ± SEM of n = 2 experiments. 
(B) PI3Kγ wild type, S582A, and phosphorylation mimicking mutants (S582E, S582D) were 
expressed together with p84 in PI3Kγ–/– BMMCs by cotransfection of 1.5 µg of each plasmid 
DNA. PI3Kγ was immunoprecipitated from cell lysates and p84 binding was analysed by Western 
blotting and quantification with ImageJ software. Data were normalised to PI3Kγ wt and 
represented as mean ± SEM of n = 3 experiments. 
(C) Same plasmids as used in (B) were transfected into HEK293 cells and PI3Kγ-p84 association 
was analysed by co-immunoprecipitation assays, Western blotting, and Odyssey infrared imaging 
system. Results from PI3Kγ wt and HA-p84 transfections were set to 1. Data are shown as mean ± 
SEM (left: IP of HA-p84, n = 4, 4, 8, 3; right: IP of PI3Kγ, n = 2 all lanes). 
(D) PI3Kγ-p84 interactions were analysed in wild type and transfected PI3Kγ–/– BMMCs. 
Exogenously expressed or endogenous PI3Kγ was immunoprecipitated from cell lysates and p84 
binding was analysed by Western blotting. Shown are representative blots of a quadruplet 
experiment. 
(E) Wild type BMMCs were mock-transfected or with GFP-PI3Kγ. Endogenous and GFP-PI3Kγ 
were immunoprecipitated from cell lysates and interaction with endogenous p84 was analysed by 
Western blotting. Shown are representative blots of a triplicate experiment. 
 
Figure 7. p84 interacts primarily with the helical domain of PI3Kγ. 
(A) Changes in deuteration levels between free and p84-bound PI3Kγ are mapped onto the crystal 
structure of PI3Kγ (PDB ID: 2CHX). Regions that are covered by peptides of PI3Kγ (labelled A-
Q) that showed greater than 0.5 or 1.0 Da changes in deuteration are colored light or dark blue, 
respectively. The greatest difference in exchange observed at any time was used for the mapping. 
Ser582 is highlighted as red spheres. The ATP competitive inhibitor PIK-90 in the crystal structure 
is shown in green as a reference point for the kinase domain. The linker regions between the RBD 
and the C2 domain and the C2 and the helical domain are shown as dashed lines. Domain coloring 
was done the following: RBD: purple, C2 domain: light brown, helical domain: green, kinase 
domain: dark grey. 
(B) The number of incorporated deuteriums in the absence (•) and presence (o) of p84 at seven 
time points are shown for peptides with more than 1.0 Da exchange difference. Data represent 
mean ± SD of two independent experiments. 
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(C) The deuterium exchange differences between free and p84-bound PI3Kγ were summed up over 
all seven time points for every identified peptide (x-axis), which were graphed according to their 
central residue number (y-axis).  
(D) p84 was coexpressed with GST-tagged or untagged PI3Kγ constructs in HEK293 cells. N-
terminal deletions of 37 or 130 amino acids are denoted ∆37 or ∆130, respectively. HA-p84 (left) or 
PI3Kγ (right) was immunoprecipitated from cell lysates with anti-HA or anti-PI3Kγ antibodies and 
protein G beads. PI3Kγ-p84 interactions were analysed by Western blotting and Odyssey infrared 
imaging system and expressed as fold of untagged, full-length PI3Kγ-p84 association. Data show 
mean ± SEM (left: n = 4, 6, 6, 6; right: n = 2, 4, 4, 4). 
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4.8 Supplemental figures 
 
Figure S1 Suppl. to Figure 3 
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Figure S2 Suppl. to Figure 4 
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Figure S3 Suppl. to Figure 5 
 
 
Results  57 
 
 
 
Results  58 
 
 
 
 
Results  59 
 
Figure S4 Suppl. to Figure 7 
 
 
Results  60 
 
Figure S5 Suppl. to Figure 7 
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4.9 Supplemental figure legends 
Figure S1. Related to Figure 3. 
(A/B) Effect of different protein kinase C (PKC)-inhibitors on PMA or adenosine induced PKB 
phosphorylation (S473) was analysed by Western blotting and quantified with Image J software. 
Wild type BMMCs were starved for 3 hours in IL-3 free medium/2%FCS and preincubated with 
the inhibitors for 20 min before stimulation. pan-PKC inh.: Ro318425, Gö9683. cPKC-inh.: 
PKC412 (CPG41251). c/aPKC-inh.: Gö6976. Rottlerin: broad acting inhibitor, not PKC-specific. 
(C) PKB activation in response to 100 nM PMA or 1 µM Thapsigargin (2 min) was analysed in wild 
type, PKCα–/–, and PKCγ–/– BMMCs. Before stimulation cells were starved as in (A/B). Cell lysates 
were analysed for PKB (S473) and MAPK (Thr183/Tyr185) phosphorylation by Western blotting. 
(D) Wild type, PKCβ–/–, and PI3Kγ–/– BMMCs (cultured for 4-7 weeks) were stimulated with 
different concentrations of Thapsigargin and degranulation was quantified by measuring release of 
β-hexosaminidase into cell supernatants. Data are the average of three independent experiments ± 
SEM. 
 
Figure S2. Related to Figure 4. 
(A/B) Identification of PI3Kγ phosphorylation sites by MS. Recombinant kinase-inactive GST-
PI3Kγ (amino acids 38-1102) was phosphorylated in vitro by recombinant PKCβ in the presence of 
100 µM ATP/[γ32P]-ATP. Proteins were separated by SDS-PAGE and trypsin-digested PI3Kγ was 
analysed by LC-MSMS. (A) Enhanced product ion spectra of the tryptic phospho-S582-peptide of 
PI3Kγ. The y- and b-fragments detected are indicated in the sequence. Fragments showing a H3PO4 
loss are marked with an asterisk. The b2, y6, and y7 fragments allow assignment of the 
phosphorylation to serine 3 in the peptide. (B) Enhanced product ion spectra of the non-
phosphorylated form of this peptide.  
(C) Relevant information for the MRM analysis of the peptides containing Ser582. The amino acid 
numbering is as in Swiss-Prot entry P48736. 
(D) Sequence alignment of the beginning of the helical domain of class I PI3Ks. Alignments were 
done by inspection of the crystal structures of PI3Kγ (1E8Y), PI3Kα (3HHM), PI3Kβ (2Y3A), and 
PI3Kδ (2WXR). Secondary structure elements are labelled as indicated in the legend. S582 is 
colored red, while cancer-associated PI3Kα mutations are marked as blue. 
 
Figure S3. Related to Figure 5. 
(A) Wild type BMMCs were transfected with empty vector or expression plasmids for GFP-PI3Kγ 
wild type or GFP-PI3Kγ S582A. Next day cells were stimulated with 200 nM PMA for 45 seconds, 
and PI3Kγ was immunoprecipitated from cell lysates. Specificity of the anti-phospho-S582 
antibodies was validated by Western blotting. 
(B) Autophosphorylation of recombinant wild type PI3Kγ-His6 and S582 mutants was analysed in 
the presence of 10 µM ATP/[32P]-ATP in kinase buffer. For background measurement, reactions 
were also performed the presence of 0.5 µM Wortmannin (Wm). Band intensities were quantified 
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with phosphoimager technology and data are expressed as fold of autophosphorylation of PI3Kγ 
wt. Data represent two triplicate experiments ± SEM. 
(C/D) Identification of PI3Kγ phosphorylation sites by MS. Recombinant kinase-inactive GST-
PI3Kγ (residues 38-1102) was phosphorylated in vitro by recombinant PKCβ2 in the presence of 
100 µM ATP/[γ32P]-ATP. Proteins were separated by SDS-PAGE and trypsin-digested PI3Kγ was 
analysed by LC-MSMS. (C) Enhanced product ion spectra of the tryptic phospho-S257-peptide of 
PI3Kγ. The y- and b-fragments detected are indicated in the sequence. Fragments showing a H3PO4 
loss are marked with an asterisk. The b3, b7, y10, and y12 fragments allow assignment of the 
phosphorylation to serine 3 in the peptide. (D) Enhanced product ion spectra of the non-
phosphorylated peptide that starts with KSLM... Shown fragmentations are derived from precursors 
with oxidized methionine. 
(E) In vitro and in vivo phosphorylation of PI3Kγ on S257 as analysed by LC-MRM. Data come 
from the same protein samples used to measure S582 phosphorylation (see figure 4D). Upper part: 
In vitro phosphorylated recombinant human PI3Kγ. The transitions 713.4 to 704.4 for the non-
modified peptide (blue) and 782.7 to 993.5 for the phosphopeptide (red) are shown. Lower part: In 
vivo phosphorylated mouse PI3Kγ. Monitored were the transition from 709.7 to 777.4 for the non-
modified peptide (blue) and the transitions from 779.0 to 1209.0, 906.5, and 746.0 for the 
phosphopeptide (red). Transitions of the non-modified peptides were set to 1 and used to 
normalize the data. 
(F) Relevant information for the MRM analysis of the peptides containing Ser257. The amino acid 
numbering is as in Swiss-Prot entries P48736 and Q9JHG7.  
(G) Kinetics of PI3Kγ phosphorylation on S257 and S582 were analysed with respect to time. 
BMMCs were IL-3 starved for 1 hour and stimulated with either 100 ng/ml DNP (pretreated with 
100 ng/ml IgE overnight) or 1 µM Thapsigargin. PI3Kγ was immunoprecipitated from cell lysates 
and phosphorylation was analysed by Western blotting and quantification with ImageJ software. 
Data were normalised to phospho-PI3Kγ/PI3Kγ values of 0.5 min stimulation with DNP or 6 min 
with Thapsigargin, which were set to 1. Data are mean values ± SEM of three separate experiments 
(n = 3). 
(H) Lipid kinase activities of recombinant PI3Kγ wild type, S257 mutants, and S257/S582 double 
mutants were measured by an in vitro kinase assay using mixed phospholipid vesicles containing 
PIP2 as substrate. Extracted lipids were separated by thin layer chromatography and PIP3 
production was quantified by phosphoimager technology. Data represent mean ± SEM of a 
triplicate experiment. 
(G) Comparison of the sequence around S257 with a PKCβ substrate motif determined by 
screening of a peptide library (Nishikawa K, J Biol Chem, 1997). Values in parentheses indicate 
relative selectivities for the amino acids (1 corresponds to no selectivity). 
(H) Alignment of the sequences adjacent to S257 of PI3Kγ from different species (obtained by 
protein blast). 
(I) Sequence alignment of the Ras binding domain (RBD) of class I PI3Ks near to S257 of PI3Kγ. 
Secondary structure assignments were done by inspection of the crystal structures of PI3Kγ (1E8Y, 
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1HE8), PI3Kα (3HHM), PI3Kβ (2Y3A), and PI3Kδ (2WXR), and are labelled as indicated in the 
legend. S257 is colored red. Mutated residues of published engineered inactivating PI3K RBD 
mutants are colored blue (DASAA) (Suire S, Nat Cell Biol, 2006) or are underlined (e.g. PI3Kγ 
K255E) (Kang S, Proc Natl Acad Sci U S A, 2006).  
(J) BMMCs were stimulated with 5 µM adenosine, 200 nM PMA, 0.5 µM Thapsigargin, or 10 
ng/ml IL-3 for 2 min. Cleared lysates were incubated with recombinant GST-RBD (of Raf) to 
capture active GTP-loaded endogenous Ras. Copurified Ras was detected by immunoblotting with 
a mix of anti-H-, anti-K-, anti-N-, and anti-pan-Ras antibodies. 
 
Figure S4. Related to Figure 7. 
PI3Kγ domain order and peptide coverage after pepsin digestion. Identified and analyzed peptides 
are shown under the primary sequence of PI3Kγ, which has been colored according to the domain 
boundaries shown above. Light or dark red lines represent peptides with greater than 0.5 or 1.0 Da 
changes in deuteration in the absence and presence of p84, respectively. Gray bars indicate peptides 
continued in the next line of the sequence. 
 
Figure S5. Related to Figure 7. 
Changes in deuteration levels of PI3Kγ in the presence of p84. Peptides spanning PI3Kγ (labelled 
A-Q) that showed greater than 0.5 Da changes in deuteration in the presence and absence of p84 
were mapped onto the crystal structure of PI3Kγ (PDB ID: 2CHX, residues 144-1093). The 
greatest difference in exchange observed at any time was used for the mapping. Ser582 is shown as 
red balls. The ATP competitive inhibitor PIK-90 is shown in green as a reference point for the 
kinase domain. The linker regions between the RBD and the C2 domain and the C2 and helical 
domain are shown as dashes lines. Domain coloring was done the following: RBD: purple, C2 
domain: light brown, helical domain: green, kinase domain: dark grey. The graphs are showing the 
number of incorporated deuteriums in the presence (o) and absence (•) of p84 at seven time points 
for peptides with more than 0.5 Da exchange difference. The last two graphs represent peptides 
with <0.5 Da deuteration changes. Data represent mean ± SD of two independent experiments. 
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4.10 Supplemental table and legend 
      PI3Kγ      PI3Kγ + p84   
Time 
Z #D S E 3 10 30 100 300 1000 3000 3 10 30 100 300 1000 3000 
1 5 5 12 85% 86% 86% 89% 90% 94% 86% 86% 84% 85% 85% 87% 89% 85% 
1 4 6 12 76% 74% 75% 77% 75% 74% 75% 81% 78% 80% 79% 80% 80% 80% 
1 3 36 41 3% 4% 5% 7% 11% 16% 19% 4% 4% 5% 6% 11% 14% 17% 
1 3 38 42 2% 4% 6% 6% 5% 7% 6% 9% 4% 3% 3% 4% 12% 9% 
2 13 42 58 28% 30% 31% 37% 39% 41% 45% 28% 27% 30% 33% 38% 41% 44% 
3 13 42 58 27% 29% 31% 36% 39% 41% 44% 27% 26% 30% 33% 37% 40% 42% 
4 13 42 58 27% 29% 30% 36% 38% 41% 44% 28% 27% 30% 33% 38% 40% 44% 
2 10 59 70 6% 9% 12% 14% 18% 22% 29% 6% 8% 11% 13% 15% 18% 23% 
1 9 60 70 6% 7% 10% 12% 14% 19% 26% 6% 7% 9% 12% 13% 15% 18% 
2 9 60 70 5% 7% 9% 12% 14% 19% 25% 5% 6% 8% 10% 12% 15% 18% 
1 3 71 75 2% 3% 2% 3% 2% 3% 5% 6% 7% 4% 7% 8% 12% 11% 
1 4 71 76 3% 2% 3% 4% 6% 8% 9% 3% 2% 3% 4% 4% 5% 6% 
1 6 77 84 51% 50% 51% 51% 50% 50% 50% 54% 52% 54% 53% 53% 54% 54% 
1 4 79 84 48% 61% 65% 74% 76% 76% 78% 47% 55% 62% 72% 76% 76% 76% 
3 9 87 98 4% 5% 3% 7% 8% 8% 11% 5% 4% 7% 5% 8% 6% 9% 
2 8 88 98 6% 8% 9% 11% 12% 14% 17% 5% 6% 7% 8% 10% 10% 12% 
3 9 88 99 4% 5% 6% 7% 8% 8% 11% 4% 4% 5% 6% 7% 7% 9% 
1 5 100 106 32% 40% 52% 57% 56% 57% 59% 32% 37% 48% 56% 58% 60% 61% 
1 5 107 113 25% 31% 38% 46% 50% 52% 50% 18% 18% 26% 39% 51% 53% 54% 
2 5 107 113 25% 29% 37% 45% 51% 52% 54% 18% 21% 29% 40% 50% 54% 55% 
2 11 107 119 9% 12% 16% 20% 26% 33% 37% 6% 7% 11% 16% 22% 27% 33% 
1 4 114 119 0% -1% -1% -1% 0% 2% 7% 0% -2% -2% -2% -2% 6% 3% 
1 6 114 121 19% 19% 19% 20% 21% 25% 30% 14% 16% 20% 20% 22% 23% 26% 
2 13 122 137 4% 5% 8% 13% 17% 19% 21% 4% 4% 6% 10% 16% 20% 21% 
3 12 123 137 7% 8% 9% 13% 18% 21% 25% 6% 7% 9% 12% 17% 20% 26% 
1 4 138 145 4% 4% 4% 8% 13% 21% 24% 6% 7% 6% 9% 14% 21% 25% 
2 4 138 145 6% 6% 10% 10% 18% 23% 47% 6% 6% 6% 8% 12% 18% 43% 
2 8 138 149 33% 37% 39% 50% 52% 54% 56% 33% 33% 39% 46% 51% 53% 52% 
1 6 150 157 -1% -1% 0% 4% 11% 17% 24% -1% -1% 0% 6% 13% 17% 23% 
2 6 150 157 3% 4% 5% 8% 14% 25% 28% 3% 4% 6% 9% 14% 20% 25% 
1 5 151 157 5% 3% 5% 10% 18% 22% 28% 4% 3% 5% 9% 17% 24% 27% 
2 5 151 157 4% 4% 5% 9% 17% 30% 34% 6% 5% 6% 11% 23% 31% 35% 
1 5 158 164 11% 13% 15% 24% 36% 45% 53% 21% 16% 22% 31% 44% 51% 59% 
2 12 161 174 20% 26% 28% 33% 37% 41% 46% 25% 28% 32% 35% 41% 45% 47% 
1 7 165 173 13% 22% 26% 32% 33% 32% 34% 18% 21% 27% 30% 32% 32% 32% 
2 7 165 173 15% 24% 27% 32% 37% 36% 36% 19% 22% 28% 30% 37% 34% 33% 
1 8 165 174 17% 24% 26% 31% 33% 35% 38% 18% 22% 26% 28% 32% 36% 36% 
1 7 174 182 2% 2% 3% 4% 8% 13% 16% 2% 3% 2% 3% 5% 11% 14% 
1 7 186 195 11% 19% 19% 25% 32% 40% 47% 15% 19% 21% 25% 34% 43% 47% 
2 7 186 195 11% 17% 20% 25% 32% 40% 48% 13% 15% 19% 24% 32% 41% 47% 
2 11 196 211 22% 25% 29% 35% 39% 42% 47% 23% 23% 29% 32% 37% 42% 45% 
3 11 196 211 22% 25% 28% 35% 38% 42% 46% 22% 23% 28% 31% 36% 41% 44% 
1 5 212 218 39% 45% 51% 60% 67% 69% 71% 47% 48% 55% 61% 69% 72% 72% 
2 5 212 218 43% 50% 55% 66% 72% 74% 76% 45% 46% 55% 63% 70% 73% 75% 
1 8 212 221 20% 26% 30% 41% 49% 53% 57% 19% 21% 27% 35% 48% 52% 56% 
2 8 212 221 25% 31% 28% 43% 52% 55% 56% 24% 29% 26% 42% 50% 54% 54% 
1 9 222 232 28% 27% 27% 29% 30% 33% 36% 28% 27% 28% 29% 30% 33% 35% 
2 9 233 245 8% 9% 10% 14% 18% 21% 25% 10% 10% 10% 14% 19% 22% 27% 
4 18 249 269 48% 48% 48% 51% 50% 50% 52% 49% 47% 50% 49% 52% 52% 53% 
2 10 270 281 -11% -12% -10% -10% -8% -8% -6% -9% -9% -11% -10% -9% -7% -7% 
1 7 273 281 1% 2% 3% 4% 6% 5% 7% 3% 1% 4% 6% 2% 3% 5% 
2 7 273 281 2% 2% 2% 2% 3% 4% 5% 3% 3% 3% 4% 3% 3% 4% 
1 7 282 291 10% 9% 9% 10% 10% 11% 15% 8% 7% 7% 6% 9% 9% 13% 
2 7 282 291 6% 8% 9% 10% 10% 11% 14% 7% 6% 6% 7% 8% 8% 11% 
2 9 292 302 5% 11% 15% 21% 21% 21% 23% 6% 8% 16% 19% 21% 21% 22% 
3 9 292 302 5% 11% 15% 21% 21% 21% 23% 7% 10% 17% 21% 23% 22% 22% 
2 8 303 315 12% 9% 13% 17% 20% 23% 22% 12% 9% 16% 16% 20% 22% 24% 
2 9 316 327 25% 28% 31% 39% 45% 50% 55% 24% 26% 28% 34% 39% 44% 49% 
1 6 328 335 67% 64% 64% 66% 66% 66% 68% 48% 51% 60% 65% 65% 67% 67% 
2 9 340 350 26% 23% 24% 25% 26% 25% 26% 15% 16% 18% 22% 23% 23% 23% 
3 9 340 350 25% 23% 23% 24% 24% 24% 25% 17% 17% 20% 23% 25% 24% 27% 
2 9 370 381 31% 35% 39% 47% 55% 56% 58% 33% 33% 38% 46% 53% 56% 57% 
2 11 382 394 9% 13% 15% 17% 19% 21% 25% 10% 11% 14% 15% 18% 20% 23% 
2 10 383 394 8% 13% 14% 16% 18% 21% 25% 9% 11% 14% 15% 18% 20% 22% 
1 7 386 394 15% 21% 23% 26% 30% 35% 41% 15% 17% 21% 23% 26% 32% 37% 
2 7 386 394 16% 24% 25% 28% 31% 34% 41% 21% 24% 24% 25% 30% 34% 42% 
2 9 395 407 11% 13% 16% 22% 25% 28% 32% 13% 13% 17% 20% 25% 29% 31% 
3 9 395 407 11% 13% 15% 22% 26% 28% 32% 12% 13% 17% 20% 25% 29% 32% 
1 4 408 413 15% 27% 32% 37% 42% 52% 62% 13% 19% 29% 35% 42% 51% 57% 
2 12 414 428 7% 10% 11% 15% 20% 22% 25% 8% 9% 8% 11% 14% 17% 20% 
2 9 417 428 3% 5% 8% 13% 19% 23% 30% 3% 2% 4% 5% 6% 11% 21% 
3 9 417 428 3% 4% 7% 11% 17% 22% 27% 4% 3% 4% 5% 8% 13% 20% 
2 7 432 441 45% 43% 45% 50% 54% 55% 54% 42% 40% 43% 45% 48% 53% 53% 
4 27 432 462 31% 30% 32% 34% 35% 35% 36% 30% 31% 32% 35% 35% 37% 35% 
1 4 461 466 0% 0% 0% 0% 0% 1% 0% -1% -1% 0% 0% 0% 1% -1% 
1 4 463 468 0% 1% 1% 5% 14% 20% 21% 5% 4% 2% 5% 11% 15% 25% 
2 7 467 475 1% 1% 7% 7% 13% 14% 14% 2% 1% 2% 8% 11% 11% 11% 
2 11 485 497 48% 47% 48% 52% 55% 55% 56% 44% 44% 45% 47% 51% 51% 52% 
2 13 498 513 17% 20% 23% 29% 35% 41% 47% 17% 18% 21% 25% 31% 36% 38% 
3 13 498 513 18% 21% 24% 30% 36% 42% 47% 18% 18% 21% 25% 31% 34% 38% 
2 15 498 515 14% 17% 20% 26% 31% 35% 41% 14% 15% 18% 23% 28% 32% 34% 
3 15 498 515 14% 16% 19% 26% 31% 36% 41% 14% 15% 18% 23% 28% 31% 34% 
1 7 520 529 33% 35% 41% 51% 52% 50% 51% 19% 21% 25% 31% 36% 37% 40% 
2 7 520 529 35% 37% 43% 51% 52% 51% 51% 20% 21% 25% 31% 37% 40% 45% 
3 24 520 551 39% 39% 42% 45% 47% 46% 48% 34% 34% 36% 39% 41% 43% 45% 
4 24 520 551 39% 39% 42% 45% 47% 46% 48% 34% 33% 35% 38% 41% 42% 45% 
5 24 520 551 35% 36% 39% 42% 43% 42% 45% 29% 30% 32% 35% 38% 37% 42% 
2 5 552 558 15% 15% 19% 18% 18% 24% 26% 19% 18% 17% 25% 36% 23% 25% 
2 13 557 573 32% 36% 42% 49% 57% 60% 64% 22% 23% 29% 37% 45% 53% 58% 
2 12 558 573 31% 35% 41% 48% 56% 58% 61% 24% 25% 30% 38% 47% 53% 56% 
2 14 558 575 27% 29% 35% 41% 50% 52% 58% 15% 19% 23% 32% 38% 42% 46% 
2 5 572 578 12% 14% 29% 33% 44% 49% 60% 14% 5% 6% 6% 9% 25% 35% 
1 3 574 578 9% 11% 15% 19% 27% 32% 37% -1% 0% 1% 2% 5% 13% 22% 
2 3 574 578 17% 21% 25% 29% 37% 43% 48% 5% 5% 8% 9% 13% 21% 31% 
2 5 574 580 13% 17% 24% 29% 38% 39% 43% 6% 6% 10% 15% 21% 25% 34% 
2 10 579 592 15% 21% 28% 36% 45% 47% 48% 5% 7% 12% 17% 26% 38% 47% 
3 8 581 592 15% 25% 32% 41% 50% 52% 54% 9% 14% 15% 20% 33% 39% 47% 
1 7 593 601 17% 28% 40% 55% 65% 67% 69% 9% 7% 15% 25% 43% 59% 66% 
2 7 593 601 18% 22% 39% 53% 64% 65% 66% 6% 13% 25% 27% 56% 60% 64% 
1 4 602 607 23% 31% 41% 52% 69% 76% 81% 21% 8% 12% 20% 38% 52% 75% 
1 4 606 611 19% 28% 37% 46% 65% 73% 79% 10% 6% 17% 21% 33% 48% 64% 
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      PI3Kγ      PI3Kγ + p84   
Time 
Z #D S E 3 10 30 100 300 1000 3000 3 10 30 100 300 1000 3000 
2 10 611 622 50% 54% 54% 56% 57% 57% 59% 52% 51% 53% 53% 56% 56% 56% 
2 9 612 622 51% 53% 52% 55% 54% 54% 55% 53% 51% 53% 52% 55% 54% 54% 
1 6 623 630 19% 29% 39% 45% 57% 70% 77% 8% 9% 18% 21% 28% 38% 54% 
1 5 636 642 15% 19% 25% 32% 38% 45% 53% 12% 12% 14% 16% 22% 28% 32% 
2 5 636 642 15% 18% 24% 31% 37% 44% 53% 11% 11% 13% 15% 20% 25% 31% 
1 6 643 650 13% 14% 19% 23% 30% 35% 45% 12% 13% 15% 15% 18% 24% 34% 
2 6 643 650 12% 15% 18% 24% 31% 37% 48% 13% 13% 14% 16% 19% 25% 35% 
2 7 643 651 12% 14% 16% 20% 27% 32% 41% 11% 12% 13% 14% 18% 21% 30% 
1 5 651 657 3% 3% 4% 6% 9% 13% 18% 3% 2% 3% 4% 9% 19% 20% 
1 6 655 662 12% 11% 8% 14% 24% 31% 39% 11% 11% 7% 11% 20% 32% 38% 
2 6 655 662 1% 3% 5% 10% 20% 30% 36% 3% 3% 4% 9% 20% 29% 37% 
1 7 655 663 2% 2% 3% 8% 20% 25% 31% 1% 2% 1% 7% 15% 25% 31% 
2 7 655 663 1% 2% 4% 9% 18% 27% 32% 1% 1% 3% 7% 16% 26% 32% 
1 3 658 662 4% 6% 8% 13% 24% 31% 33% 4% 4% 6% 10% 19% 29% 32% 
1 4 658 663 0% 1% 1% 4% 17% 25% 25% 1% 1% 1% 4% 17% 25% 21% 
2 4 658 663 -3% -2% 0% 7% 15% 20% 22% 4% 4% 4% 7% 16% 21% 26% 
3 12 663 677 3% 4% 5% 6% 7% 7% 9% 3% 3% 4% 5% 6% 6% 7% 
2 11 664 677 3% 4% 6% 7% 8% 9% 10% 2% 2% 5% 6% 7% 7% 8% 
3 11 664 677 4% 5% 6% 8% 8% 9% 10% 2% 3% 4% 5% 8% 7% 8% 
4 14 698 713 4% 5% 6% 9% 12% 17% 20% 4% 4% 5% 8% 13% 17% 21% 
1 9 719 729 0% 1% 3% 7% 10% 16% 25% -1% 0% 4% 8% 12% 21% 29% 
1 8 720 729 2% 6% 9% 12% 14% 19% 27% 3% 3% 6% 9% 12% 19% 28% 
2 8 720 729 3% 5% 9% 13% 16% 24% 31% 4% 4% 7% 10% 15% 22% 33% 
1 6 730 737 1% 1% 1% 1% 1% 1% 1% 1% 0% 0% 0% 0% 1% 1% 
1 4 742 747 9% 17% 28% 40% 51% 61% 69% 7% 12% 23% 38% 48% 60% 68% 
1 5 748 754 69% 69% 71% 75% 76% 77% 81% 77% 74% 75% 75% 77% 77% 78% 
2 18 748 767 64% 62% 63% 64% 66% 64% 66% 64% 62% 63% 64% 64% 65% 65% 
2 11 755 767 64% 68% 69% 66% 70% 73% 74% 61% 65% 68% 68% 69% 70% 72% 
1 4 762 767 3% 4% 4% 6% 8% 11% 24% 9% 2% 2% 4% 7% 12% 17% 
2 12 768 782 30% 37% 46% 62% 67% 67% 69% 31% 35% 46% 58% 66% 67% 66% 
3 12 768 782 30% 39% 45% 59% 64% 64% 66% 31% 34% 45% 56% 64% 65% 65% 
1 5 783 791 2% 1% 2% 3% 7% 11% 13% 0% 1% 1% 2% 5% 10% 11% 
2 5 783 791 -3% -1% 1% 3% 5% 6% 10% 0% 1% 5% 2% 5% 7% 8% 
2 10 783 796 3% 3% 3% 6% 12% 18% 22% 3% 3% 3% 7% 12% 18% 22% 
3 10 783 796 3% 3% 5% 7% 12% 18% 21% 4% 3% 3% 6% 12% 18% 21% 
4 16 797 815 7% 7% 10% 13% 15% 16% 18% 6% 7% 8% 11% 15% 17% 17% 
1 7 816 825 36% 41% 49% 60% 65% 67% 69% 34% 36% 45% 55% 61% 63% 65% 
1 4 824 829 30% 38% 43% 52% 55% 56% 60% 38% 40% 51% 56% 55% 56% 63% 
2 11 830 842 4% 6% 10% 15% 18% 19% 21% 3% 3% 8% 13% 16% 19% 21% 
3 11 830 842 2% 5% 8% 13% 16% 20% 21% 2% 3% 7% 13% 19% 19% 20% 
1 3 844 848 4% 3% 6% 7% 16% 5% 4% 1% 6% 6% 7% 9% 6% 5% 
1 5 849 855 1% 1% 0% 0% 5% 6% 3% 0% 0% 0% -1% 6% -1% 1% 
1 4 859 864 0% 0% 1% 4% 1% 1% 1% 7% 0% 1% 1% 1% 2% 1% 
2 13 863 878 4% 4% 4% 8% 13% 17% 21% 4% 4% 4% 6% 12% 16% 21% 
2 12 865 878 4% 5% 5% 8% 11% 14% 17% 4% 4% 4% 6% 9% 12% 16% 
2 14 865 880 3% 6% 6% 8% 8% 11% 12% 3% 3% 3% 7% 8% 11% 12% 
1 7 870 878 5% 6% 6% 10% 15% 18% 22% 6% 5% 6% 8% 14% 18% 21% 
1 7 879 887 22% 31% 37% 45% 50% 53% 55% 26% 31% 36% 45% 51% 54% 56% 
2 7 879 887 26% 34% 39% 44% 53% 52% 54% 28% 41% 40% 41% 48% 52% 54% 
2 12 888 901 46% 45% 47% 51% 54% 58% 63% 43% 43% 45% 48% 50% 55% 59% 
4 21 888 910 23% 25% 28% 29% 32% 34% 38% 23% 24% 27% 28% 31% 34% 36% 
1 7 902 910 7% 9% 9% 11% 17% 21% 23% 5% 5% 6% 7% 11% 14% 17% 
3 6 911 919 9% 9% 8% 11% 15% 19% 22% 6% 4% 5% 6% 8% 11% 16% 
3 11 911 924 14% 16% 19% 23% 27% 32% 41% 15% 13% 18% 22% 27% 33% 40% 
1 5 920 926 4% 11% 12% 13% 12% 16% 20% 4% 4% 4% 7% 8% 14% 21% 
1 8 925 934 3% 2% 1% 1% 2% 1% 3% 3% 1% 0% 2% 1% 0% 2% 
1 4 929 934 1% 1% 1% 2% 2% 2% 2% 1% 2% 1% 2% -1% 1% 0% 
1 3 935 939 -4% -4% -4% -4% -4% -4% -4% 0% 1% 2% 2% 2% 1% -1% 
2 12 940 953 2% 1% 2% 3% 5% 7% 9% 2% 1% 2% 3% 5% 7% 8% 
3 12 940 953 1% 1% 2% 2% 4% 7% 9% 1% 1% 2% 2% 4% 7% 8% 
1 5 954 960 4% 7% 10% 18% 22% 25% 28% 4% 5% 10% 17% 22% 25% 28% 
2 10 961 972 29% 30% 31% 34% 36% 35% 38% 29% 28% 31% 31% 34% 34% 36% 
3 10 961 972 27% 29% 30% 33% 35% 34% 37% 28% 27% 30% 31% 33% 34% 36% 
2 13 961 975 32% 33% 33% 36% 38% 37% 40% 33% 33% 36% 35% 37% 37% 37% 
3 13 961 975 35% 34% 34% 37% 37% 37% 40% 34% 32% 33% 33% 36% 36% 38% 
2 14 961 976 38% 39% 40% 42% 44% 43% 46% 38% 37% 39% 39% 41% 42% 43% 
3 14 961 976 38% 39% 40% 41% 43% 42% 44% 38% 37% 40% 39% 41% 42% 43% 
2 9 962 972 34% 36% 38% 41% 42% 43% 45% 35% 35% 37% 40% 40% 42% 44% 
3 12 976 991 8% 8% 9% 13% 16% 15% 18% 10% 10% 17% 15% 19% 18% 20% 
3 13 976 992 12% 11% 12% 16% 19% 18% 21% 13% 11% 14% 16% 19% 19% 21% 
2 11 977 991 12% 11% 14% 17% 20% 20% 21% 12% 11% 12% 16% 20% 20% 21% 
3 11 977 991 13% 13% 14% 18% 20% 22% 24% 14% 13% 13% 17% 20% 23% 22% 
2 9 980 992 3% 4% 6% 8% 11% 12% 12% 3% 2% 4% 8% 12% 10% 14% 
2 11 993 1006 16% 15% 16% 20% 22% 23% 27% 16% 15% 16% 20% 21% 23% 22% 
3 11 993 1006 21% 20% 19% 22% 26% 28% 31% 18% 19% 18% 22% 26% 25% 29% 
1 5 1007 1013 3% 3% 2% 3% 4% 3% 5% 7% 4% 6% 0% 5% 3% 6% 
1 6 1007 1014 2% 3% 3% 3% 4% 4% 5% 2% 2% 1% 1% 4% 2% 4% 
2 6 1007 1014 0% 0% -2% -1% 0% 4% 1% 3% 2% -1% -1% 2% 1% 1% 
2 11 1015 1027 1% 2% 2% 3% 6% 8% 9% 1% 1% 1% 2% 5% 8% 9% 
3 11 1015 1027 3% 3% 4% 5% 8% 10% 13% 2% 2% 2% 3% 6% 9% 10% 
1 6 1019 1026 8% 10% 11% 13% 17% 24% 24% 13% 16% 13% 17% 25% 20% 21% 
2 6 1019 1026 7% 7% 7% 10% 15% 17% 19% 11% 11% 10% 15% 20% 23% 19% 
1 3 1031 1035 -3% -2% -2% -2% -1% 1% 2% -2% -1% -1% -1% -1% 0% -1% 
2 9 1035 1046 7% 12% 13% 16% 17% 20% 25% 7% 9% 12% 14% 17% 20% 24% 
2 12 1035 1049 30% 34% 37% 44% 50% 52% 56% 31% 31% 36% 43% 49% 54% 56% 
1 5 1043 1049 27% 33% 36% 45% 54% 61% 64% 30% 29% 32% 37% 51% 58% 62% 
1 6 1043 1050 21% 23% 31% 39% 49% 57% 62% 20% 18% 25% 33% 44% 54% 59% 
2 6 1043 1050 22% 23% 28% 38% 47% 52% 56% 22% 20% 23% 31% 41% 49% 52% 
1 4 1050 1055 1% 2% 1% 0% -1% -1% -1% 9% 1% 1% 0% 0% -1% 0% 
3 18 1050 1069 11% 10% 10% 12% 12% 14% 18% 11% 10% 9% 9% 10% 12% 17% 
3 20 1050 1071 9% 10% 10% 11% 12% 14% 16% 9% 9% 10% 9% 11% 12% 14% 
4 20 1050 1071 10% 11% 11% 13% 14% 15% 17% 10% 10% 11% 12% 14% 15% 18% 
2 19 1051 1071 11% 11% 11% 13% 13% 14% 17% 11% 11% 10% 11% 12% 13% 15% 
3 19 1051 1071 10% 11% 10% 12% 12% 13% 16% 11% 10% 11% 11% 12% 12% 15% 
4 19 1051 1071 10% 10% 11% 12% 13% 13% 16% 11% 10% 11% 10% 11% 14% 15% 
4 21 1051 1073 9% 9% 10% 11% 12% 12% 14% 11% 10% 11% 11% 12% 12% 13% 
2 11 1072 1084 12% 17% 23% 34% 41% 41% 42% 13% 15% 23% 33% 40% 41% 42% 
3 11 1072 1084 12% 16% 21% 32% 39% 41% 44% 11% 13% 22% 32% 38% 41% 42% 
1 6 1085 1092 31% 38% 49% 58% 57% 59% 58% 31% 34% 44% 55% 61% 59% 62% 
2 6 1085 1092 22% 39% 57% 66% 69% 68% 66% 23% 34% 55% 69% 72% 72% 71% 
1 3 1088 1092 37% 63% 69% 74% 74% 73% 75% 43% 53% 68% 73% 75% 76% 77% 
 
Relative % deuteration 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% 55% 60% 65% 70%-95% 
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Table S1. Related to Figure 7. 
Deuterium exchange data of all analysed peptides (202 peptides) of PI3Kγ in the absence or 
presence of p84 are summarized in tabular form. Percent hydrogen deuterium exchange was 
calculated for each of the seven time points and colored according to the legend. Data show the 
mean of two independent experiments. The charge state (Z), maximal number of exchangeable 
amide hydrogens (#D), starting residue number (S), and ending residue number (E) are displayed 
for every peptide.  
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5. Discussion 
 
5.1 Allergy depends on PI3K 
In allergy mast cells are activated through the high-affinity receptor for IgE (FcεRI). Receptor 
crosslinking by IgE/allergen engages the mast cells full mediator release program, leading to 
granule exocytosis and the production of lipid mediators, cytokines, and chemokines. Preformed 
granule stored histamine and both stored and newly synthesized TNFα exert very broad and potent 
effector functions. Through activation of the H1 receptor, histamine induces vascular leakage, 
tissue swelling, smooth muscle contraction, and cytokine production. TNFα on the other hand 
upregulates and activates adhesion molecules on blood vessels and thereby promotes the 
recruitment of neutrophils and eosinophils, and as well, stimulates cytokine production. 
Pharmacological targeting of these molecules or cognate receptors has proofed useful to combat 
allergy-associated symptoms. However, their dedication is limited to some inflammatory conditions, 
and more powerful drugs that for example already interfere with mediator secretion would be 
beneficial. Since early on it has been recognized that phosphoinositide 3-kinase (PI3K) is essential 
to antigen-induced mast cell activation, making it to an interesting drug target. However the 
mechanisms of PI3K activation and regulation by the FcεRI are incompletely understood and 
controversial. This study confirms PI3Kγ’s central role in mast cell degranulation and opens insight 
into novel regulation mechanisms. 
 
5.2 Ca2+ mobilisation triggers PI3K activation in mast cells 
We have shown that the class IB PI3K isoform PI3Kγ controls mast cell activation in vivo by 
IgE/antigen in a model of passive systemic anaphylaxis (Laffargue M, Immunity, 2002). By analysis 
of PI3Kγ–/– bone marrow-derived mast cells (BMMCs), we found that PI3Kγ partially controls mast 
cell degranulation by integrating autocrine and paracrine GPCR-derived signals into the FcεRI 
pathway. Synergistic signalling readily allows intracellular barriers to be overcome, leading to 
massive mast cell degranulation. Here we showed that the FcεRI also directly couples to PI3Kγ 
independently of GPCRs. Signalling to degranulation requires to overcome a threshold 
concentration of intracellular Ca2+. Thapsigargin and other Ca2+ mobilising agents are widely used 
to trigger exocytosis at this receptor-distal step. We show that PI3Kγ–/– BMMCs fail to degranulate 
in response to Thapsigargin, and thereby identify the step of PI3Kγ activation to be downstream of 
the Ca2+ signal. Thapsigargin thereby activates PI3Kγ independently of autocrine-released adenosine 
and other GPCR-ligands, since Thapsigargin-induced degranulation is insensitive to the treatment 
with adenosine deaminase or B. Pertussis Toxin (Figure 1). Initially we observed reduced Ca2+ 
mobilisation in PI3Kγ–/– BMMCs in response to IgE/DNP (Laffargue M, Immunity, 2002, Fig. 1A) 
or Thapsigargin (not shown). This however, we found to be derived from artificial Ca2+ signals in 
wild type BMMCs caused by Fura-2's property to partition into granules leading to dye release into 
the medium upon stimulation (Almers W and Neher E, FEBS Lett, 1985; Di Virgilio F, Cell 
Calcium, 1990; Vorndran C, Biophys J, 1995). In later experiments with other fluorescent Ca2+ 
chelators like Fura-4F or Fura-FF no differences between wild type and PI3Kγ–/– BMMCs were 
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observed (PI3K in signalling and disease, abstract, 2003, Katja Björklöf). As Thapsigargin does not 
activate PI3Kγ in the presence of Ca2+ chelators, Ca2+ influx is the trigger that activates PI3Kγ 
(Figure 2A, B). Interestingly, threshold levels for PI3Kγ activation lay in the low micromolar range 
(Figure 2C), which cells only can achieve by the uptake of external Ca2+. Other receptors, like some 
GPCRs, that promote low Ca2+ signals by internal store depletion can not couple to “Ca2+-
sensitive” PI3Kγ (Figure 2E). FcεRI crosslinking triggers a strong and sharp rise of intracellular 
Ca2+ followed by a plateau phase of sustained decayed Ca2+ influx (reviewed in (Ma HT and Beaven 
MA, Crit Rev Immunol, 2009)). Several evidence indicate that PI3K activation by the FcεRI occurs 
downstream of the initial peak of Ca2+ mobilisation. First, in the absence of Ca2+, FcεRI 
crosslinking fails to promote protein kinase B (PKB) activation, which is strictly controlled by 
PI3K-derived PIP3 (Figure 5B). Second, studies with the PI3K-inhibitor Wortmannin have shown 
that initial PLCγ activation, inositol trisphosphate (IP3) production, and Ca2+ mobilisation are not 
affected by this drug (Tkaczyk C, J Biol Chem, 2003). In some studies reduced Ca2+ mobilisation 
was reported owing to Fura-2-dependent artefacts (Lam RS, Cell Physiol Biochem, 2008). Third, 
PI3K activation absolutely depends on PKCβ2 (Figure 3), which requires Ca2+ for its activation. 
Fourth, if PI3K activation would occur upstream of Ca2+ mobilisation, degranulation triggered by 
Thapsigargin or ionophores should be Wortmannin-insensitive and PI3K-independent which is not 
the case (Figure 1) (Marquardt DL, J Immunol, 1996). FcεRI-induced Ca2+ mobilisation is regulated 
by PLCγ, which is cooperatively activated by Syk, LAT1, and SLP-76 (Kambayashi T, Mol Cell Biol, 
2010). LAT1 anchors PLCγ directly but also recruits it through SLP-76 (Saitoh S, J Exp Med, 2003). 
Impaired LAT1 signalling is partially rescued through LAT2 redistribution into the LAT1 
compartment leading to recruitment of SLP-76-PLCγ by this adaptor. LAT1-LAT2 double 
knockout BMMCs show a complete block of PLCγ activation and Ca2+ mobilisation (Zhu M, J Exp 
Med, 2004; Kambayashi T, Mol Cell Biol, 2010). Data on PKB activation in LAT deficient BMMCs 
have been published only in two studies. Unexpectedly, Roget K. et al. reported unimpaired PKB 
activation in both LAT1–/– and LAT1-LAT2–/– BMMCs (stimulation time, DNP concentration 
unknown) (Roget K, J Immunol, 2008). But also unexpectedly, these cells as well as the wild type 
BMMCs showed a SHIP–/– or Lyn–/– like phenotype, at least insofar as degranulation was not 
inhibited at supraoptimal antigen concentrations (Gimborn K, J Immunol, 2005; Hernandez-
Hansen V, J Immunol, 2004). Concurrently they also reported a role for LAT in negative signalling 
(Malbec O, J Immunol, 2004; Roget K, J Immunol, 2008). The route of PI3K activation has not 
been analysed in these studies. Reduced SHIP activation with concomitant continued PIP3 
accumulation might have been responsible for PKB activation. Consistently, in another report, 
PKB activation was greatly reduced at 2 min in LAT1–/– BMMCs, but was normal at late timer 
points (Kambayashi T, Immunol Rev, 2009). Alternatively, these cells might have gained the ability 
to activate PI3K by other means. In studies done by other groups, LAT deficient BMMCs showed 
normal inhibition of degranulation at supraoptimal antigen concentrations (Saitoh S, Immunity, 
2000; Saitoh S, J Exp Med, 2003; Zhu M, J Exp Med, 2004). Whether reduced degranulation 
correlates with reduced PI3K activation has not been investigated in these reports. It can be 
speculated that the different behaviour of LAT–/– BMMCs of distinct groups is related to the age of 
Discussion  69 
 
 
the mast cells, which over prolonged culture time loose inhibitory control mechanisms or gain new 
functions. Whatsoever, it would be important to analyse PKB activation at optimal antigen 
concentrations and at early time points, when PIP3 levels are not influenced by defects in SHIP 
activation. Furthermore, interpretation of adaptor knock-out phenotypes is complicated by the 
multifunctionality of these proteins. In this respect, analysis of LAT knock-in BMMCs harboring 
specific protein binding site mutations would be interesting. 
 
5.3 PI3Kδ, p85 regulatory subunits, Gab2, and Fyn are not direct regulators of the 
FcεRI 
While PI3K is accepted as an essential controller of FcεRI-induced mast cell degranulation, the role 
of individual family members and their mode of activation have been controversial. Apart from 
PI3Kγ, PI3Kδ has been reported to control mast cell degranulation (Ali K, Nature, 2004). 
Additionally, there has been provided evidence, but also disproof, for a role of tyrosine kinase Fyn 
and the adaptor protein Gab2 as PI3K and degranulation regulators (Parravicini V, Nat Immunol, 
2002; Gu H, Nature, 2001). 
In vivo the most ubiquitously expressed class IA PI3K regulatory subunit p85α is not required for 
IgE-dependent mast activation in a model of passive systemic anaphylaxis (Fukao T, Nat Immunol, 
2002). Consistently, p85α–/– BMMCs also degranulate normally (Fukao T, Nat Immunol, 2002; 
Tkaczyk C, J Biol Chem, 2003). It might be possible that p85α function is compensated by another 
“p85” regulatory subunit. However, p85α-p55α-p50α–/– fetal liver-derived mast cells (FLMCs) also 
readily degranulate, despite class IA PI3K expression and PI3K activation, as assessed by loss of 
proliferation and migration in response to stem cell factor (SCF), is severely compromised in these 
cells (Lu-Kuo JM, J Biol Chem, 2000; Tan BL, Blood, 2003). Importantly, PIP3 downregulation by 
SHIP seems to be intact, as these cells do not show a phenotype of exaggerated PKB activation. As 
for p85α, genetic deletion of p85β also does not impair degranulation of BMMCs (Lu-Kuo JM, J 
Biol Chem, 2000; Tkaczyk C, J Biol Chem, 2003). 
In vivo mast cell degranulation in the ear of PI3Kδ kinase inactive (D910A/D910A) as well as 
Gab2–/– mice is reduced by half compared with wild type mice, which correlates well with the 
reported 50% reduction in mast cell numbers at this location (Ali K, Nature, 2004; Yu M, J Biol 
Chem, 2006; Nishida K, Blood, 2002). Peculiarly, degranulation has been reported being reduced by 
50% in PI3KδD910A/D910A BMMCs, despite PKB was readily activated in these cells in response to 
stimulation of the FcεRI. In regard of these in vivo and in vitro results, unambiguous interpretation 
of PI3Kδ function is not possible and needs further investigation. 
Gab2 is a widely expressed adaptor protein with an N-terminal PIP3-selective PH domain, several 
tyrosine and serine/threonine phosphorylation sites, and two proline-rich motifs. Gab2 has been 
implicated in growth factor and cytokine signalling in cultured cells (Gu H, Mol Cell, 1998; Nishida 
K, Blood, 1999), but its concrete physiological roles in vivo are unknown, and Gab2–/– mice have 
been reported to be generally healthy (Gu H, Nature, 2001). Gab2 functions have mainly been 
studied in mast cell, yielding to controversial results. Whereas IgE/antigen-induced PI3K activation 
and mast cell degranulation have been reported to be reduced in Gab2–/– BMMCs (Gu H, Nature, 
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2001), Gab2 downregulation by siRNA had no effect on degranulation (Barbu EA, J Biol Chem, 
2010). In agreement with a role of Gab2 in FcεRI signalling, stimulation of wild type BMMCs 
induced or increased Gab2 phosphorylation (Gu H, Nature, 2001; Yu M, J Immunol, 2006; 
Parravicini V, Nat Immunol, 2002). However, in another study, where stimulation was done in 
serum-containing medium, no change of Gab2 phosphorylation following FcεRI activation was 
reported (Hernandez-Hansen V, J Immunol, 2004). Interestingly, Gab2 has been shown to control 
chemokine mRNA (MIP-1α/β, MCP-1) induction both at suboptimal and optimal antigen 
concentrations and FcεRI occupancy (Gonzalez-Espinosa C, J Exp Med, 2003). Further, 
transcription of the MCP-1 gene has also been observed to be induced in IgE loaded mast cells 
(Saitoh S, Immunity, 2000). As Gab2 phosphorylation and signalling in vitro seems to be influenced 
by mast cell starvation and stimulation conditions, Gab2 might affect FcεRI signalling through mast 
cell steady state and well-being modulation. Overall, the discussed publications rather ascribe a 
minor role of Gab2 to mast cell degranulation, as observed impairments likely result from indirect 
effects (reduced mast cell numbers in vivo, serum starvation in vitro).  
While having an controversial role in FcεRI signalling, PI3Kδ, p85α, and Gab2, all regulate in some 
way mast cell homing to certain body locations (Ali K, Nature, 2004; Fukao T, Nat Immunol, 2002; 
Gu H, Nature, 2001; Nishida K, Blood, 2002; Yu M, J Biol Chem, 2006). In the corresponding 
knock-out or knock-in mice, mast cell numbers in the peritoneal cavity and intestine are severely 
reduced and reach only half-normal levels in the ear dermis. Additionally, p85α and Gab2–/– mice 
also have almost no mast cells in the stomach, which is less affected in PI3KδD910A/D910A mice. Mast 
cell homing and maintenance in vivo depends on Kit receptor activation by stem cell factor (SCF) 
(reviewed in (Galli SJ, Am J Pathol, 1993)). Activated Kit autophosphorylates on several tyrosine 
residues and thereby switches on diverse effector pathways, which separately or in cooperation 
regulate mast cell survival, proliferation, migration, and adhesion (Serve H, EMBO J, 1995; 
Timokhina I, EMBO J, 1998; Kissel H, EMBO J, 2000; Kimura Y, Proc Natl Acad Sci U S A, 
2004). PI3Kδ is the principal Kit-coupled PI3K isoform, being recruited mainly by p85 binding to 
phosphorylated tyrosine 719 on Kit (Yee NS, J Biol Chem, 1994). How and whether Gab2 
connects to Kit is unknown at present. Since SCF-induced PI3K activation in not affected in  
Gab2–/– BMMCs (Yu M, J Biol Chem, 2006), this adaptor might control Kit responses by a separate 
or downstream pathway. PI3Kδ and p85α control mast cell adhesion, chemotaxis, and proliferation 
(Ali K, Nature, 2004; Ali K, J Immunol, 2008; Lu-Kuo JM, J Biol Chem, 2000; Fukao T, Nat 
Immunol, 2002; Tan BL, Blood, 2003). While Gab2 also regulates mast cell proliferation, especially 
at high SCF concentrations (Nishida K, Blood, 2002; Yu M, J Immunol, 2006), a possible role in 
movement has not been investigated yet. The mechanism by which Gab2 regulates mast cell tissue 
homing is unknown, but might involve Kit signalling and/or growth factor-induced gene 
transcription in mast or tissue cells. All in all, current knowledge collectively assigns important roles 
to PI3Kδ in Kit signalling, whereas GPCRs and the FcεRI mainly couple to PI3Kγ. 
While Lyn controls the phosphorylation of the FcεRI β- and γ-chains and thereby initiates Syk 
activation and Ca2+ mobilisation (Nishizumi H and Yamamoto T, J Immunol, 1997), another 
protein tyrosine kinase, Fyn, has been suggested to control PI3K activation in mast cells (Parravicini 
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V, Nat Immunol, 2002). Follow-up studies however reported conflicting results ranging from zero 
to an essential role in PI3K activation as well as in vitro and in vivo mast cell degranulation (Barbu 
EA, J Biol Chem, 2010; Odom S, J Exp Med, 2004; Kambayashi T, Immunol Rev, 2009). The 
reason for these discrepancies has not been unravelled. But as Ca2+ mobilisation is sufficient to 
activate PI3K in mast cells, there seems to be no need for a separate pathway. While Thapsigargin-
induced degranulation is blocked in PI3Kγ–/– BMMCs (Figure 1), Fyn–/– BMMCs degranulate 
normally in response to this agent (Sanchez-Miranda E, Biochem Biophys Res Commun, 2010), and 
therefore Fyn should be dispensable for PI3Kγ activation. 
Despite PI3K is essential for mast cell degranulation, its effector pathways are vaguely 
characterised. Potential PIP3 effectors are the PH-domain containing proteins PKB, PLCγ, Btk, and 
Vav. PLCγ and Btk controlled sustained Ca2+ mobilisation (Kawakami Y, J Immunol, 2000; Deng 
Z, Biophys J, 2009; Iwaki S, J Biol Chem, 2005) could regulate activation of the Ca2+-sensing 
component of the fusion machinery (Baram D, Immunol Rev, 2001). It is possible that a PKB 
catalyzed phosphorylation event is essential for degranulation, or that recruitment of another PH-
domain-containing protein is required. A degranulation regulator downstream of PI3K is 
phospholipase D (Lin P and Gilfillan AM, Eur J Biochem, 1992; Cissel DS, J Pharmacol Exp Ther, 
1998). Its product diacylglycerol (DAG) might regulate granule-plasma membrane fusion via DAG-
sensitive Munc13 proteins (Elstak ED, Blood, 2011; Brose N and Rosenmund C, J Cell Sci, 2002). 
Cytoskeletal rearrangements might be regulated by the guanine nucleotide exchange factor Vav 
which mediates Rac activation (Crespo P, Nature, 1997). 
 
5.4 PKCβ emerges to be a novel PI3Kγ activator 
Protein kinase C (PKC) activation is a key event to mast cell degranulation. Despite this, PKC's 
function and substrates remained obscure. By analysis of BMMCs derived from isoform-specific 
knock-out mice, PKCβ was identified to be essential for FcεRI and ionomycin triggered mast cell 
degranulation (Nechushtan H, Blood, 2000). We confirm this (Figure 3E, Figure S1D) and show 
that PKCβ regulates degranulation by PI3Kγ activation (Figure 3-5). Additionally, we also show 
that direct activation of PKCβ by phorbol myristate acetate (PMA) is sufficient trigger PI3K and 
PKB activation in mast cells (Figure 3C, 3F-H, 5A/C). PMA by itself however does not trigger 
mast cell degranulation, because granule-membrane fusion is additionally controlled by Ca2+-
regulated events. Interestingly, PKCβ-dependent PI3K activation depends on relatively high Ca2+ 
concentrations, lying in the low micromolar range (Figure 2C). With respect to this, in vitro studies 
have identified a special high Ca2+ requirement for the activation of PKCβ2 compared with PKCβ1 
or PKCα (Keranen LM and Newton AC, J Biol Chem, 1997). Whereas PKCβ2 required a 40-fold 
greater Ca2+ concentration for half-maximal activation than membrane binding, this difference was 
only 10- and 2-fold for PKCβ1 and PKCα, respectively. Apart from PKCβ2, BMMCs also express 
high amounts of PKCα. Despite these two PKCs share high homology and substrate sequence 
specificity, PKCα can not complement for PKCβ. Of the two splice variants of PKCβ, PKCβ2 is 
expressed at much higher levels than PKCβ1 (own observations, (Kawakami Y, J Immunol, 2000)), 
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and therefore likely dominates signalling in mast cells. PKCβ1 and PKCβ2 only differ in their last 
50-52 amino acids. The specific role of the PKCβ's C-termini is currently unknown. 
So far three PKC targets have been identified in mast cells: myosin heavy and light chain und the 
vesicle fusion protein SNAP-23 (Ludowyke RI, J Biol Chem, 1989; Ludowyke RI, J Immunol, 1996; 
Ludowyke RI, J Immunol, 2006; Hepp R, J Biol Chem, 2005). Whether these phosphorylation sites 
play a physiological role in mast cells and beyond is not yet known. Therefore, the function of PKC 
in mast cell degranulation is still enigmatic. While myosin regulates the reorganisation of actin 
filaments, SNAP proteins are part of the cell's membrane fusion machinery. Mast cell degranulation 
is accompanied by the disassembly of the cortical F-actin ring, subsequent increased actin 
polymerisation, and rearrangement of the tubulin network (Pfeiffer JR, J Cell Biol, 1985; Apgar JR, 
Mol Biol Cell, 1994; Hajkova Z, J Immunol, 2011). Whereas actin filament stabilizing or 
destabilizing agents only minimally affect degranulation by Ca2+ mobilising agents (Sasaki J, J Exp 
Med, 2005), microtubule modifying drugs completely block histamine release (Urata C and 
Siraganian RP, Int Arch Allergy Appl Immunol, 1985). A possible regulation of the actin-myosin 
network by PKC should therefore not be a prerequisite for exocytosis. Apart from regulation of 
cytoskeletal dynamics, PKC has been proposed to regulate granule-membrane fusion (reviewed in 
(Morgan A, Biochem Soc Trans, 2005)). This assumption originated from the observation that 
diacylglycerol (DAG) analogs trigger granule release in some exocytotic cell types. However by now, 
other phorbol ester sensitive proteins which regulate membrane fusion have been identified, like  
e.g. the Munc-13 proteins. FcεRI triggers phosphorylation of SNAP-23 in mast cells. Despite 
sensitive to PKC-inhibitors and PKCβ deficiency ((Hepp R, J Biol Chem, 2005), own observations), 
IKKβ is rather the direct kinase (Suzuki K and Verma IM, Cell, 2008). As only one of the two 
identified sites is conserved in humans, the relevance of this finding is unclear. SNAP-23 
phosphorylation in other cell types has not yet been reported. Of note, costimulation of the FcεRI 
with Kit or adenosine rescues defective antigen-induced degranulation of PKCβ–/– BMMCs 
((Fehrenbach K, J Immunol, 2009) and not shown, one experiment). The exocytotic machinery 
seems therefore to be intact in these cells, which corroborates our finding that PKCβ acts at an 
earlier step in the degranulation pathway. In some cell types, protein kinase D (PKD) is another 
PKC downstream target. In mast cells PKD activation is not blocked by PKC-inhibitors und also 
not required for degranulation ((Murphy TR, J Immunol, 2007), own observations). 
Within this study we unravelled a key function of PKC in mast cells. We identified PKCβ to be the 
direct activator of class IB PI3Kγ downstream of the FcεRI. In this novel pathway, store-operated 
Ca2+ influx activates PKCβ, which interacts with and activates PI3Kγ by phosphorylation (Figures 
2-5). Mass spectrometry identified the PKCβ-targeted sites to lie at two very critical regions within 
PI3Kγ. Serine 582 lays at the beginning of the helical domain, while S257 sits in the Ras binding 
domain (RBD). The helical domain beginning is famous for harbouring activating mutations of 
PI3Kα in cancer (Samuels Y, Science, 2004). But also the RBD domain is interesting. PI3Kγ with 
an artificially mutated RBD (PI3Kγ DASAA) is functionally dead in vivo, as mutant and knock-out 
neutrophils are equally impaired (Suire S, Nat Cell Biol, 2006). Further overexpressed PI3Kγ needs 
a functional RBD to transform chicken fibroblasts, which however additionally depends on the 
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presence of serum, but not on an artificial membrane tag (Kang S, Proc Natl Acad Sci U S A, 2006). 
In vitro characterisation of recombinant PI3Kγ phosphorylation site mutants identified S582 as a 
switch site for activation. The activity of the phosphoserine-mimicking PI3Kγ mutant (S582E) was 
increased 2-fold compared with wild type PI3Kγ (Figure 5D, E), which is an increase similar to that 
published for activated PI3Kα mutants (Miled N, Science, 2007, (Suppl); Carson JD, Biochem J, 
2008; Gymnopoulos M, Proc Natl Acad Sci U S A, 2007, (Suppl)). On the other hand, mutation of 
S257 had no effect on PI3Kγ's in vitro lipid kinase activity (Figure S3H). Still it should be kept in 
mind that detection of PI3K activation is limited by the already high activity state of this enzyme in 
vitro. Excited by the gain of activity of the helical domain mutant, we focused further experimental 
work on the analysis of S582. This strategy was further substantiated by the fact that the function of 
the RBD of PI3Ks is unknown at present and therefore tricky to investigate. Despite engineered 
PI3K RBD mutants showed functional defects in several studies (Zhao L and Vogt PK, Proc Natl 
Acad Sci U S A, 2008; Zhao L and Vogt PK, Cell Cycle, 2010; Gupta S, Cell, 2007; Suire S, Nat Cell 
Biol, 2006; Kang S, Proc Natl Acad Sci U S A, 2006; Kurig B, Proc Natl Acad Sci U S A, 2009; 
Sasaki AT, J Cell Biol, 2004; Orme MH, Nat Cell Biol, 2006), a prove for the claimed direct (or 
even indirect) involvement of Ras is missing. Other regulatory functions of the RBD should 
therefore be considered with equal plausibility, and may for example involve the interaction with 
another protein or membrane lipid. Importantly, we did not observe Ras activation by Thapsigargin 
(Figure S3L), and others showed no inhibition of FcεRI-mediated mast cell degranulation by Ras 
prenylation inhibitors (farnesyltransferase inhibitors) (Fujimoto M, Eur J Pharmacol, 2009; Mor A, 
Inflammation, 2011). 
Characterisation of S582 showed that its phosphorylation in BMMCs depends on p84-free PI3Kγ, 
as this site is not accessible in the exogenously expressed PI3Kγ-p84 complex (Figure 6A). In 
accordance with this, endogenous PI3Kγ coimmunoprecipitates, both, endogenous or exogenous 
p84 much less efficiently than exogenously expressed PI3Kγ (Figure 6D, E). PI3Kγ-p84 binding 
also varies within mast cell lines. While PI3Kγ efficiently associates with p84 in the human mast cell 
line HMC-1, it does this poorly in rat basophilic leukaemia cells (RBL-2H3) (not shown). Currently 
the reason for these disparate interaction affinities is unclear. We also observed that endogenous 
PI3Kγ is the better substrate for S582 phosphorylation than exogenous wild type PI3Kγ (Fig 6A, 
and not shown). This may be caused by the observed association of endogenous p84 with 
exogenous PI3Kγ, but also might arise from the reduced responsiveness of the transfected pool of 
cells (transfection efficiency ~75%). BMMCs transfected by nucleofection (Amaxa) are poorly 
viable and partially refractory to stimulation. If expressed at around physiological levels (1-2-fold of 
endogenous), transiently expressed wild type PI3Kγ (without or with p84) only partially 
complements PKB activation in PI3Kγ–/– BMMCs compared with wild type BMMCs (Thesis Figure 
1A and 2). This might derive from different localisation or processing of endogenous than 
exogenous PI3Kγ and/or disturbed functional integrity of the cell by the harsh transfection method 
(plasmid DNA gets “injected” in the nucleus). Upon several fold overexpression of PI3Kγ in 
PI3Kγ–/– BMMCs, PMA or Thapsigargin trigger levels of PKB phosphorylation as seen in wild type 
BMMCs (Thesis Figure 3). The relevance of this finding has however to be interpreted with 
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precaution as being dependent on unphysiological presets. In fact, overexpressed PI3Kγ can be 
oncogenic in vivo (Kang S, Proc Natl Acad Sci U S A, 2006) overcoming cell inherent control 
mechanisms. 
Despite the limited applicability of nucleofection of BMMCs for functional assays, expression of 
PI3Kγ S582 point mutants in PI3Kγ–/– BMMCs identified two things. First, co-
immunoprecipitation studies showed reduced binding of the phosphorylation site-mimicking 
mutants PI3Kγ S582E or S582D to p84 compared to wild type PI3Kγ or PI3Kγ S582A (Figure 
6B). This result could be confirmed by expression of the same constructs and pulldown assays in 
HEK293 cells (Figure 6C), and showed that S582 lays at the interphase of PI3Kγ and p84. This 
conclusion is in consent with the finding that S582 is inaccessible for phosphorylation if PI3Kγ is 
bound to p84 (Figure 6A). We additionally characterised the p84-PI3Kγ binding interphase by 
deuterium exchange mass spectrometry, which confirmed that p84 interacts with the helical domain 
beginning (Figure 7). Second, while wild type PI3Kγ and the S582 mutants were expressed at 
similar levels in PI3Kγ–/– BMMCs if coexpressed with p84 (Figure 6B), expression of the PI3Kγ 
constructs alone differed quantitatively (Figure 5F). Whereas wild type and the S582A mutant of 
PI3Kγ were strongly expressed in the absence of p84, expression of the two phosphorylation site-
mimicking mutants was strongly downregulated early after transfection (Figure 5F). This might be a 
sign of increased activity of these mutants, as cells often downregulate expression of harmfully 
activated proteins. In contrast to BMMCs, expression of PI3Kγ S582E or S582D was not affected 
in HEK293, which are devoid of endogenous PI3Kγ. But expression was also reduced in Sf9 cells 
(4-5-fold), which also downregulate constitutively active PI3Kα (H1047R/L, C420R, E545K; p85a: 
N564D) (Mandelker D, Proc Natl Acad Sci U S A, 2009; Hon WC, Oncogene, 2012). Since this 
instability in BMMCs made it impossible to compare signalling between the mutants in a 
physiological environment, and because of the mentioned disadvantages of nucleofection, we tried 
to generate stably transfected BMMCs by lentivirus-based approaches. Unfortunately, this was 
hampered by two reasons. On one hand, high viral titers that effectively promoted GFP expression, 
were toxic to BMMCs, and secondly, cells, infected with either low or high titer virus supernatants, 
very quickly lost transgene expression. More intense characterisation of the PKCβ phosphorylation 
sites in BMMCs was therefore not possible to us by technical reasons. Despite this, our analyses 
showed that non-canonical, PKCβ-activated PI3Kγ operates in an adaptor-free manner, and is 
regulated by phosphorylation of S582. Contemporaneously we identified S582 to lie centrally in the 
p84-binding region of PI3Kγ, which we mapped to the helical domain beginning. 
As PKCβ interacts with and phosphorylates PI3Kγ, our data support a model of direct activation of 
PI3Kγ by PKCβ. There exists the possibility that PKCβ potentiates PI3Kγ activation by 
phosphorylation of another protein, thereby generating a docking site for PI3Kγ translocation. In 
view of our finding that the N-terminal domain is not involved in p84 binding, but would be free 
for an unknown recruitment function, in analogy to class IA PI3K targeting by p85, this hypothesis 
merits warranty. Despite expression of membrane-anchored PI3K generally promotes constitutive 
PKB activation in cell lines, the sole addition of a membrane-targeting tag is not sufficient for full 
PI3K activation in primary cells or in vitro assays (Costa C, Proc Natl Acad Sci U S A, 2007; Zhao 
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JJ, Proc Natl Acad Sci U S A, 2005; Krugmann S, Biochem J, 2002). Accordingly, we did not 
observe PKB phosphorylation following transfection of PI3Kγ-CAAX into PI3Kγ–/– BMMCs (one 
experiment) (Thesis Figure 4A). Moreover, PKB activation induced by helical domain mutations in 
PI3Kα depends on a functional Ras binding domain (RBD) and is not affected by deletion of the 
N-terminal adaptor-binding domain (ABD) (Zhao L and Vogt PK, Proc Natl Acad Sci U S A, 2008; 
Zhao L and Vogt PK, Cell Cycle, 2010).  
We think that PKCβ mainly targets the plasma-membrane located pool of PI3Kγ, which has been 
determined to constitute 5-8% of total PI3Kγ in neutrophils (Suire S, Curr Biol, 2002). Part of 
PI3Kγ also locates to the membrane in macrophages, where it reaches similar levels to PI3Kγ-
CAAX in knock-in macrophages (Costa C, Proc Natl Acad Sci U S A, 2007). As the expression 
level of membrane-anchored PI3K is likely limited due to space-constraints, such restrictions may 
also influence total levels of membrane-located PI3K in wild type cells. Interestingly, the relative 
level of PI3Kγ S582 phosphorylation by PMA in wild type BMMCs was 1.5-fold of S582 
phosphorylation of PI3Kγ-CAAX transfected into PI3Kγ–/– BMMCs (one experiment) (Thesis 
Figure 4B). In addition to cells, PI3Kγ also spontaneously associates with lipid vesicles in vitro. 
Here, membrane binding is promoted by inclusion of a high ratio of negatively charged 
phospholipids like PtdIns(4,5)P2 or phosphatidylethanolamine (PE) and prevented by an excess of 
neutral lipids like phosphatidylcholine (PC) (Krugmann S, Biochem J, 2002). Additionally to activity 
regulation, PI3Kγ phosphorylation might also influence the affinity to membranes and orientation. 
While we found evidence for S582 to regulate catalytic activity, it might be possible that 
phosphorylation of S257 affects plasma membrane binding. Apart from PI3Kγ activation, it is also 
conceivable that PKCβ carries additional PI3Kγ to the plasma membrane, as activated PKCβ 
interacts with PI3Kγ in coimmunoprecipitation assays (Figure 4B). As both proteins are highly 
expressed in BMMCs, an encounter would be statistically favoured. PI3K translocation is very 
difficult to detect by microscopy or membrane fractionation techniques. Therefore, people generally 
prefer to monitor PIP3 production by means of translocation of engineered GFP-PH-domain 
fusion constructs (Voigt P, J Biol Chem, 2006). Studies quantifying PI3K translocation in cells 
reported translocation of only a minority total PI3K (~5%) (Domin J, J Biol Chem, 1996). Bulk 
PI3K translocation seems therefore not to be required for signal propagation. Future experiments 
will be required to address such aspects in more detail. 
Whereas adenosine activates PI3Kγ in a Gβγ-dependent manner in BMMCs (Bohnacker T, Sci 
Signal, 2009), antigen, Thapsigargin, and PMA activate PI3Kγ through PKCβ. Besides mast cells, 
endothelial cells (HUVEC, BREC, HBMEC, HMEC-1) also express PI3Kγ but not p101 (Hsieh 
SN, Diss, 2003, Friedrich Schiller University, Jena, Germany). It would therefore be interesting to 
analyse whether PI3Kγ is also regulated by PKC in these cells. Furthermore, PI3Kγ can also be 
regulated in a p101-independent manner in cells expressing p101. In neutrophils for example, p101 
is required for migration towards fMLP or C5a, but is dispensable for reactive oxygen species 
(ROS) production, which may be regulated by PI3Kγ in an adaptor-free or p84-dependent manner 
(Suire S, Nat Cell Biol, 2006). PMA also promotes PKB activation in cell types other than mast cells 
like 3T3-L1 adipocytes or primary human blood-derived B cells (Nave BT, Biochem J, 1996; 
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Barragan M, J Leukoc Biol, 2006). All in all these examples illustrate that future work will likely 
reveal further important roles of the PKC-PI3K pathway additional to mast cell degranulation. 
 
5.5 Regulation of PI3Kγ by the helical domain 
Serine 582 is located at the beginning of the helical domain of PI3Kγ and is conserved in higher 
vertebrates such as mammals and birds (no blastp entry available for reptiles) (Figure 4F). Mast cells 
have been found in all classes of vertebrates including as well amphibians and fish (Mulero I, Proc 
Natl Acad Sci U S A, 2007). Intriguingly, only mast cells from an evolutionarily advanced 
phylogenetic order of fish, the Perciformes, store histamine in their granules and use it as 
inflammatory mediator. Other fish species and also amphibians (frog, newt) lack histamine or 
serotonin, and do not respond to histamine administration (Mulero I, Proc Natl Acad Sci U S A, 
2007). The PKC-PI3Kγ pathway might therefore have evolved at about the same time as histamine 
started to regulate immunity. However, as IgE is exclusively produced in mammals, degranulation 
must be triggered by a different stimulus in other classes. 
The helical domain (also called PIK domain or accessory domain) is conserved in PI3- and PI4-
kinases, but its function is not known. Certainly it is important for the proteins structural integrity, 
as being involved in extensive interdomain interactions. The PI3Kγ helical domain folds into a 
stack of five A/B pairs of antiparallel helices (Walker EH, Nature, 1999). The surface formed by 
the A helices interacts with the catalytic domain, while the “B surface” is mainly solvent exposed. 
Further interactions by the helical domain are mediated by loops contacting the C2 and Ras-binding 
domain (RBD). S582 sits in the B helix of the first helical pair, which intrahelical loop contacts 
regulatory helices in the C-terminal lobe of the kinase domain (Thesis Figure 5). As S582 points 
inward of the published crystal structure, this region, at least in the phosphorylated state, must 
adopt a different conformation. Since we found that untagged PI3Kγ ∆143 is structurally impaired 
with respect to p84 binding compared to GST-∆143-PI3Kγ and full-length PI3Kγ (Figure 7D), it is 
likely that truncated PI3Kγ folds improperly. With respect to this, it might be of note to mention 
that the catalytic loop of PI3Kγ ∆143 is locked in an inactive conformation in published crystal 
structures (Walker EH, Nature, 1999; Pacold ME, Cell, 2000). For comparison, active side amino 
acids in the catalytic loop of PI3Kδ (∆ABD) or Vsp34 (∆C2) are oriented in a catalytic competent 
manner (Walker EH, Nature, 1999; Berndt A, Nat Chem Biol, 2010; Miller S, Science, 2010). It is 
also feasible that PKCβ binding induces a conformational change that exposes S582, because PMA 
could stimulate some phosphorylation of PI3Kγ ∆143 in BMMCs. But whether phosphorylation 
efficiency equalls that of wild type PI3Kγ is unclear, as N-terminal truncated PI3Kγ was expressed 
at a much higher level than full-length PI3Kγ, despite of transfection of equal amounts of plasmid 
DNA (one experiment) (Thesis Figure 1B).  
Interestingly, all known activating helical domain-associated mutations found in PI3Kα in cancer 
lay, as S582, at the beginning of the helical domain (P539, Glu542, Glu545, and Q546) (marked by 
stars in Thesis Figure 5) (Samuels Y and Velculescu VE, Cell Cycle, 2004). Among all identified 
oncogenic mutations in PI3Kα, two helical domain, E545K and E542K, and a C-terminal 
mutation, H1047R, occur most frequently. These mutations cause an approximate 2-fold gain of 
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enzymatic activity in vitro, promote PKB activation and oncogenic transformation in cell culture 
models, and induce tumour growth of xenograft transplants in vivo (Zhao JJ, Proc Natl Acad Sci U 
S A, 2005; Resnick AC, Proc Natl Acad Sci U S A, 2005; Isakoff SJ, Cancer Res, 2005; Pang H, 
Cancer Res, 2009). Increased PKB activation has been reported in immortalized, genetically 
engineered (HMEC) (Zhao JJ, Cancer Cell, 2003; Zhao JJ, Proc Natl Acad Sci U S A, 2005), 
spontaneously immortalized (MCF-10A) (Isakoff SJ, Cancer Res, 2005), and breast cancer-derived 
(MDA-MB-231) (Pang H, Cancer Res, 2009) human mammary epithelial cells, as well as in primary 
chicken embryo (Resnick AC, Proc Natl Acad Sci U S A, 2005; Zhao L and Vogt PK, Proc Natl 
Acad Sci U S A, 2008) and NIH-3T3 fibroblasts (Ikenoue T, Cancer Res, 2005). Unfortunately, it 
has not been published whether these mutations also promote PI3K activation in standard cell lines 
such as HEK293 or COS-7 cells. It is likely that increased PI3K signalling depends on a second 
signalling input, which is not shut on in every cell line and cell type.  
It is thought that the helical domain mutations in PI3Kα relieve inhibitory contacts between the 
nSH2 of p85 and PI3Kα. This has been derived from in vitro data analysing charge-reversal 
mutations of PI3Kα and p85α biochemically, and analysis of the crystal structure of the PI3Kα 
H1047R/p85α-niSH2 complex (fragment 322-694 of p85α) (Miled N, Science, 2007; Mandelker D, 
Proc Natl Acad Sci U S A, 2009). While the niSH2 fragment of p85 blocks the activity of 
monomeric wild type PI3Kα 2-fold, the PI3Kα helical domain hot spot mutants are already fully 
active and neither inhibited by p85 nor further activated by phosphopeptides (Miled N, Science, 
2007; Carson JD, Biochem J, 2008). Whether these in vitro results directly apply in vivo has not 
been investigated, presumably due to difficulties to address this experimentally. Additional studies 
indicate that helical domain mutations also regulate PI3Kα activity by an inherent and not only 
p85-dependent mechanism. Monomeric mutant PI3Kα is more active than monomeric wild type 
PI3Kα both in vitro and in cultured cells ((Ikenoue T, Cancer Res, 2005; Gymnopoulos M, Proc 
Natl Acad Sci U S A, 2007); (Miled N, Science, 2007) (Suppl; vitro); (Zhao L and Vogt PK, Proc 
Natl Acad Sci U S A, 2008), (cells)). In cellular studies, effects of the binding of endogenous p85 to 
transfected PI3Kα can be prevented by the use of N-terminally truncated PI3Kα (∆72) (Zhao L 
and Vogt PK, Proc Natl Acad Sci U S A, 2008). Whether oncogenic PI3Kα helical domain 
mutations induce structural changes, for example in the kinase domain, is unknown, as there are no 
crystal structures available. 
Since PI3Kα activity can be modulated at the level of the helical domain, we wanted to know 
whether this also applies for PI3Kγ and S582. Analysis of the phosphorylation-mimicking PI3Kγ 
S582E mutant showed that this is indeed the case, as its enzymatic activity was increased 2-fold in 
vitro compared with wild type PI3Kγ. Unfortunately, we could not directly address increased PI3K 
signalling in vivo, as it was impossible to express the phosphorylation-mimicking mutants at 
adequate levels in BMMCs. However, as already mentioned, the strong downregulation of these 
mutants likely derives from a gain of function trait. 
Apart from the helical domain, activating PI3Kα mutations lie within or near the last four helices of 
the catalytic domain. They form a regulatory square that holds the activation and catalytic loop in 
place (Zhang X, Mol Cell, 2011). Since the loop of the helical domain beginning directly contacts 
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the regulatory square, it might regulate catalysis by forwarding conformational changes. Therefore, 
despite located at distinct positions of the same helix, S582 of PI3Kγ and E542 or E545 of PI3Kα 
might affect lipid kinase activity by a similar allosteric way.  
Characterisation of PI3Kα helical domain mutants in chicken embryo fibroblasts (CEFs) showed 
that PKB activation and cellular transformation is dependent on functional Ras binding domain 
(RBD). Mutation of lysine 227 to glutamate in the RBD abrogates E545K-dependent cellular 
outcomes (Zhao L and Vogt PK, Proc Natl Acad Sci U S A, 2008). While RBD mutations 
interfered with signalling of bovine and human PI3Kα E545K, PKB activation induced by the 
H1047R mutation was blocked only by modification of the human but not bovine RBD (Zhao L 
and Vogt PK, Proc Natl Acad Sci U S A, 2008; Zhao L and Vogt PK, Cell Cycle, 2010). In these 
studies, the functional role of the RBD has not been investigated. As the cells were serum-starved 
only, stimulus-triggered signalling events should not play a role. Rather appropriate steady-state 
signalling might be of importance. So far PI3Kα helical and Ras binding domain double mutants 
have only been investigated in CEFs but not other cell types. It is therefore premature to conclude 
that the gain of activation induced by helical domain mutations depends on RBD coregulation in 
every case. Yet such observations show, that PI3K activation inside cells can depend on more than 
one upstream signal and domain. Interestingly, we not only found phosphorylation of S582 of 
PI3Kγ by PKCβ in vitro or BMMCs but also concomitant phosphorylation of S257 in the RBD 
(Figure S3C-E, G). It is therefore tempting to speculate that in cells both phosphorylations are 
required to promote PI3Kγ activation. For example, phosphorylation of S257 might impact PI3Kγ-
plasma membrane or -coregulator binding, and its possible role are under investigation. 
 
5.6 Regulation of PI3Kγ by the Ras binding domain 
Despite the Ras binding domain (RBD) is essential to PI3Kγ function in vivo (Suire S, Nat Cell 
Biol, 2006; Kang S, Proc Natl Acad Sci U S A, 2006) its mechanism of action is unclear. The RBD 
of PI3K has little sequence homology with the RBD of Raf or RalGEF and therefore constitutes a 
different domain group. Despite this, the RBDs of all three groups fold into a similar structure. 
Interestingly, S257 lays in a region in the RBD (amino acids 255-265) that is disordered in the 
crystal structure of PI3Kγ, but is ordered in the structure of PI3Kγ complexed to Ras (Walker EH, 
Nature, 1999; Pacold ME, Cell, 2000). S257 lays at the edge of the Ras-PI3Kγ interphase, is largely 
solvent exposed, and not buried in the interface (Thesis Figure 6). The serine side chain hydroxyl 
group lies at bonding distance to Gln 25 of Ras, but this interaction does not seem to be essential 
for complex formation. Whether S257 phosphorylation is of physiological importance we do not 
know. As S257 is located at the border of the Ras binding site, phosphorylation might have no 
effect on Ras binding or may regulate its dislocation. With respect to mast cell degranulation, S257 
may regulate PI3Kγ activation in concert with S582. It is conceivable that the RBD regulates PI3Kγ 
function by different independent mechanisms. Depending on the context, phosphorylation or 
activator protein interaction may be involved. 
PI3Kγ (∆143, V223K)-Ras (H-Ras⋅GMPPNP) crystals were obtained with a PI3Kγ mutant having 
increased Ras binding affinity (V223K). Since recombinant PI3Kγ ∆143 has a 10-fold lower in vitro 
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Ras binding affinity than GST-PI3Kγ (Pacold ME, Cell, 2000), it might be possible that the N-
terminal region is not only important for the structural integrity of the helical (Figure 7D) but also 
the Ras binding domain. As Ras-PI3Kγ binding is mediated by hydrogen bond and salt bridge 
interactions (beyond the farnesyl moiety), association force depends on the ionic strength of the 
microenvironment. Ras not only interacts with the RBD of PI3Kγ but also contacts the catalytic 
domain. Ras-PI3Kγ binding induces conformational changes in the C2 domain and the C-terminal 
lobe of the kinase domain. PI3Kγ substrate binding and catalysis might be enhanced by the 
movement of backbone helices that hold the activation loop in place. 
In vitro and ectopic expression experiments have identified several interesting characteristics of 
Ras-PI3K interaction. These data contribute to the elucidation of RBD functions, stimulate ideas, 
and help to design future experiments. In vitro, recombinant PI3Kγ interacts in a GTP-dependent 
manner with unmodified bacterially expressed Ras (uRas) (Rubio I, Biochem J, 1997; Rubio I, Eur J 
Biochem, 1999; Pacold ME, Cell, 2000). In contrast to uRas, farnesylated Ras (mRas, m: modified) 
can bind PI3Kγ both in the GTP- and GDP-loaded state, but binding efficiency is much better for 
GTP-loaded Ras at low Ras concentrations (10 nM (far below Kd) vs. 1 µM Ras) (Rubio I, Eur J 
Biochem, 1999). Additionally, PI3Kγ also forms a high stringency complex with mRas-GTP that is 
inaccessible to the activity of GTPase-activation protein (GAP) (H-Ras 10-20%, K-Ras4B 50%). 
Despite PI3Kγ binds to u- and mRas, only mRas enhances lipid kinase activity in vitro. Ras binding 
probably increases the affinity for PIP2, as PI3Kγ activation by mR-Ras-GTPγS is most notably 
increased at PIP2 concentrations below 10 µM, but is only minimally (1.5 fold) affected at high PIP2 
concentrations (above 50 µM) (Suire S, Curr Biol, 2002). In vitro and in heterologous expression 
systems, active Ras does not promote PI3Kγ membrane translocation (Suire S, Curr Biol, 2002). 
Ras therefore likely activates PI3Kγ by an allosteric mechanism. In vivo activation of PI3Kγ by 
constitutively active Ras might be direct or indirect, because active Ras also promotes cytokine 
release in cultured cells (Ancrile B, Genes Dev, 2007; Sparmann A and Bar-Sagi D, Cancer Cell, 
2004). Furthermore it is also possible that PI3Kγ is activated in vivo by another farnesylated protein 
or another Ras family member, and that in vitro association with classical Ras represents 
crossreaction. Indeed, the Ras proteins constitute a big protein family which member-functions are 
mostly undefined. PI3Kγ might interact with its physiological binding partner with much higher 
affinity. Raf for example has a much higher Ras binding strength than PI3K or RalGEF, which 
likely explains why Ras only promotes plasma membrane translocation of Raf but not PI3K. 
Moreover, only the RBD of Raf is suited for Ras⋅GTP pulldown assays. Ras-PI3K interaction is 
experimentally difficult to detect, as it is not possible to copurify the complex at an equal 
stochiometric ratio. Whereas precipitated Ras or PI3K is easily visible by Coomassie dye staining, 
detection of the copurified binding partner requires Western blotting. 
Examination of the structure of the RBD of class I PI3Ks identifies a region of no homology 
between β-sheet 2 and 3. In PI3Kγ (PDB: 1E7U), part of this region is disordered (amino acids 
255-265), but folds into an ordered loop containing a small α-helix when cocrystallized with Ras 
(PDB: 1HE8) (Pacold ME, Cell, 2000) (Figure S3K). The corresponding region in PI3Kα is 
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ordered and folds after a turn into a long α-helix (aa 237- 247) (PDB: 2RD0, 3HHM) (Huang CH, 
Science, 2007; Mandelker D, Proc Natl Acad Sci U S A, 2009). In comparison with PI3Kγ, PI3Kα 
also shows different in vitro Ras binding characteristics. Recombinant PI3Kα binds both to uRas 
and mRas in a strictly GTP-dependent manner (Rodriguez-Viciana P, Nature, 1994). On the other 
hand, activation is as well dependent on posttranslational modification (Rodriguez-Viciana P, 
EMBO J, 1996). Further, Ras pulldown assays work efficiently with a RBD containing construct (aa 
133-314) of PI3Kα, but not with the corresponding fragment of PI3Kγ (aa 220-311).  
All in all, current evidence strongly suggests that PI3Kγ is physiologically regulated at the level of 
the RBD. Whether this involves Ras, a Ras-like protein, and/or phosphorylation on S257 requires 
further investigation. The RBD might not only regulate stimulus-induced PI3K activation, but 
might also promote constitutive PI3K membrane association through a growth/survival factor 
activated farnesylated protein. Because of distinct structure and behaviour among PI3Ks, the RBD 
likely, beyond other mechanisms, regulates isoform-specificity. Whether interaction with Ras itself 
plays a physiological role in this process is not yet clear (Karasarides M, J Biol Chem, 2001). 
 
5.7 Regulation of PI3Kγ by adaptor proteins 
PI3Kγ interacts with two adaptor subunits, p101 or p84, which expression is regulated in a cell 
type-specific manner. While mast cells only express p84, neutrophils and monocytes express both 
adaptors, and lymphocytes mainly p101 (Bohnacker T, Sci Signal, 2009). p84 and p101 share 30% 
sequence identity and 37% sequence similarity (Suire S, Curr Biol, 2005) and exhibit several 
identical characteristics. Both adaptors associate with PI3Kγ in coimmunoprecipitation assays 
following coexpression, and are required for fMLP- or Gβγ-induced PIP3 production in 
heterologous expression systems (HEK293) (Brock C, J Cell Biol, 2003; Voigt P, J Biol Chem, 
2006). However, whereas p101 potentiates PI3Kγ activation by Gβγ subunits in vitro and is 
translocated by them to the plasma membrane in cells (Stephens LR, Cell, 1997; Brock C, J Cell 
Biol, 2003), p84 does not share these characteristics (Kurig B, Proc Natl Acad Sci U S A, 2009). In 
the presence of p84 instead, Gβγ-dependent PI3Kγ activation is sensitive to expression of the 
GTPase activation domain of neurofibromin 1 (GAPNF1) (Kurig B, Proc Natl Acad Sci U S A, 2009) 
as well as cholesterol depletion (Bohnacker T, Sci Signal, 2009). GAPNF1 inhibits basal Ras 
activation in HEK293 cells but likely also acts on other targets. In neutrophils, in contrast to 
HEK293 cells (Kurig B, Proc Natl Acad Sci U S A, 2009), p101-regulated PI3Kγ activation also 
depends on an intact Ras binding domain (Suire S, Nat Cell Biol, 2006). Despite mechanistic basics 
are incompletely understood, these data show that coactivators and adaptor proteins regulate PI3Kγ 
activation in versatile ways. 
As PI3Kγ complexed to p84 was resistant to S582 phosphorylation (Figure 6A), we unexpectedly 
obtained information on the p84 binding site. Our data show that p84 binds to PI3Kγ through the 
helical domain beginning (Figure 7A-C) and not the N-terminal region (Figure 7D) as has been 
anticipated in analogy to adaptor binding in class IA PI3K. In fact, the interaction site between p84 
and PI3Kγ has not yet been characterised experimentally. We show here that N-terminally 
truncated (∆130) GST-tagged PI3Kγ interacts with p84 equally well as full-length PI3Kγ (Figure 
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7D). Despite the N-terminus of PI3Kγ is not involved in p84 binding, it is required for the 
structural integrity of the p84 binding site, as untagged N-terminally truncated PI3Kγ (∆130) fails to 
interact with p84. The GST-tag therefore acts as protein stabilizer rescuing p84 binding. 
It is likely that also p101 interacts with the helical domain of PI3Kγ, since our results are in consent 
with previous publications analysing the interaction of PI3Kγ with p101. Krugmann et al. showed 
reduced binding of p101 to different long (∆122-∆369) N-terminal deletion mutants of Myc- or 
His-tagged PI3Kγ, but they did not analyse GST-tagged deletion mutants (Krugmann S, J Biol 
Chem, 1999). This however was done by Maier et al. who observed equal association of p101 with 
GST-PI3Kγ and GST-PI3Kγ ∆97 upon copurification from baculovirus-infected Sf9 cells (Maier 
U, J Biol Chem, 1999). 
Untagged PI3Kγ ∆130 is functionally dead in vivo, as it does not support PKB activation in 
BMMCs (one experiment) (Thesis Figure 1). Additionally it is expressed at much higher levels than 
full-length PI3Kγ following transfection of equal amounts of plasmid DNA. Decreased degradation 
might be caused by lower inherent basal activity and structural changes affecting proteasom 
recognition. Similar to PI3Kγ ∆130 in BMMCs, PI3Kγ ∆143 is expressed at much higher levels in 
Sf9 cells. In vitro, recombinant GST-tagged PI3Kγ ∆130 was found to have increased lipid kinase 
and autophosphorylation activity than “full-length” GST-PI3Kγ (∆37) und reacted efficiently with 
Wortmannin (Stoyanova S, Biochem J, 1997). This shows that GST-tagging not only rescues p84 
binding but also positively affects lipid kinase activity. While there is no information available on 
the in vitro activity of untagged PI3Kγ ∆130, two groups reported normal basal activity of C-
terminally His-tagged PI3Kγ ∆143 (Krugmann S, Biochem J, 2002; Walker EH, Nature, 1999). 
However, as enzymatic properties have not been characterized in detail, differences to wild type 
PI3Kγ might not have come to light. While increasing N-terminal truncations reduce basal lipid 
kinase activity at least in vivo, PI3Kγ is catalytically dead following removal of more than 169 
amino acids (Krugmann S, Biochem J, 2002). Crystallisation of PI3Kγ ∆143 secured a shapshot of 
PI3Kγ with the catalytic loop in an inactive conformation. For comparison, in the structures of 
PI3Kδ (∆ABD) or Vsp34 (∆C2), active site amino acids in the catalytic loop are oriented in a 
catalytic competent manner (Walker EH, Nature, 1999; Berndt A, Nat Chem Biol, 2010; Miller S, 
Science, 2010). Because of the observations, that p84 fails to interact with PI3Kγ ∆143 and that the 
regulatory S582 points inward of the crystal structure, it would be interesting to know whether the 
helical domain beginning folds differently in the full-length enzyme. 
Following ectopic expression in cell lines, PI3Kγ and p84 form a stable complex that can be 
efficiently coimmunoprecipitated (Figure 6A-E, 7D) (Suire S, Curr Biol, 2005; Voigt P, J Biol 
Chem, 2006). Association is not required for stability as either protein is also expressed efficiently 
alone, but cotransfection augments expression levels. p101 interacts more strongly with PI3Kγ and 
is less stable than p84 in the absence of PI3Kγ. Analysis of endogenous p84 expression in PI3Kγ–/– 
cells showed stable expression in the bone marrow, but downregulation in bone marrow-derived 
mast cells and macrophages, neutrophils, and splenocytes (Bohnacker T, Sci Signal, 2009). As p84 
levels were normal in cells expressing kinase-dead PI3Kγ (PI3KγKR/KR), p84 expression is positively 
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influenced by the presence of this kinase. Despite of this interdependence, endogenous PI3Kγ and 
p84 coimmunoprecipitate from BMMCs only poorly and much less efficiently than the exogenously 
expressed proteins. Because of this and as PKCβ only targets p84-free PI3Kγ, it would be 
interesting to know, whether PI3Kγ levels exceed that of p84. Some PI3Kγ/p84 would then be 
available for activation by GPCRs, while single PI3Kγ is available for PKCβ. Alternatively, free 
PI3Kγ might localise to a region in cells that is not accessible for p84, or is processed in way that 
prevents p84 binding. Whether PI3Kγ activation by PKCβ occurs completely independent on p84 
or requires its presence indirectly, we do not know, as investigation of this would require the 
availability of p84–/– BMMCs. Actually, it might be possible that p84 not only blocks PI3Kγ 
activation by PKCβ but also by GPCRs, as it does not serve as Gβγ recruitment adaptor for PI3Kγ 
as p101 (Kurig B, Proc Natl Acad Sci U S A, 2009). Furthermore, sequence identity of both 
adaptors is quite low. Consistently, BMMCs, which do not express p101, are resistant to stimulation 
by several GPCR ligands. So far adenosine is the only known ligand that triggers PI3Kγ activation 
in a GPCR-dependent manner in BMMCs (Bohnacker T, Sci Signal, 2009). It would therefore be 
important to analyse, whether adenosine-stimulated PI3Kγ activation depends on endogenously 
expressed p84. It has been proposed that adenosine- and p84-dependent PI3Kγ activation depends 
on coactivation by a Ras family member (Kurig B, Proc Natl Acad Sci U S A, 2009). Since Ras 
targets the RBD of PI3Kγ and not p84, the function of this adaptor is unclear in this model. 
Additionally, GFP-tagged PI3Kγ or p84 do not translocate in a microscopically detectable manner 
in complemented and stimulated PI3Kγ–/– BMMCs or transfected HEK293 cells. It might be 
possible that growth factor or constitutively activated Ras locates some PI3Kγ at the plasma 
membrane, where it is accessible to allosteric activation by the receptor and Gβγ subunits. In 
HEK293 cells for example, both the fMLP receptor and Gβγ subunits potentiate activation of 
PI3Kγ-CAAX (Brock C, J Cell Biol, 2003).  
 
5.8 Regulation of class I PI3Ks by phosphorylation 
We discovered a new mechanism of PI3K regulation. We identified the serine/threonine kinase 
PKC to regulate PI3K activation by phosphorylation. The regulatory sites in PI3Kγ could be 
mapped to S582 and S257. Some other serine/threonine phosphorylation sites of PI3K and the p85 
adaptor have been published. These are however targeted by the PI3K’s inherent protein serine 
kinase activity. In contrast to lipid kinase activity, protein kinase activity of class IA PI3K is Mn2+-
dependent in vitro. On the other hand, class IB PI3Kγ operates with both Mn2+ and its 
physiological cofactor Mg2+. Recombinant PI3Kγ and PI3Kδ autophosphorylate themselves in their 
C-termini – PI3Kγ on Ser1101 and PI3Kδ on Ser1039 (Stoyanova S, Biochem J, 1997; 
Vanhaesebroeck B, Proc Natl Acad Sci U S A, 1997). Whereas autophosphorylation does not affect 
lipid kinase activity of PI3Kγ, the activity of PI3Kδ is decreased. PI3Kα transphosphorylates its 
tightly bound adaptor subunit, p85α or p85β, at the end of the interSH2 domain on S608 
(Carpenter CL, Mol Cell Biol, 1993; Dhand R, EMBO J, 1994). In the crystal structure of PI3Kα 
(2Y3A), S608 is located in a disordered stretch that folds over the catalytic site. Phosphorylation is 
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therefore facilitated by vicinity, which explains why PI3Kα only phosphorylates tightly bound p85. 
In contrast to PI3Kα, PI3Kβ and PI3Kδ do not phosphorylate p85. Whereas S608 is conserved in 
p85α, this is not true for p85β. It was shown that phosphorylated PI3Kα/p85 has a 2-fold 
decreased basal activity in vitro (Dhand R, EMBO J, 1994). Since S608 is prephosphorylated to a 
great extent in cell lines (Domin J, J Biol Chem, 1996), it has been hypothesized that this helps to 
keep PI3Kα at low basal state in quiescent cells (Dhand R, EMBO J, 1994). Whether mutation of 
S608 would relieve some inhibition of endogenous PI3Kα in vivo is unknown. However, 
baculovirus-expressed wild type and mutated p85 inhibit PI3Kα lipid kinase activity identically in in 
vitro assays using PtdIns as substrate. Analysis of phosphorylation of coexpressed PI3Kα-p85α in 
Sf9 cells by in vivo labelling with [32P]-orthophosphate revealed p85α to contain phospho-serine 
and -threonine and PI3Kα to contain phospho-serine (Dhand R, EMBO J, 1994). Following 
activation of T lymphocytes by the T cell antigen receptor (TCR)/CD3 complex or activation of 
PKC by phorbol ester, p85α-associated PI3K gets rapidly and exclusively phosphorylated on serine 
residues (Reif K, J Biol Chem, 1993). On the other hand, p85α basal serine phosphorylation does 
not change during T cell activation, but p85β gets phosphorylated on threonine residues. The 
identity of the phosphorylation sites, whether they are targeted by PKC, and whether they regulate 
PI3K activation in vivo is unknown. 
Additional to serine/threonine residues, p85 regulatory subunits have also been reported to become 
tyrosine phosphorylated on several and distinct residues in a stimulus-specific fashion. p85 is 
phosphorylated by the Src family kinases Lck and Abl on tyrosine 688 in vitro or after their 
overexpression in COS-7 cells (von Willebrand M, J Biol Chem, 1998). Y688 is conserved in p85α, 
β (Y686), and γ (Y422) and is located in the cSH2 domain of p85. It has been proposed that 
phosphorylation Y688 releases inhibition of PI3K by p85 (Cuevas BD, J Biol Chem, 2001; Zhang 
X, Mol Cell, 2011). Insulin stimulates phosphorylation of exogenously expressed p85α at Y368, 
Y580, and Y607 in Chinese hamster ovary (CHO) cells overexpressing the human insulin receptor 
(IR). While recombinant IR phosphorylates recombinant full-length p85 only on Y607, p85 
truncation mutants were phosphorylated at all three sites. Metabolic labelling experiments showed 
that platelet-derived growth factor (PDGF) stimulates in vivo phosphorylation of p85 on tyrosine 
residues in NIH-3T3 cells, while phospho-serine content remained unchanged (Domin J, J Biol 
Chem, 1996). Recombinant PDGF receptor phosphorylates recombinant p85 on S508 in vitro. 
Mutation of S508 to phenylalanine abrogates phosphopeptide detection by two-dimensional 
chromatography, both in the in vitro assay or following PDGF-stimulation of p85-transfected 
COS-6M cells (Kavanaugh WM, Biochemistry, 1994). Despite identification of all these 
serine/threonine and tyrosine phosphorylation sites, evidence for a physiological role in vivo is so 
far missing. 
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5.9 Notes 
Dose response behaviour of LAT–/– BMMCs 
Dose response intact: 
LAT1–/– 
LAT1–/–, 1YF, 2YF, 3YF, 4YF (Retroviral compl.) 
LAT2–/–  (LAT1–/– degr. only) 
LAT1–/–, LAT2–/– 
 
Saitoh S, Immunity, 2000 
Saitoh S, J Exp Med, 2003 
Volná P, J Exp Med, 2004 
Zhu M, J Exp Med, 2004 
Degranulation at supraoptimal antigen concentrations: 
LAT1–/–, LAT2–/–, DKO (mice from Volná) 
LAT1–/–, LAT-YYYY, FYYY, YFFF, FFFF (knock-in) (FFFF degranul., but Ca2+) 
 
Roget K, J Immunol, 2008 
Malbec O, J Immunol, 2004 
Dose response not analysed:  
LAT1–/–, LAT2–/–, DKO; SLP-76–/– (DNP until 30 ng) (text only: pPKB mentioned 
to be normal) 
LAT1–/–, SLP-76–/–, Fyn-SLP-76–/– 
 
Kambayashi T, Mol Cell Biol, 2010 
Kambayashi T, Immunol Reviews, 
2009 
 
Effect of serum starvation on Gab2 phosphorylation in BMMCs 
Stimulated pGab2 Starving and stimulation conditions        (*no serum!) Reference 
yes 2 µg/ml IgE, 4 h (in what?) 
Resuspension in Tyrode’s buffer* before stimulation 
10 ng/ml DNP (2, 5, 10 min) 
Gu H, Nature, 2001 
yes IgE-containing hybridoma supernatant, ON 
Starved in IMDM/1%BSA* 3-4 h  
Resuspension in Tyrode’s buffer* before stimulation 
10 ng/ml DNP (5, 10 min) 
Yu M, J Immunol, 2006 
(same group as Gu H, 2001) 
RBL-2H3: increased 
phosphorylation 
BMMCs: increase over 
basal (Fig. 2a, Fig. 1d 
unclear) 
SCF starvation ON 
1 µg/ml IgE in IL-3 free medium 
Resuspension in Tyrode’s buffer* (washed twice) 
Stimulation with 10-100 ng/ml DNP 
Parravicini V, Nat Immunol, 2002 
no (already 
phosphorylated) 
RPMI 1640 complete w/o IL-3, 1 µg/ml IgE ON 
10 ng/ml DNP-BSA 
Hernandez-Hansen V, J Immunol, 
2004 
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Cell lines supporting helical domain mutation-dependent PKB activation 
Reference Cells Mutations Activity in vitro P-PKB in cells 
Zhao JJ, Caner 
Cell, 2003 
Engineered HMEC (hTERT, SV 
40 LT, endog. cMyc) 
Myr-Flag-PI3Kα – P-PKB induction 
Zhao JJ, PNAS, 
2005 
Engineered HMEC (hTERT, SV 
40 LT, endog. cMyc) 
HA-tagged, H1047R, 
E545K 
– P-PKB induction, 
(more than Myr-) 
Kang S, 2005 
(Vogt lab) 
RCAS vector transfeced primary 
chicken embryo fibroblasts 
(passaged 3 times) 
(40 h 0.5% FCS/0.1% chicken 
serum, 2 h no serum at all) 
E542K, E545K, 
H1047R (tagged?) 
IP: PI3Kα, PI as 
substrate, activity 
(p85 binding not 
shown)* 
P-PKB induction 
Gymnopoulos 
M, 2007 
(Vogt lab) 
 
RCAS vector transfeced primary 
chicken embryo fibroblasts, 
(40 h 0.5% FCS/0.1% chicken 
serum, 2 h no serum at all) 
Rare mutations (incl. 
E545A, E545G, 
H1047L) 
IP: PI3Kα, PI as 
substrate, activity 2-
3-fold (Suppl) 
Increased PKB (over 
PI3Kα wt) 
Zhao L, 2008 
(Vogt lab) 
RCAS vector-transfeced primary 
chicken embryo fibroblasts 
(passaged 3 times) 
(40-44 h 0.25% FCS/0.05% 
chicken serum, 2 h no serum at 
all) 
E542K, E545K, 
H1047R 
(∆p85, K227) 
– P-PKB induction 
Ikenoue T, 
2005 
Stably transfected NIH-3T3, 12 h 
0.1% serum 
E542K, E545K, 
H1047R 
IP: Myc (from 
starved HEK293T), 
PI as substrate, 
activity 
Increased P-PKB 
(NIH-3T3) 
Pang, H, 
Cancer Res, 
2009 
Stably transfected MDA-MB-231, 
starved 4 h 
(knockdown of human, expr. of  
bovine PI3Kα) 
E545K, H1047R, C-
terminal Myc-tag 
– P-PKB induction 
(further increased by 
EGF) 
Isakoff SJ, 
Cancer Res, 
2005 
Stable MCF-10A& (Puro). Starved 
24 h in growth medium w/o 
EGF, insulin. &Spontaneously 
immortalized breast/mammary 
epithelial cells. 
HA-PI3Kα E545K, 
H1047R (bovine) 
 Increase P-PKB, 
growth-factor ind. P-
PKB 
*Miled: Myc-PI3Kα (bovine) wt, E542K, E545K, Q546K.                                 with PIP2? 
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Mast cell homing and function 
 p85α–/– (p55-p50α+/+) Gab2–/– PI3KδD910A 
Mast cell numbers:    
Peritoneum 
 
 
24% (FACS) (1) 0%(ns), ~5% (ab), ~5% (ns) 8% (ab-s) 
Dermis: Ear 
 Back 
 Thigh 
Skin 
Back: Dermis 
Back: Hypodermis 
65% (tb) 
77% 
nd 
100% (tb) (ns); ~43% 
50-70% (ns) 
50-70% (ns) 
60% (ab) 
~67% (tb) (not signif.) 
~50% (tb)  
53% (tb) 
86% (not signif.) (tb) 
Stomach Mucosa 
 Subm. 
 Muscularis 
Forestomach 
Glandular stomach 
0% (tb, ab-s, chest) 
0% (2) 
0% 
 
 
 
~8% (ab) 
~5% (ab) 
90% (not signif.) (tb) 
57% (tb) 
57% (tb) 
Jejunum    (low # 
Ileum          in wt) 
Colon 
0% (2) 
0% 
0% 
nd 26% (tb) 
5% (not signif.) (tb) 
0% (tb) 
Mice responses:    
PSA 
 
ok (Evans b., plasma hist., 
survival) 
 (plasma hist.) nd 
PCA nd 55% (dorsal ear, Evans b.) Ear: 20% (E. b.); 40% 
Back: 60% (Evans b.) 
BMMC responses:    
BMMC culture IL-3 2-4 ng/ml IL-3; IL-3 
supernatant; 4 ng/ml IL-3 
10 ng/ml IL-3 + 20 ng/ml 
SCF; both 20 ng/ml 
Proliferation  
 
 
 
IL-3 ok; SCF   (3) 
IL-3: 10 ng/ml, SCF:  200 ng/ml 
IL-3+SCF: ok               (4) 
nd; IL-3 ~ok (0.5-20 ng/ ml); 
SCF low (50 ng/ml) ok, SCF 
high (200) ; SCF (50 ng/ml) 
30-70% 
IL-3 (5), SCF,  
IL-3+SCF: no prolif. (3H-
Thymidine). No PIP3 in 
response to SCF; nd 
Survival (growth factor 
deprivation) 
IL-3 ok; SCF ok nd; ok; nd nd; nd 
PKB activation SCF 
 
 IL-3 
 
~70% (almost ok) 
 
nd 
nd;  (100 ng/ml); ok 
 
 (Gu, not shown); nd; nd 
;  
 
slightly ; nd 
Adhesion SCF 
 
Migration SCF 
discussion part: no polarity in 
chemotaxis assay, but 
infiltration in vivo 
nd  (1-20 ng/ml); blocked 
 
; nd 
Degranulation 
 
 
 
 
 
ok (β-Hexo) 
4 h 1 µg/ml IgE w/o IL-3 
10 ng/ml DNP 
 (3H-Serotonin) 
6 h 1 µg/ml IgE 
3, 10, 30, 100 ng/ml DNP 
55% (β-Hexo), still sensitive 
to Ly294002. 100 ng/ml IgE/200 
ng/ml DNP com-plexes. Diff. much 
less with 10 ng/ml DNP; 50% (β-
Hexo ), (100 ng/ml IgE, 30 ng/ml 
DNP) 
Other notes 
 
 
   
References: (Fukao T, Nat Immunol, 
2002), review in (Koyasu S, 
Novartis Found Symp, 2005) 
(Gu H, Nature, 2001), 
(Nishida K, Blood, 2002) 
(diff. mice), (Yu M, J Biol 
Chem, 2006) 
(Ali K, Nature, 2004), (Ali K, 
J Immunol, 2008) 
tb: toluidine blue   ab: alcian blue   s: safranin   bs: beberine-sulfate   chest: chloroacetate esterase activity 
ok: normal response   nd: not determined   ns: not shown   : reduced     greatly reduced 
Discussion  87 
 
 
 
KitY567F KitY569F KitY567F, Y569F KITY719F Gab2–/–-KITY719F 
Mast cell numbers:     
2% (tb, ab-s, bs) 
 
 
 ~0% 27% (tb); 42% (tb, ab-s, 
bs, images in Agosti et 
al), ~25% (ns) 
0% (ns) 
Dorsal skin mast 
cells: 100% 
Tail dermis: ok 
Tail dermis: ok Tail dermis: ~0% Ear: ~63%; dorsal skin 
mc: 100% (tb); dors. 
skin mc: 100% 
 
~100% (tb) 
~100% (tb) 
~15% (tb) 
 
 
 
60% (tb) 
~0% (tb) 
 
~ok 
 
 
 
 
~60% 
~0% 
0%! 
nd nd 
nd 
 
 
nd nd nd nd 
Mice responses:     
nd 
 
nd nd nd nd 
nd 
 
nd nd nd nd 
BMMC responses:     
–, IL-3 supern. 
 
– – IL-3 supern.; IL-3 
supern. 
4 ng/ml IL-3 
 
nd 
SCF: ok ( reduced 
at ≤10 ng/ml)  
(6) 
nd nd SCF: 60% (200 ng/ml); 
70% (50 ng/ml) 
IL-3: nd 
(6) 
SCF: 20% 
nd 
SCF: ok      (6) 
nd nd SCF: 40% (200 ng/ml); nd    
IL-3: ok           (6) 
nd 
nd 
 
 
 
nd nd SCF:  (residual) 
 PKB kinase acti-vity 
(H2B) (but also high signal 
in unst. cells) 
SCF: 0% 
nd 
 
 
nd nd nd nd 
nd 
 
 
 
 
 
nd nd nd nd 
SCF: pY719, p85 
binding ok 
 Mega-stomach, -
colon (but not in 
W mice) 
 JNK activity (GST-
Jun) 
 JNK activity 
(GST-Jun) 
(Kimura Y, Proc 
Natl Acad Sci U S A, 
2004), (Agosti V, J 
Exp Med, 2004) 
(Kimura Y, Proc 
Natl Acad Sci U S 
A, 2004) 
(Kimura Y, Proc 
Natl Acad Sci U S 
A, 2004) 
(Kissel H, EMBO J, 
2000), (Agosti V, J Exp 
Med, 2004), (Yu M, J 
Biol Chem, 2006) 
(Yu M, J Biol Chem, 
2006) 
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Remarks:  
(1) Restoration by i. p. injection of BMMCs. Normal maturation there, since normal response to bacterial infection 
(TNF-α release). 
(2) Restoration by i. v. injection of bone marrow, but not BMMCs (-> environmental defects, requirement of other 
BM-derived cells). But recruitment of injected BMMCs to small intestine after previous subcutaneous infection with 
worm (S. venezuelensis) (inflammation-induced migration). But only Th2-preconditioned BMMCs (with IL-4, IL-10) 
can combat infection (impaired cytokine production by mesenteric p85α–/– lymphocytes in response to soluble 
worm antigen). 
(3) PKB activation only slightly reduced (by 30%). PI3Kδ expression levels normal (PI3Kα greatly reduced). Reduced 
proliferation may result from reduced JNK activation. Proliferative defect by SCF completely rescue in the presence 
of IL-3. 
(4) p85α-p55α-p50α–\– fetal liver-derived mast cell (Lu-Kuo JM, J Biol Chem, 2000): Reduced expression of PI3Kα, 
PI3Kβ, and PI3Kδ. Normal growth in IL-3 containing medium. Cells survive in the presence of SCF, but do not 
proliferate (cell#, 3H-Thymidine). PKB phosphorylation in response to SCF only slightly reduced (blot unclear) 
(IgE/MAR induced PKB activation normal). 
(5) Reduced degranulation (~50%) in response to SCF, normal in response to rat IgE (5, 20 µg/ml)/MAR (= F(ab’)2 
anti-rat IgG, 25 µg/ml) (10 Mio cells/ml)**. Degranulation (β-hexo) abrogated by LY294002. (**SHIP activation 
intact?  likely yes: no increased pPKB) 
(6) FLMCs degranulate in response to SCF**. p85α is expressed at much higher levels than p85β, and is responsible 
for the major p85-associated PI3K activity. FLMCs express p85α and p50α (p55α not detectable). 
p85α-p55α-p50α–\– fetal liver-derived mast cell (Tan BL, Blood, 2003): Greatly reduced migration to fibronectin 
coated transwells in response to SCF. 
(7) Personal comment: But BMMCs develop normally from bone marrow!  
(8) Wsh/Wsh BMMCs transduced with Kit Y567F, Y719F, or Y567F/Y719F (Timokhina I, EMBO J, 1998; Serve H, 
EMBO J, 1995):  
 Proliferation, SCF:  Y567F: ~50%    Y719F: ~70%    Y567F/Y719F: ~0% 
 Apoptosis, SCF:  Y567F: ~50%    Y719F: ~50%    Y567F/Y719F: ~100% 
 IL-3: both ok. SCF + Wm: ~30%    + PP1: 60% 
 Single mut, Wort, PP1: reduced JNK activation (IKA, GST-Jun). Double mut, Wort/PP1: greatly reduced. 
 Adhesion, SCF: Y719F: 50%    SCF + Wm: 0% 
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5.10 Thesis figures 
 
Thesis Figure 1 
 
 
 
Thesis Figure 2 
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Thesis Figure 3 
 
 
 
Thesis Figure 4 
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Thesis Figure 5 
 
A 
 
 
 
B 
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C 
 
 
Thesis Figure 6 
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Figure legends to “Thesis figures” 
 
Thesis Figure 1. (A) Exogenously expressed PI3Kγ can not fully complement endogenous PI3Kγ.  
Wild type or PI3Kγ–/– BMMCs were transfected with vector or 3 µg of PI3Kγ expression plasmid 
(totally 10 µg plasmid DNA). Next day, cells were IL-3 starved for 1 hour and stimulated with 200 
nM PMA for 30 s. PI3Kγ immunoprecipitations and cell lysates were analysed by Western blotting 
with the indicated antibodies. 
(B) N-terminal truncated PI3Kγ is highly overexpressed and does not support PKB activation. 
PI3Kγ–/– BMMCs were transfected with 0.75 µg of PI3Kγ ∆130 expression plasmid (totally 10 µg 
plasmid DNA) and stimulated and analysed as described in (A). 
 
Thesis Figure 2. Exogenously expressed PI3Kγ can not fully complement endogenous PI3Kγ. 
Wild type or PI3Kγ–/– BMMCs were transfected with vector or 1 µg of PI3Kγ and 1 µg of p84 
expression plasmids (totally 10 µg plasmid DNA). Cells were incubated with 100 ng/ml IgE 
overnight and starved next day for 2.5 hours in IL-3 free medium. Stimulations (16 ng/ml DNP) 
were stopped with ice-cold medium and cells were immediately centrifuged and lysed with 1x 
Laemmeli sample buffer. PKB phosphorylation and exogenous protein expression were analysed by 
immunoblotting. 
 
Thesis Figure 3. Several fold overexpression of PI3Kγ complements PKB phosphorylation. 
Wild type or PI3Kγ–/– BMMCs were transfected with 13 µg of vector or 4 µg of PI3Kγ and 4 µg of 
p84 expression plasmids (totally 13 µg plasmid DNA). Cells were starved for 3 hours in growth 
medium/2% FCS and stimulated with 50 nM PMA or 2 µM adenosine. Stimulations were stopped 
on ice and cells were harvested by centrifugation and lysed with 1x Laemmeli sample buffer. PKB 
phosphorylation and exogenous protein expression were analysed by immunoblotting. 
 
Thesis Figure 4. (A) Artificially membrane-attached PI3Kγ is inactive in BMMCs. 
(B) Level of endogenous PI3Kγ S582 phosphorylation (1.5-fold over PI3Kγ-CAAX) lies in the 
range of PI3Kγ-CAAX expression, assuming the later gets fully phosphorylated. 
(A/B) Wild type BMMCs were transfected with vector DNA or 0.5 µg of expression plasmids of 
EGFP-PI3Kγ and p84. PI3Kγ–/– BMMCs were transfected with 2 µg of PI3Kγ-CAAX and 0.5 µg 
of p84 expression plasmids (totally 8 µg plasmid DNA). Cells were incubated overnight with 100 
ng/ml IgE and IL-3 starved before stimulation with 200 nM PMA or 100 ng/ml DNP for 45 s. Cell 
lysates (A) and anti-PI3Kγ immunoprecipitations (B) were analysed by Western blotting with the 
indicated antibodies. 
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Thesis Figure 5. Model of PI3Kγ activation by Ser582 phosphorylation. 
(A) S582 (O: red, C: brown, N: blue balls) lies in the B helix of the first antiparallel A/B helix pair 
(light blue) of the helical domain (green) of PI3Kγ. The intrahelical loop (red) of this helix pair 
interacts with the C-terminal lobe of the kinase domain, including helix kα10 of the regulatory 
square (orange) and helix kα9 (violet). As these two helices build a wall of the pocket that 
surrounds the activation and catalytic loops, S582 phosphorylation might trigger PI3Kγ activation 
by inducing a conformational change in the catalytic centre. In the crystal structure of PI3Kγ ∆143 
(PDB ID: 1E7U), S582 is slightly buried looking more inside than outside of the structure. Because 
of this and other reasons it is likely that the beginning of the helical domain adopts a different 
conformation in the full-length enzyme and in the phosphorylated state. S582 lays in the same 
region as oncogenic helical domain-associated mutations in PI3Kα. For comparative purpose the 
corresponding residues in PI3Kγ have been marked by yellow colour and a star (*). For better view 
on kα9, kα10, and the loop, the C2 domain has been deleted from the shown structure. 
(B) Same structure as in (A) but viewed from the opposite side and including the C2 domain. 
Ser582 side chain hydroxyl group: O: red, H: gray. 
(C) Side view on Ser582. 90° rotation with respected to (B). 
 
Thesis Figure 6. Ser257 is located at the edge between PI3Kγ and Ras in the crystal structure. 
Section of the crystal structure of PI3Kγ with Ras (PDB ID: 1HE8). The surfaces of Ras and the 
loop of the PI3Kγ that gets ordered upon Ras binding are shown. The Ras binding domain (RBD) 
is coloured green. The S257 residue is coloured blue and the hydroxyl group oxygen is coloured red.  
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6. Material and methods 
 
6.1 Plasmids 
Full-length untagged human PI3Kγ was expressed from pcDNA3 (Invitrogen) (Bondeva T, 
Science, 1998) and S582 and S257 point mutations were introduced by polymerase chain reaction 
(PCR) using the overlap extension technique (Ho SN, Gene, 1989). Mouse PKCβ2 cDNA was 
obtained from Jae-Won Soh (PKClab.org) and inserted BamHI-BstEII-XhoI into pcDNA3 
containing a Kozak translation initiation sequence and the human influenza hemagglutinin (HA)-tag 
between HindIII and BamHI (pcDNA3-kzHA). The catalytic part of PKCβ2 (PKCβ2-CAT) 
including amino acids 302-673, was amplified from full-length PKCβ2 with the forward primer 5’-
ccgcaGGATCCcagaagtttgagagagccaagattg and the reverse primer 5’-ggcgTCTAGAttagctcttgacttcag-
gttttaaaaattc and inserted BamHI-XbaI into pcDNA3-kzHA. The pseudosubstrate deletion mutant 
of PKCβ2 was produced by the overlap extension technique with primers lacking the coding 
sequence for amino acids 19-31 of PKCβ2 (forward: 5’-gagcacagtgcacgaggtgaagaaccacaaattcac, 
reverse: 5’-cacctcgtgcactgtgctctcctcgccc) and two helper primers. The baculovirus transfer plasmid 
encoding GST-PI3Kγ (pAcG2T-PI3Kγ, codons 38-1102) has been described (Stoyanov B, Science, 
1995). The transfer plasmid for baculovirus-mediated expression of C-terminal His-tagged full-
length human PI3Kγ has been derived from pVL1393 (Invitrogen) containing codons 144-1102 of 
human PI3Kγ (kindly obtained from R. Williams, (Pacold ME, Cell, 2000)) by inclusion of codons 
1-143 by PCR. Serine 582 or S257 mutations were introduced into this construct by insertion of a 
PciI-EcoRI or BstEII-EcoRI fragment from mutant PI3Kγ in pcDNA3, respectively. All constructs 
were confirmed by sequencing. 
 
6.2 Mice 
C57BL/6J mice were from Jackson Laboratories. PKCβ (Leitges M, Science, 1996; Standaert ML, 
Endocrinology, 1999) and PI3Kγ knock-out mice (Hirsch E, Science, 2000) have been described 
and were both on a pure C57BL/6J genetic background. Experiments were carried out in 
accordance with institutional guidelines and national legislation. 
 
6.3 Cell Culture 
Mouse bone marrow-derived mast cells (BMMCs) were developed from progenitor cells by 
culturing femoral bone marrow of 8-12 week old mice in the presence of 2 ng/ml IL-3 for 4 weeks. 
Femurs were cut off at both ends and the marrow collected by centrifugation. Cells were 
resuspended in Icove’s modified Dulbecco’s medium (IMDM) (Sigma) supplemented with 10% 
heat-inactivated fetal calf serum (HI-FCS), 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml 
streptomycin, 50 µM β-mercaptoethanol, 2 ng/ml recombinant murine IL3 (Peprotech), and 5 
ng/ml SCF and cultured at 37°C, 5% CO2. IL3 (but not SCF) was readded every second or third 
day. Non-adherent cells were transferred to new flasks and diluted weekly to 0.5 Mio/ml using 80% 
of fresh and 20% of conditioned medium. Differentiation of BMMCs was confirmed by measuring 
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expressing of c-Kit and IgE receptors by flow cytometry. BMMCs were used for experiments after 
4 weeks of culture until maximally 16 weeks.  
The human embryonic kidney 293 (HEK293) cell line was grown in Dulbecco’s modified essential 
medium (DMEM) supplemented with 10% HI-FCS, 2 mM L-glutamine, 100 units/ml penicillin, 
and 100 µg/ml streptomycin at 37°C, 5% CO2. 
Spodoptera frugiperda (Sf9) cells were grown in IPL-41 medium (Genaxxon Bioscience) 
supplemented with 10% HI-FCS (Sigma-Aldrich), 2% yeastolate, 1% lipid concentrate, 50 µg/ml 
gentamicin (all Invitrogen), and 2.5 µg/ml amphotericin B (Genaxxon Bioscience). Sf9 cells were 
cultured as adherent or suspension culture at 27°C. Suspension cells were grown in Erlenmeyer 
flasks in a shaking incubator at 75-90 rpm.  
 
6.4 Transfection of HEK293 cells 
HEK293 cells were seeded into 6 cm dishes (1.32 Mio/dish). Next day, cells were transfected with 
JetPEITM (Polyplus-transfection) using 2.5 µg of total plasmid DNA. DNA concentrations were 
kept constant by the addition of empty pcDNA3 vector (Invitrogen). Cells were incubated with the 
transfection mixture for 5-8 hours, then the medium was exchanged and the cells left in the 
incubator overnight. 
 
6.5 Stimulation of BMMCs 
For stimulation of BMMCs through the Fc epsilon receptor I (FcεRI), cells were passively 
sensitized with 100 ng/ml anti-dinitrophenyl (DNP)-specific immunoglobulin E (SPE-7, Sigma) 
overnight in complete growth medium. Next day, cells were centrifuged for 5 min at 146 g and 
resuspended IL-3 free growth medium containing 2% or 10% FCS. Degranulation was induced by 
the addition of DNP coupled to human serum albumin (DNP30-40-HSA) (Sigma) at concentrations 
between 5 and 100 ng/ml. Other stimuli used to trigger BMMC activation were Thapsigargin 
(0.03125-1 µM, Sigma), phorbol 12-myristate 13-actetate (PMA) (50-200 ng/ml, Alexis), adenosine 
(1 µM, Sigma), stem cell factor (SCF) (10 ng/ml, Peprotech), and interleukin-3 (IL-3) (10 ng/ml, 
Peprotech). Stimulations were done at 37°C for the indicated times. Preincubation with B. Pertussis 
Toxin (PTx) (100 ng/ml, Sigma) was done for 4 hours, and adenosine deaminase (ADA) (10 
units/ml, Sigma) was added 1 min before stimulation. Pretreatment time was 15 min for 
Wortmannin (100 nM) and 20 min for the PKC inhibitors (Ro318425 (1 µM), Gö9683 (0.5 µM), 
Gö6976 (0.5 µM), Rottlerin (10 µM) (all Calbiochem), PKC412 (CPG41251) (1 µM, Novartis)). For 
Western blot analysis of PKB and MAPK phosphorylation, stimulations were stopped on ice and 
the cells were collected by centrifugation for 1 min at 2000 g at 4°C and immediately lysed in 1x 
Laemmli sample buffer [62.5 mM Tris/HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 
bromophenolblue]. 
 
6.6 (Co-)Immunoprecipitation (IP) 
Transfected HEK293 cells were washed with 3 ml of phosphate buffered saline (PBS) and lysed 
with 500 µl of NP-40 lysis buffer [50 mM Tris/HCl, pH 7.4, 138 mM NaCl, 2.7 mM KCl, 5% 
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glycerol, 1% NP-40] supplemented with protease inhibitors [20 µM leupeptin, 18 µM pepstatin, 5 
µg/ml aprotinin, phenylmethylsulfonylfluorid (PMSF)], phosphatase inhibitors [40 mM NaF, 2 mM 
Na3VO4 (Fluka)], 0.5 mM EDTA, and 0.5 mM EGTA (both Fluka) for 15 min on ice. Insoluble 
material was pelleted by centrifugation at 16’000 g for 10 min at 4°C. 50 µl of clarified lysate was 
mixed with 5x Laemmli sample buffer and used to examine exogenous protein expression. The 
remainder of lysate was incubated with either anti-PI3Kγ (6.4.1) or anti-HA (HA.11, Covance) 
antibodies for 1 hour at 4°C on a rotating wheel, followed the incubation with 25 µl of 
GammaBind Plus Sepharose (50 % slurry) (Amersham Biosciences) for another 2 hours. 
Immuncomplexes were washed 3x with NP-40 lysis buffer containing NaF and NaVO3, 1x with 0.1 
M Tris/HCl pH 7.4, 0.5 M LiCl2, and 1x with phosphate buffered saline pH 7.4. Bound proteins 
were eluted by the addition of 62.5 µl 1x Laemmli sample buffer, heated to 95°C for 3 min, and 
stored at -80°C until SDS-PAGE analysis. 
Unstimulated and stimulated BMMCs were collected by centrifugation and lysed in NP-40 lysis 
buffer supplemented with protease inhibitors, phosphatase inhibitors [40 mM NaF, 10 mM β-
glycerophosphate, 5 mM sodium pyrophosphate (all Fluka)], 2 mM EDTA, and 2 mM EGTA for 
15 min on ice. After removal of cell debris, lysates were precleared with 10 µl of protein A or G 
agarose beads (50% slurry) (Millipore, Amersham) for 30 min at 4°C. Supernatants were then 
transferred to new tubes and an aliquot (termed lysate) saved to analyse cell stimulation. Rest of the 
cleared lysate was incubate with anti-PI3Kγ (6.4.1) antibodies for 1-2 hours at 4°C, followed by 
additional incubation for 2-5 hours with 25 µl of protein A or G-agarose beads (50% slurry). Bead-
PI3Kγ complexes were washed 2x with NP-40 lysis buffer, 2x with 0.1 M Tris/HCl pH 7.4, 0.5 M 
LiCl2, 0.2% NP-40, and again 1x with NP-40 lysis buffer before resuspension in 1x Laemmli sample 
buffer. Lysates and immunoprecipitates were analysed by Western blotting. 
 
6.7 Western Blotting 
Protein samples were heated to 95°C for 5 min, centrifuged for 2 min at 16’000g, separated by 
SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to polyvinylidene fluorid (PVDF)-
membranes (Millipore) by semi-dry transfer. Membranes were blocked with 5% (w/v) milk powder 
(Migros, Schweiz) in TBS-T buffer [20 mM Tris/HCl, pH 7.6, 137 mM NaCl, 0.1% (v/v) Tween 20 
(Fluka)]. Blots were incubated overnight at 4°C with the primary antibody, followed by incubation 
with horseradish peroxidase (HRP)-coupled secondary goat anti-mouse or anti-rabbit antibodies 
(Sigma). Protein bands were visualized by enhanced chemiluminescence (ECL) (Millipore). 
Phospho-specific antibodies were kept in TBS-T/1% BSA (w/v) [P-PKB S473 (Sigma, 4058), P-
PKB T308 (Sigma, 4056 or 9275), P-MAPK (Sigma, M8159 or Promega, V8031), P-PI3Kγ S582 or 
S257 (antisera against phospho-peptide, affinity-purified, Eurogentec or AMS Biotechnology)], all 
others in TBS-T/1% (w/v) milk powder [PI3Kγ (raised against amino acids 97-335, ascites by 
Eurogentec), PKCβ2 (Santa Cruz, sc-210), PKCα (sc-208), PKCγ (sc-211), β-Tubulin (Boehringer 
Mannheim), α-Tubulin (Sigma, T9026), HA (Covance, MMS-101R), p84 (rabbit antisera produced 
by Zymed, (Bohnacker T, Sci Signal, 2009)), PKB (gift from B. Hemmings)].  
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Quantifications of Western blots have been done which ImageJ 1.42q software (NIH) after 
scanning of developed X-ray films (Fuji) on an Epson Perfection scanner (4990 Photo) as a 16-bit 
grayscale images without adjustments. Scanned images were inverted with ImageJ and bands were 
selected with the rectangle tool. Pixel values of the band and a background area above or below the 
selected band were used to calculate final intensities. Levels of protein phosphorylation were 
normalised to the total level of the protein and expressed in correlation to the signal obtained by a 
freely chosen stimulated sample. 
 
6.8 β-Hexosaminidase release assay 
Mast cell degranulation was assessed by measuring the release of β-hexosaminidase into cell 
supernatants (Schwartz LB, J Immunol, 1979; Ozawa K, J Biol Chem, 1993). BMMCs were cultured 
at 0.8-1 Mio cells/ml in complete growth medium overnight and were, if required, sensitized with 
100 ng/ml IgE. Cells were wash ones and resuspended in PIPES-buffered solution [25 mM PIPES 
pH 7.4, 119 mM NaCl, 5 mM KCl, 5.6 mM glucose, 1 mM CaCl2, 0.4 mM MgCl2, 0.1 % fatty-acid 
free, low endotoxin bovine serum albumin (LE-BSA, Sigma)]. 0.5 Mio cells were stimulated with 
DNP or Thapsigargin in a total volume of 500 µl in 24 well plates. Following incubation at 37°C 
for 20 min, plates were centrifuged at 4°C at 330 g for 5 min. 100 µl aliquots (triplicate) of 
supernatant were transferred to 96 well plates. For determination of total β-hexosaminidase, 
unstimulated cells were lysed by the addition of PIPES-buffered solution/0.1% Triton X-100 for 10 
min, and 100 µl aliquots (triplicate) were transferred to the 96 well plate. β-hexosaminidase activity 
was assessed by incubation with 100 µl of substrate solution [100 mM p-nitrophenyl-N-acetyl-β-D-
glucosaminidine (p-NAG) in 0.1 M sodium acetate pH 4] for 1 h at 37°C. The reaction was stopped 
with 100 µl of 0.15 M Na2CO3/NaHCO3, and the amount of produced p-nitrophenol was assessed 
by measuring absorbance at 410 nm on a spectrophotometer (Spectramax 340). Background values 
were obtained from lysates of unstimulated cells incubated without p-NAG. The amount of β-
hexosamidinase released was calculated by using the formula: Release (R) [%] = (AStimulated – 
AUnstimulated)/(ATotal unstimulated – ATotal background)*100 
 
6.9 Cytosolic Ca2+ concentrations 
BMMCs were washed with and resuspended in HEPES buffer [10 mM HEPES/NaOH pH 7.5, 
137 mM NaCl, 2.7 mM KCl, 5 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 0.1 % fatty acid free BSA]. 
Cells were loaded with 4 µM Fura-4F/AM for 10 min, washed twice, and resuspended in HEPES 
buffer containing different Ca2+ concentrations ([Ca2+]e (extracellular) = 0 - 1 mM) in order to modulate 
maximal stimulated Ca2+ uptake ([Ca2+]i). Cells were stimulated in final volume of 3 ml (0.5 Mio/ml) 
in a continuously stirred cuvette at 37° in a fluorescence spectrometer (Perkin Elmer LS50B). The 
excitation wavelength was alternated between 340 and 380 nm and fluorescence emission was 
measured at 510 nm. Data points were recorded every 200 ms. Samples were run first for 1 min to 
record the baseline and were then treated with 0.5 µM Thapsigargin for 5 min. Ca2+ levels were 
then adjusted to 2 mM and maximal Fura fluorescence (Fmax) was determined after cell 
permeabilisation with 0.1% Triton X-100. Minimal fluorescence (Fmin) values were obtained after 
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addition of 4 mM EGTA. After subtraction of autofluorescence, [Ca2+]i was calculated using the 
equation of Grynkiewicz et al, 1985 ([Ca2+]i = Kd[(R - Rmin)/(Rmax - R)](F380 EGTA/F380 Triton), R = 
F340/F380). To correlate intracellular Ca2+ concentrations with PKB phosphorylation, [Ca2+]i levels 
between 2 min and 2 min and 2 seconds were averaged and plotted against relative levels of 
phosphorylated PKB (S473). Phospho-PKB levels were obtained from cells (1.5 ml) taken out of 
the cuvette 2 min after stimulation. Lysed cells were analysed by Western blotting and PKB 
phosphorylation was quantified by intensity measurements with ImageJ software. 
 
6.10 Cellular PdtIns(3,4,5)P3 measurements 
Cellular PtdIns(3,4,5)P3 levels have been measured as described (Arcaro A and Wymann MP, 
Biochem J, 1993) with some modifications. BMMCs were cultured for 2 hours in phosphate-free 
RPMI medium/2% FCS at 37°C and 5% CO2, followed by labelling with 1 mCi/ml [32P]-
orthophosphate for 4 h. Cells were washed, stimulated, and lysed by the addition of 
chloroform/methanol (1:2, v/v, with butylated hydroxytoluene and carrier phosphoinositides). 
Lipids were extracted, deacylated, and separated by high pressure liquid chromatography (HPLC). 
 
6.11 Production of recombinant PI3Kγ 
Recombinant human PI3Kγ was expressed as glutathione S-transferase (GST)-fusion protein (N-
terminal) or was tagged C-terminal with six histidines. PI3Kγ protein was expressed in Sf9 cells by 
infection with recombinant baculoviruses. The recombinant baculovirus for the expression of GST-
PI3Kγ (amino acids 38-1102) has been described (Stoyanov B, Science, 1995). Recombinant 
baculoviruses expressing wild type or mutant (S582A, S582E) PI3Kγ-His6 have been obtained by 
cotransfection of 2 µg of transfer plasmid and 0.25 µg of BaculoGold DNA (BD Biosciences) into 
Sf9 cells as described by the manufacturer. 
For protein production, infected Sf9 cells were harvested 2-2.5 days postinfection, were washed 
twice wish PBS, und lysed in either GST- or His-lysis buffer [GST-buffer: 50 mM Tris/HCl, pH 
7.5, 150 mM NaCl, 5 mM EDTA, 1 mM NaF, 1 mM DTT, 1% Triton-X100; His-buffer: 50 mM 
NaH2PO4·2H2O/NaOH, pH 8, 300 mM NaCl, 20 mM imidazol, 5% glycerol, 1% NP-40] 
containing protease inhibitors. GST-tagged PI3Kγ was purified on glutathione sepharose 4B 
(Amersham Biosciences) beads and eluted with 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 5 mM 
EDTA, 1 mM DTT, 5% glycerol, 20 mM glutathione after extensive washing. PI3Kγ-His6 was 
purified by using nickel-nitrilotriacetic acid (Ni-NTA) superflow agarose beads (Qiagen) and was 
eluted with 50 mM NaH2PO4·2H2O/NaOH, pH 8, 300 mM NaCl, 250 mM imidazol. Proteins 
were mixed 1:1 with storage buffer [80 mM HEPES/NaOH pH 7.4, 4 mM EDTA, 2 mM DTT, 20 
mM benzamidine, ~90% ethylenglycol] and stored at -20°C, or alternatively, kept at 4°C in elution 
buffer/2 mM EDTA/1 mM DTT/10 mM benzamidine. Protein concentrations were quantified by 
Coomassie-stained SDS-PAGE gels with the Odyssey infrared imaging system and Odyssey v.2.1 
software (LI-COR Biosciences) using bovine serum albumin (BSA) as standard. Purified proteins 
were diluted to equal concentrations and quantified once more. 
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6.12 In vitro kinase assay 
Recombinant GST-PI3Kγ wild type (wt) or kinase inactive mutant (KR, Lys833 mutated to Arg) 
were incubated at an equal molar ratio with recombinant PKCβ2 (40 ng) (Invitrogen) in 1x kinase 
buffer (KB) [50 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 1 mM DTT, 0.03% Triton X-
100] in the presence of 10 µM adenosine 5’-triphosphate (ATP) and 5 µCi of [γ32P]-ATP [Perkin 
Elmer, 6000 Ci/mmol] per sample in a final volume of 40 µl. Kinase reactions were prewarmed for 
2 min at 30°C, started by the addition of 4 µl of ATP-mix (in H2O) in 20 second intervals, and 
incubated at 30°C for 30 min on an heat block with shaking (1200 min-1). Reactions were 
terminated by the addition of 5x Laemmeli sample buffer and the proteins were resolved by SDS-
PAGE. Gels were stained with Coomassie brilliant blue (Serva blue G) and dried onto a Whatmann 
paper. 32P-incorporation was visualized by autoradiography. For quantification, gels were exposed 
to a storage phosphor screen (GP, Kodak), which was scanned with a phosphoimager (Typhoon 
9400). Band intensities were quantified with ImageQuant TL Software (Amersham Biosciences). As 
standard, a dilution series of the ATP/[γ32P]-ATP-mix was spotted onto the Whatmann paper. 
Some of the samples were incubated in the presence phosphatidylserine (PS, Sigma) lipid vesicles 
(0.1 mg/ml) containing 1-oleoyl-2-acetyl-sn-glycerol (OAG, 0.01 mg/ml, Cayman Chemical). PS in 
CHCl3/MeOH 2:1 was mixed with OAG in acetonitril in a Eppendorf tube, dried by a stream of 
nitrogen gas, and resuspended in 1x KB by sonication.  
 
6.13 In vitro lipid kinase assay 
Assays were performed in a final volume of 50 µl in 1.5 ml Eppendorf tubes in 1x lipid kinase 
buffer (LKB) [40 mM HEPES, pH 7.4, 150 mM NaCl, 4 mM MgCl2, 1 mM DTT, 0.1 mg/ml fatty-
acid free BSA] in the presence of PtdIns(4.5)P2-containing lipid vesicles, 10 µM adenosine 5’-
triphosphate (ATP), and 4 µCi of [γ32P]-ATP [Perkin Elmer, 6000 Ci/mmol] per sample. 
Phospholipid composition of the lipid vesicles has been chosen to mimic relative mole ratios found 
in the inner leaflet of the plasma membrane (PE/PS/PC/SM/PIP2 = 30/20/10/4.5/1.2-4.6). 
Lipids dissolved in CHCl3/MeOH (2:1) were combined in a glass tube [f. c. in assay: 130 µM PE, 87 
µM PS, 43 µM PC, 20 µM SM, 5-20 µM PIP2], dried under a steam of nitrogen gas, and 
resuspended in 1x LKB without BSA by sonication (3x 15 seconds at an amplitude of 30%) on ice 
with a tip sonicator (U200S, IKA Labortechnik). Recombinant wild type or mutant PI3Kγ-His6 
(200 ng/reaction) were diluted into 1x LKB and added (8 µl) to 4 µl of mastermix [1xLKB, but 
with 1.05 mg/ml BSA] followed by the addition of 30 µl of lipid mix. Samples were mixed and kept 
on ice for additional 20 min, were then warmed up to 30°C for 2 min on a heat block before 
starting the reaction by the addition of 8 µl of ATP-mix in 1x LKB without BSA. Samples were 
incubated for 10 min at 30°C with shaking (1200 min-1) on a heat block. The reaction was stopped 
by the addition of 100 µl 1 N HCl and the lipids were extracted by the addition of 200 µl 
CHCl3/MeOH 1:1 and vortexing. Phases were separated by centrifugation for 2 min at 9300 g, the 
lower organic phase was transferred to a new tube, and the lipids dried under a low heat vacuum in 
a Speed-Vac (Univapo 150H). Lipids were redissolved in CHCl3/MeOH 4:1 and loaded onto a 
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potassium oxalate-pretreated silica gel 60 W F254S plate (Merck) for separation by thin layer 
chromatography (TLC) in a horizontal tank using CHCl3/acetone/MeOH/acetic acid/H2O 
(80/30/26/24/14 v/v) as mobile phase. Dried plates were exposed to Fuij Super RX X-ray films 
and phosphoimager screen and quantified by phosphoimager technology. 
L-α-phosphatidylcholine from chicken egg (PC), sphingomyelin from porcine brain (SM), and L-α-
phosphatidylinositol(4,5)bisphosphate from porcine brain, triammonium salt (PIP2) were purchased 
from Avanti Polar Lipids, while L-α-phosphatidylserine (PS) from bovine brain and L-α-
phosphatidylethanolamine from egg yolk, type III (PE) were obtained from Sigma-Aldrich. 
 
6.14 Mass spectrometry 
The PI3Kγ protein band was excised from the gel, reduced with 10 mM DTT, alkylated with 55 
mM iodoacetamide, and cleaved with porcine trypsin (Promega, Madison, USA) in 50 mM 
ammonium bicarbonate (pH 8.0) at 37°C overnight (Shevchenko A, Anal Chem, 1996). The 
extracted peptides were analyzed by capillary liquid chromatography tandem mass spectrometry 
(LC-MSMS) using a Magic C18 100 µm x 10 cm HPLC column (SwissBioanalytics, Switzerland) 
connected on line to a 4000 Q Trap (MDS Sciex, Concord, Ontario, Canada) as described earlier 
(Vichalkovski A, Oncogene, 2010). Data analysis was done with Mascot (Perkins DN, 
Electrophoresis, 1999) searching the protein sequence database UNIPROT_15.6. from Feb 2010 
(9421896 sequences; 1248797668 residues). Relative quantification of the peptides was done with 
multiple reaction monitoring (MRM) using the same instruments and identical chromatographic 
conditions. The approach was described earlier (Hess D, J Biol Chem, 2008). 
 
6.15 Protein expression and purification for deuterium exchange studies 
The PI3Kγ alone and PI3Kγ/p84 complex were expressed in Sf9 cells using the pFastBac system 
(Invitrogen). Cells were resuspended in sonication buffer (50 mM Tris/HCl pH 8, 100 mM NaCl, 1 
mM PEFA, 25 mM imidazole) and lysed by sonication on ice for 10 minutes. The lysates were 
ultracentrifuged at 35’000 rpm for 45 minutes at 4 °C in a Ti45 rotor. The soluble cell lysate was 
filtered through a 0.45 µM filter. Subsequently, the lysate was passed over a Ni-NTA 5 ml Fast 
Flow column (GE Healthcare) and eluted with an imidazole concentration gradient from 25 to 200 
mM. The protein was further purified by ion-exchange HiTrap Q (5ml), Heparin agarose (5ml), and 
Superdex 200 (16/60) gel-filtration chromatography. The protein was eluted from the gel filtration 
column in 20 mM Tris pH 7.5, 100 mM NaCl, 5 mM DTT, and 1 mM (NH4)2SO4.  
 
6.16 Deuterium exchange sample preparation 
5 µl of stock protein solutions (Hs_PI3Kγ-His6: 30 µM; Hs_PI3Kγ-His6/Mm_p84-His6: 35μM) 
were prepared in 20 mM Tris pH 7.5, 100 mM NaCl, 5 mM DTT, and 1 mM ammonium sulfate. 
Exchange reactions were initiated by addition of 25 µl of a 98% D2O solution containing 10 mM 
HEPES pH 7.2, 50 mM NaCl, and 2 mM DTT, giving a final concentration of 82% D2O. 
Deuterium exchange reactions were allowed to carry on for seven time periods, 3, 10, 30, 100, 300, 
1000, and 3000 seconds at 23ºC. On-exchange was stopped by the addition of 40 µl of quench 
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buffer containing 1.2% formic acid and 0.833 M guanidine-HCl, which lowered the pH to 2.6. 
Samples were then immediately frozen in liquid nitrogen until mass analysis. 
 
6.17 Protein digestion and peptide identification 
Different digestion conditions were employed to optimize the peptide digestion map. These 
optimizations included changing denaturant concentration, flow rate over pepsin, and denaturation 
time. Peptide identification was performed by running tandem MS/MS experiments using a Sciex 
QStar Pulsar hybrid QqTOF (Applied Biosystems). Data was analyzed using Mascot software v. 2.2 
(Matrix Science) to identify all peptides based on fragmentation and peptide mass, and these 
identifications were then manually validated using DXMS software (Sierra Analytics) to test for 
correct m/z state, and the presence of overlapping peptides. 
 
6.18 Measurement of deuterium incorporation 
Samples were thawed rapidly on ice and then injected onto an online HPLC system that was 
immersed in ice. The protein was run over an immobilized pepsin column (Applied Biosystems, 
Poroszyme®, 2-3131-00) at 50 µl/min, and collected over a 1.7 µm particle C18 peptide trap (2.1 
mm x 8 mm, Waters Van-guard) for five minutes. The trap was then switched in line with a 1.7 µm 
particle, 1 mm x100 mm C18 column (Waters Acquity UPLC) with a vanguard pre-column and 
peptides were eluted by a 5-45% gradient of buffer A (0.1% formic acid) and buffer B (80% 
acetonitrile, 20% H2O, 0.02% formic acid) over 22 minutes and injected onto a Sciex QStar Pulsar 
hybrid QqTOF (Applied Biosystems) which collected mass spectra from a range of 350 to 1300 
m/z. 
Mass analysis of the peptide centroids was performed as described previously using the software 
DXMS (Sierra Analytics) (Burke JE, Biochemistry, 2008; Burke JE, Structure, 2011). Briefly, all 
selected peptides passed the quality control threshold of the software, and were then manually 
examined for accurate identification and deuterium incorporation. Results are shown as relative 
levels of deuteration with no correction for back exchange as described previously (Iacob RE, Proc 
Natl Acad Sci U S A, 2009). The real level of deuteration will be ~25-35% higher than what is 
shown, based on tests performed with fully deuterated standard peptides. All experiments were 
repeated in duplicate, and we found that the average error was less than 0.2 Da. For this reason we 
consider all changes greater than 0.5 Da that occur at more than one time point as significant. The 
resulting deuterium incorporation was graphed versus the on-exchange time. All deuterium 
exchange data for all peptides analyzed (202 peptides) is shown in tabular form (Table S1). 
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7. Plasmid list 
 
7.1 Plasmids engineered during this study 
 
Number Plasmid Name Insert 
971 pcDNA3<kzNHA>#971 HA-Tag 
972 pcDNA3<CHA>#972 HA-Tag 
973 pcDNA3<kzNGST>#973 GST 
974 pcDNA3<CGST>#974 GST 
975 pcDNA3<CYFP>#975 EYFP 
976 pcDNA3<CHA><kzPKCβ2 REG>#976 PRKCB, PKCb, REG 
977 pcDNA3<kzNHA><PKCβ2 CAT>#977 PRKCB, PKCb, CAT 
978 pcDNA3<kzNHA><PKCβ2 WT>#978 PRKCB, PKCb, AA1-673 
979 pcDNA3<CGST><kzPKCβ2 REG>#979 PRKCB, PKCb, REG, AA1-301 
980 pcDNA3<kzNGST><PKCβ2 CAT>#980 PRKCB, PKCb, CAT, AA302-673 
981 pcDNA3<kzNGST><PKCβ2 WT>#981 PRKCB, PKCb, AA1-673 
982 pcDNA3<CYFP><kzPKCβ2 REG>#982 PRKCB, PKCb, REG, AA1-301 
983 pEYFP-C1<PKCβ2 CAT>#983 PRKCB, PKCb, CAT, AA302-673 
990 pcDNA3-tkGST<PKCβ2 CAT>#990 PRKCB, PKCb, AA302-673 
991 pcDNA3-tkGST<PKCβ2 WT>#991 PRKCB, PKCb, AA1-673 
992 pcDNA3<kzNHA><PKCβ2 CAT-KR>#992 PRKCB, PKCb, CAT, AA302-673 
994 pcDNA3<kzNHA><hsPI3Ka>#994 PI3K alpha, PI3Ka, p110a, HA 
995 pcDNA3<hsPI3Ka>#995 PI3K alpha, PI3Ka, p110a 
996 pVL1393<hsPI3Ka>#996 PI3K alpha, PI3Ka, p110a 
997 pcDNA3<kzNHA><Mm_PKCb1 WT>#997 PRKCB1, PKCb1, PKCb 
998 pcDNA3<kzNHA><PKCβ2 ∆PS>#998 PRKCB, PKCb, DPS (∆AA19-31) 
1036 pcDNA3<kzNHA><PKCβ2 ∆PS-KR>#1036 PRKCB, PKCb, DPS 
1037 pEYFP-C1<PKCβ2 ∆PS>#1037 PRKCB, PKCb, DPS 
1038 pEYFP-C1<PKCβ2 ∆PS-KR>#1038 PRKCB, PKCb, DPS 
1042 pEYFP-C1<PKCb2 CAT-KR>#1042 PRKCB, PKCb, CAT 
1043 pVL1393<Mm_p87-(His)6>#1043 p87 PIKAP, His6 
1053 pVL1393<kzNHA><PKCb2 WT>#1053 PRKCB, PKCb 
1054 pVL1393<kzNHA-PKCb2 DPS>#1054 PRKCB, PKCb, DPS (unstable expr.) 
1055 pVL1393<kzNHA-PKCb2 CAT>#1055 PRKCB, PKCb, CAT 
1066 pVL1393<Hs_PI3Kg WT>#1066 PI3Kg, p110g 
1067 pVL1393<Hs-PI3Kg KR>#1067 PI3Kg, p110g 
1068 pcDNA3<Hs_PI3Kg WT>#1068 PI3Kg, p110g 
1069 pVL1393<Hs_p87>#1069 p87 PIKAP 
1117 pCR4Blunt-TOPO<Hs_p101>#1117 p101 
1124 pcDNA3.1zeo<kzVenus[1]-Mm_PKCβ2 WT-CHA>#1124 PRKCB, PKCb 
1125 pcDNA3.1zeo<kzNHA-MmPKCβ2 WT-Venus[1]>#1125 PRKCB, PKCb 
1126 pcDNA3.1zeo<kzVenus[1]-Mm_PKCβ2 ∆PS-CHA>#1126 PRKCB, PKCb, DPS 
1127 pcDNA3.1zeo<kzNHA-MmPKCβ2 ∆PS -Venus[1]>#1127 PRKCB, PKCb, DPS 
1128 pcDNA3<kzVenus[2]-Hs_PI3Kg-CHA>#1128 PI3Kg, p110g 
1129 pcDNA3<kzNHA-Hs_PI3Kg-Venus[2]#1129 PI3Kg, p110g 
1131 pEGFP-C1<Mm_PKCβ2 WT>#1131 PRKCB, PKCb 
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1132 pEGFP-C1<Mm_PKCβ2 ∆PS>#1132 PRKCB, PKCb, DPS 
1133 pEGFP-C1_with NotI&XbaI EGFP 
1134 pEGFP-C1<Hs_p101>#1134 p101 
1135 pEGFP-C1<Hs_p87>#1135 p87 PIKAP 
1158 pVL1393<Hs_PI3Kg KR-GST>#1158 PI3Kg, p110g, GST 
1159 pVL1393<Hs_PI3Kg KR S257A-GST>#1159 PI3Kg, p110g, GST 
1164 pcDNA3<Hs_PI3Kg-EGFP>#1164 PI3Kg, p110g 
1165 pcDNA3<Hs_PI3Kg S257A-EGFP>#1165 PI3Kg, p110g 
1166 pcDNA3<Hs_PI3Kg S257E-EGFP>#1166 PI3Kg, p110g 
1167 pcDNA3<Hs_PI3Kg S257D-EGFP>#1167 PI3Kg, p110g 
1168 pVL1393<Hs_PI3Kg S257A-GST>#1168 PI3Kg, p110g 
1202 pVL1932<His-Mm_PKCb2 CAT>#1202 PRKCB, PKCb, CAT 
1203 pVL1392<His-Mm_PKCb2 WT>#1203 PRKCB, PKCb 
1204 pVL1932<His-Mm_PKCb2 CAT KR>#1204 PRKCB, PKCb, CAT 
1205 pVL1392<His-Mm_PKCb2 KR>#1205 PRKCB, PKCb 
1216 pVL1393<Hs_PI3Kg WT-His>#1216 PI3Kg, p110g, His6 
1217 pVL1393<Hs_PI3Kg KR-His>#1217 PI3Kg, p110g 
1218 pVL1393<Hs_PI3Kg S257A WT-His>#1218 PI3Kg, p110g 
1219 pVL1393<Hs_PI3Kg S257A KR-His>#1219 PI3Kg, p110g 
1220 pVL1393<Hs_PI3Kg S257E WT-His>#1220 PI3Kg, p110g 
1221 pVL1393<Hs_PI3Kg S257D WT-His>#1221 PI3Kg, p110g 
1222 pVL1393<Hs_PI3Kg S582A WT-His>#1222 PI3Kg, p110g 
1223 pVL1393<Hs_PI3Kg S582A KR-His>#1223 PI3Kg, p110g 
1224 pVL1393<Hs_PI3Kg S582E WT-His>#1224 PI3Kg, p110g 
1225 pVL1393<Hs_PI3Kg S257A S582A WT-His>#1225 PI3Kg, p110g 
1226 pVL1393<Hs_PI3Kg S257A S582A KR-His>#1226 PI3Kg, p110g 
1227 pVL1393<Hs_PI3Kg S257E S582E WT-His>#1227 PI3Kg, p110g 
1233 pLenti CMV MCSmod#1233 - 
1234 pcDNA3<Hs_PI3Kg WT 3’UTR>#1234 PI3Kg, p110g 
1235 pcDNA3<Hs_PI3Kg S257A WT 3’UTR>#1235 PI3Kg, p110g 
1236 pcDNA3<Hs_PI3Kg S257E WT 3’UTR>#1236 PI3Kg, p110g 
1237 pcDNA3<Hs_PI3Kg S257D WT 3’UTR>#1237 PI3Kg, p110g 
1238 pcDNA3<Hs_PI3Kg S582A WT 3’UTR>#1238 PI3Kg, p110g 
1239 pcDNA3<Hs_PI3Kg S582E WT 3’UTR>#1239 PI3Kg, p110g 
1240 pcDNA3<Hs_PI3Kg S257A S582A WT 3’UTR>#1240 PI3Kg, p110g 
1241 pcDNA3<Hs_PI3Kg S257E S582E WT 3’UTR>#1241 PI3Kg, p110g 
1242 pEGFP-C1<Hs_PI3Kg S257A WT>#1242 PI3Kg, p110g 
1243 pEGFP-C1<Hs_PI3Kg S257E WT>#1243 PI3Kg, p110g 
1244 pEGFP-C1<Hs_PI3Kg S257D WT>#1244 PI3Kg, p110g 
1245 pEGFP-C1<Hs_PI3Kg S582A WT>#1245 PI3Kg, p110g 
1246 pEGFP-C1<Hs_PI3Kg S582E WT>#1246 PI3Kg, p110g 
1247 pEGFP-C1<Hs_PI3Kg S257A S582A WT>#1247 PI3Kg, p110g 
1248 pEGFP-C1<Hs_PI3Kg S257E S582E WT>#1248 PI3Kg, p110g 
1249 pLenti CMV<Hs_PI3Kg WT>#1249 PI3Kg, p110g 
1250 pLenti CMV<Hs_PI3Kg S257A WT>#1250 PI3Kg, p110g 
1251 pLenti CMV<Hs_PI3Kg S257E WT>#1251 PI3Kg, p110g 
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1252 pLenti CMV<Hs_PI3Kg S257D WT>#1252 PI3Kg, p110g 
1253 pLenti CMV<Hs_PI3Kg S582A WT>#1253 PI3Kg, p110g 
1254 pLenti CMV<Hs_PI3Kg S582E WT>#1254 PI3Kg, p110g 
1255 pLenti CMV<Mm_PKCb2 WT>#1255 PRKCB, PKCb 
1256 pLenti CMV<Mm_PKCb1 WT>#1256 PRKCB1, PKCb1 
1278 pcDNA3<Hs_PI3Kg S582D WT 3’UTR>#1278 PI3Kg, p110g 
1279 pEGFP-C1<Hs_PI3Kg S582D WT>#1279 PI3Kg, p110g 
1280 pLenti CMV<Hs_PI3Kg S582D WT>#1280 PI3Kg, p110g 
1281 pVL1393<Hs_PI3Kg S582D WT>#1281 PI3Kg, p110g 
1282 pLenti CMV EGFP#1282 EGFP 
1338 pSYFP1-C1#1338 SYFP1 
1339 pTurquoise-C1#1339 mTurquoise 
1350 pSYFP1-C1<Mm_PKCb2 WT> PRKCB, PKCb 
1351 pSYFP1-C1<Mm_PKCb2 KR>#1351 PRKCB, PKCb 
1352 pSYFP1-C1<Mm_PKCb2 DPS>#1352 PRKCB, PKCb, DPS 
1353 pSYFP1-C1<Mm_PKCb2 DPS-KR>#1353 PRKCB, PKCb, DPS 
1354 pSYFP1-C1<Mm_PKCb2 CAT>#1354 PRKCB, PKCb, CAT 
1355 pTurquoise<Mm_PKCb2 WT>#1355 PRKCB, PKCb 
1356 pTurquoise<Mm_PKCb2 DPS>#1356 PRKCB, PKCb, DPS 
1357 pTurquoise<Mm_PKCb2 CAT>#1357 PRKCB, PKCb, CAT 
1358 pLenti CMV SYFP1#1358 SYFP1 
1359 pLenti CMV mTurquoise#1359 mTurquoise 
1360 pSYFP1-C1<Mm_PKCb2 S660A>#1360 PRKCB, PKCb 
1361 pcDNA3<kNHA><Mm_PKCb2 T500E>#1361 PRKCB, PKCb 
1362 pcDNA3<kNHA><Mm_PKCb2 DPS T500E>#1362 PRKCB, PKCb, DPS 
1363 pcDNA3<kNHA><Mm_PKCb2 CAT T500E>#1363 PRKCB, PKCb, CAT 
1371 pLenti CMV SYFP1<Hs_PI3Kg>#1371 PI3Kg, p110g 
1372 pLenti CMV mTurquoise<Hs_PI3Kg>#1372 PI3Kg, p110g 
1376 pcDNA3-tkGST<Hs_PI3Kg wt>#1376 PI3Kg, p110g 
1377 pcDNA3-tkGST<Hs_D130-PI3Kg>#1377 PI3Kg, p110g 
1378 pcDNA3<Hs_D130-PI3Kg>#1378 PI3Kg, p110g 
 
7.2 Other plasmids entered into the database 
 
Number Name Gene 
942 GST-pmt2<PKCβ2-CAT>#942 PRKCB, PKCb, CAT 
943 GST-pmt2<PKCβ2-REG>#943 PRKCB, PKCb, REG 
1039 pIRES2-EGFP#1039 - 
1040 pIRES2-EGFP<rRack1>#1040 rack1, rack, Gnb 
1041 pRevTRE<rRack1>#1041 rack1, rack, Gnb 
1044 pVL1392#1044 - 
1045 pVL1393#1045 - 
1200 pVL1393<Hs_D143-PI3Kg-His>#1200 PI3Kg, p110g, His6 
1228 pLenti CMV MCS - 
1229 pLenti EF DsRed DsRed 
1230 pMDL g-p RRE  
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1231 lenti REV vector  
1232 lenti VSV-G vector  
1334 pSYFP1-C1<Hs_PI3Kg>#1334 PI3Kg, p110g 
1335 pTurquoise-C1<Hs_PI3Kg>#1335 PI3Kg, p110g 
1336 pSYFP1-C1<Hs_PKCb2>#1336 PRKCB, PKCb 
1337 pTurquoise-C1<Hs_PKCb2>#1337 PRKCB, PKCb 
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Abstract
All class I phosphoinositide 3-kinases (PI3Ks) associate tightly with regulatory subunits through interactions that have been
thought to be constitutive. PI3Kc is key to the regulation of immune cell responses activated by G protein-coupled
receptors (GPCRs). Remarkably we find that PKCb phosphorylates Ser582 in the helical domain of the PI3Kc catalytic subunit
p110c in response to clustering of the high-affinity IgE receptor (FceRI) and/or store-operated Ca2+- influx in mast cells.
Phosphorylation of p110c correlates with the release of the p84 PI3Kc adapter subunit from the p84-p110c complex. Ser582
phospho-mimicking mutants show increased p110c activity and a reduced binding to the p84 adapter subunit. As
functional p84-p110c is key to GPCR-mediated p110c signaling, this suggests that PKCb-mediated p110c phosphorylation
disconnects PI3Kc from its canonical inputs from trimeric G proteins, and enables p110c to operate downstream of Ca2+ and
PKCb. Hydrogen deuterium exchange mass spectrometry shows that the p84 adaptor subunit interacts with the p110c
helical domain, and reveals an unexpected mechanism of PI3Kc regulation. Our data show that the interaction of p110c
with its adapter subunit is vulnerable to phosphorylation, and outline a novel level of PI3K control.
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Introduction
Class I phosphoinositide 3-kinases (PI3Ks) produce the lipid second
messenger phosphatidylinositol(3,4,5)-trisphosphate [PtdIns(3,4,5)P3]
and consist of a p110 catalytic and a regulatory subunit. The class IA
catalytic subunits, p110a, b, and d, are constitutively bound to p85-
related regulatory proteins that link them to the activation by protein
tyrosine kinase receptors. The only class IB PI3K member, p110c, is
activated downstream of G protein-coupled receptors (GPCRs), and
interacts with p101 or p84 (also known as p87PIKAP) adaptor subunits
[1–3]. A tight complex of the p110c catalytic subunit (PK3CG) with
p101 was first discovered in neutrophils [1]. The p101 subunit (PI3R5)
sensitizes PI3Kc for activation by Gbc subunits of trimeric G proteins,
and is essential for chemotaxis of neutrophils towards GPCR-ligands
[1,4,5].
Mast cells do not express p101; however, they do express the
homologous adaptor protein p84 ([PI3R6]) [6], which shares 30%
sequence identity with p101. Both p101 and p84 potentiate the
activation of p110c by Gbc, but the p110c-p101 complex is
significantly more sensitive towards Gbc, and displays an
enhanced translocation to the plasma membrane as compared
with p110c-p84 [7]. Although p84 is absolutely required to relay
GPCR signals to protein kinase B (PKB/Akt) phosphorylation and
degranulation [6], its role is not completely understood: contrary
to p110c-p101, p110c-p84 requires additionally the presence of
the small G protein Ras, and might operate in distinct membrane
micro-domains [6,7].
Interestingly, genetic ablation of p110c blocks high-affinity IgE
receptor (FceRI)-dependent mast cell degranulation in vitro and in
vivo [8]. In part this is due to the fact that initial IgE/antigen-
mediated mast cell stimulation triggers the release of adenosine
and other GPCR ligands to feed an autocrine/paracrine activation
of PI3Kc, which then functions as an amplifier of mast cell
degranulation. Interestingly, a substantial part of the observed
PI3Kc-dependent histamine-containing granule release (ca. 40%)
was found to be resistant to Bordetella pertussis toxin (PTx)
pretreatment [9,10]. Furthermore, although adenosine activates
PI3Kc via the A3 adenosine receptor (A3AR; [ADORA3]), A3AR
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null mice are still sensitive to passive systemic anaphylaxis, and
degranulation in A3AR
2/2 bone marrow-derived mast cells
(BMMCs) upon antigen stimulation remains functional [11,12].
This and the strong degranulation phenotype of PI3Kc2/2
BMMCs suggest that GPCR signaling does not generate the full
input to PI3Kc-dependent degranulation, but a GPCR-indepen-
dent activation mechanism for PI3Kc has yet to be defined.
Here we identify a mechanism that activates PI3Kc indepen-
dently of GPCRs: we demonstrate that (i) IgE/antigen complexes
and extracellular Ca2+ influx activate PI3Kc, (ii) PI3Kc is
operationally linked to the FceRI specifically by PKCb (PRKCB),
(iii) and that the phosphorylation of Ser582 located in the helical
domain of p110c by PKCb leads to the dissociation of the p84
adapter to decouple phosphorylated p110c from GPCR inputs.
Further we characterize the p110c-p84 interface, and delineate an
activation process that seems to be conserved among class I PI3Ks.
Results
Thapsigargin-Induced Mast Cell Activation Needs PI3Kc
A committed step in mast cell activation is the influx of
extracellular Ca2+ by store-operated Ca2+ entry (SOCE) [13].
Thapsigargin, which inhibits the sarco/endoplasmic reticulum
Ca2+ reuptake ATPase (SERCA), causes depletion of Ca2+ stores,
triggering SOCE. The latter achieves full-scale degranulation of
BMMCs [14]. Surprisingly, BMMCs devoid of the p110c catalytic
subunit of PI3Kc lost their responsiveness to thapsigargin and
matched degranulation responses attained by wortmannin-pre-
treated cells (Figure 1A). To investigate if thapsigargin-triggered,
p110c-dependent degranulation involved release of adenosine,
BMMCs were preincubated with adenosine deaminase (ADA)
(Figure 1B) to convert adenosine to inosine, which has a very low
affinity for adenosine receptors. ADA attenuated degranulation
induced by IgE/antigen but did not affect thapsigargin-stimulated
degranulation in wild type cells and did not further attenuate
γ
β
γ
γ
γ
Figure 1. Thapsigargin-induced mast cell degranulation re-
quires PI3Kc, but not GPCR signaling. (A) Granule release of wild
type and p110c2/2 BMMCs was determined detecting b-hexosamini-
dase (b-Hex) release into extracellular media. BMMC stimulation with
IgE/antigen was initiated with the antigen (Ag, DNP-HSA at 10 ng/ml;
100 ng/ml IgE overnight). Alternatively, BMMCs were stimulated by the
addition of thapsigargin (1 mM). Where indicated, BMMCs were
preincubated for 15 min with 100 nM wortmannin. Released b-Hex
was quantified 20 min after stimulation, and is expressed as mean 6
standard error of the mean (SEM) (n= 3; p-values in all figures are * or &:
p,0.05, **: p,0.005; ***: p,0.0005; * depict here comparison with
respective wild type control; & refer to comparison of untreated versus
treated samples). (B) Granule release was assessed as above, but ADA
(10 units/ml) was added to BMMC suspensions 1 min before stimulation
where depicted. (C) Wild type or p110c2/2 BMMCs were stimulated
with adenosine (Ade; 1 mM) or thapsigargin (1 mM) for 2 min, and
phosphorylation of PKB/Akt on Thr308 (pPKB), total PKB and p110c was
analyzed by Western blotting. BMMCs were incubated in starving
medium (2% FCS, without IL-3) for 3 h before stimulation, and
pretreated with ADA where indicated. (D) Heterotrimeric Gai proteins
were inactivated by preincubation of wild type and p110c2/2 BMMCs
with 100 ng/ml PTx for 4 h, before thapsigargin (Tg) or adenosine was
added as in (C).
doi:10.1371/journal.pbio.1001587.g001
Author Summary
Phosphoinositide 3-kinases (PI3Ks) are involved in most
essential cellular processes. Class I PI3Ks are heterodimers:
class IA PI3Ks are made up of one of a group of regulatory
p85-like subunits and one p110a, p110b, or p110d catalytic
p110 subunit, and are activated via binding of their p85
subunit to phosphorylated tyrosine receptors or their
substrates. The only, class IB PI3K member, PI3Kc, operates
downstream of G protein-coupled receptors (GPCRs).
Recent work suggested that PI3Kc also operates down-
stream of IgE-antigen complexes in mast cell activation,
but no mechanism was provided. We show that clustering
of the high-affinity IgE receptor FceRI triggers a massive
calcium ion influx, which leads to PKCb activation. In turn,
PKCb phosphorylates Ser582 of the PI3Kc catalytic p110c
subunit’s helical domain. Downstream of GPCRs, p110c
requires a p84 adapter to be functional. Phospho-
mimicking mutations at Ser582 disrupt the p84-p110c
interaction, and cellular Ser582 phosphorylation correlates
with the loss of p84 from p110c. Thus our data suggest
that PKCb phosphorylates and activates p110c down-
stream of calcium ion influx, while simultaneously discon-
necting the phosphorylated p110c from GPCR signaling.
Exploration of the p84-p110c interaction surface by
hydrogen- deuterium exchange mass spectrometry con-
firmed that the p110c helical domain forms the main p84-
p110c contact surface. Taken together, the results suggest
an unprecedented mechanism of PI3Kc regulation.
A Molecular Switch on PI3Kc
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residual degranulation in p110c null BMMCs. Likewise, presence
of ADA did not reduce the phosphorylation of PKB/Akt in
response to thapsigargin via the p110c-dependent pathway
(Figure 1C) but did reduce phosphorylation of PKB/Akt in
response to adenosine—illustrating that the added ADA removes
adenosine quantitatively. PTx treatment of BMMCs (Figure 1D)
blocked adenosine—but not thapsigargin-stimulated PKB/Akt
phosphorylation.
To exclude that autocrine/paracrine signaling to p110c
occurred through PTx-insensitive Gaq subunits to phospholipase
b (PLCb [PLCB2, PLCB3]), and a subsequent Ras activation by
the Ras guanine nucleotide exchange factor RasGRP4 as
described earlier in neutrophils [15], we used platelet activating
factor (PAF) to trigger cyclic AMP-responsive element-binding
protein (CREB) phosphorylation. PAF was reported earlier to
trigger a PTx-insensitive Ca2+ release from mast cells [9], and
induced here a robust CREB phosphorylation comparable to
adenosine and IgE/antigen. In contrast, PAF failed to trigger
phosphorylation of PKB/Akt by itself, and did not enhance
signaling of IgE/antigen to PKB/Akt (Figure S1).
Altogether, these results clearly illustrate that thapsigargin
stimulates BMMCs via a PI3Kc-dependent activation pathway,
which operates separately from adenosine-induced activation of
Gai/o trimeric G proteins.
Thapsigargin-Induced PI3Kc Is Downstream of
Extracellular Ca2+ Influx
PI3Kc activation has been linked to ligation of GPCRs [1,16],
but not to elevated intracellular Ca2+ concentration ([Ca2+]i). We
therefore chelated extracellular Ca2+ using EDTA, and buffered
intracellular Ca2+ with the cell permeable Ca2+ chelator 1,2-Bis(2-
aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid tetrakis(acetox-
ymethyl ester) (BAPTA-AM). Extracellular and intracellular Ca2+
chelation prevented phosphorylation of PKB/Akt induced by
thapsigargin or the Ca2+ ionophore ionomycin, while IL-3 and
adenosine signaling to PKB/Akt remained unperturbed (Figure 2A
and 2B).
Interestingly, the concentration of Ca2+ required to trigger
PI3Kc-dependent phosphorylation of PKB/Akt exceeded peak
concentrations that are reached by GPCR stimulation: GPCR
agonists release Ca2+ only from internal stores (maximum
[Ca2+]i,300 nM), while thapsigargin (Figure 2C–2F) and IgE/
antigen trigger SOCE and elevate [Ca2+]i to mM concentrations
[9,14,17]. Moreover, the correlation of maximally achieved
[Ca2+]i after thapsigargin revealed a steep, switch-like activation
of PKB/Akt. While Ca2+ release from internal stores triggered by
Gai-coupled GPCRs (such as the A3AR stimulated by N
6-(3-
iodobenzyl)-adenosine-59-N-methylcarbox-amide [IB-MECA]) is
sensitive to PTx, thapsigargin-induced SOCE is not. Ca2+-induced
activation of PI3Kc only occurs after SOCE, and is therefore
clearly separated from the GPCR/trimeric G protein/PI3Kc axis.
PKCb Links Ca2+ Mobilization to PI3Kc Activation
Protein kinase C (PKC) inhibitors (Ro318425, Go¨6983,
Go¨6976) targeting classical and atypical PKCs, and the inhibitor
PKC412, which mainly inhibits classical PKCs, all substantially
blocked PKB/Akt phosphorylation in response to thapsigargin
and phorbol 12-myristate 13-acetate (PMA) (Figures 3A and S2A).
Rottlerin, with a limited selectivity for PKCd, had no effect on
PKB/Akt activation. GPCR-dependent PI3Kc activation by
adenosine was resistant to all tested PKC inhibitors (Figure
S2B). The inhibitor profile suggested that a classical PKC activates
PI3Kc. While PKB/Akt activation by PMA and thapsigargin was
blocked in PKCb2/2 BMMCs (Figure 3B), signaling in PKCa2/2
and PKCc2/2 BMMCs remained intact (Figure S2C). Deletion of
PKCb eliminated phosphorylation of PKB/Akt on Thr308 and
Ser473 completely, whereas a residual signal on Ser473 was
observed after PI3K-inhibition by wortmannin. This may be
explained by the observation that PKCb2 can function as a
Ser473 kinase [18]. Adenosine, IL-3, and stem cell factor (SCF)-
induced PKB/Akt activation was not affected by elimination of
PKCb (Figure 3C), demonstrating that PKCb does not relay
adenosine signals to PI3Kc, and is not required in cytokine and
growth factor receptor-dependent activation of class IA PI3Ks in
mast cells.
The direct measurement of phosphoinositides in BMMCs
confirmed that ablation of PKCb or its inhibition eliminated
production of PtdIns(3,4,5)P3 triggered by thapsigargin and PMA,
but not adenosine (Figure 3D–3F). Interestingly, the link between
PKCb and PI3Kc seems to be transient in nature, as PMA
stimulation triggers short lived PtdIns(3,4,5)P3 peaks (Figure 3F).
Impaired FceRI-triggered degranulation has been reported in
both p110c2/2 [9] and PKCb2/2 BMMCs [19], and the
sensitivity of degranulation to PKC inhibition fits the phospho-
PKB/Akt output (Figure 3G). This, combined with the similarity
of p110c and PKCb null phenotypes in IgE/antigen-induced
degranulation (Figure 3H), suggests a direct link of PKCb and
PI3Kc downstream of FceRI.
PKCb Binds and Phosphorylates PI3Kc
Co-expression of p110c with tagged full length or truncated
PKCb2 (Figure 4A) revealed that only the catalytic domain
fragment and a pseudo-substrate deletion mutant of PKCb2
formed complexes with p110c (Figure 4B), suggesting that the
presence of the pseudo-substrate in PKCb results in a closed
conformation that is unable to interact with p110c. An in vitro
protein kinase assay with recombinant PKCb2 and glutathione S-
transferase (GST)-tagged wild type p110c or catalytically inactive
p110c (KR; Lys833Arg mutant) as substrate, showed that PKCb
robustly phosphorylated p110c (Figure 4C). The capability of
p110c to auto-phosphorylate [20] was not required in the process.
Analysis of phosphorylated, catalytically inactive p110c by
liquid chromatography tandem mass spectrometry (LC-MS/MS)
identified Ser582 as a target residue of PKCb
(YESP[582]LKHPK; spectra in Figure S3). Mass spectrometric
multiple reaction monitoring (MRM) (Figure S3C) showed that
Ser582 phosphorylation was absent in assays lacking PKCb, or
when PKC-inhibitor was added (Figure 4D). Ser582 phosphory-
lation was also detected by MRM in PMA and IgE/antigen
stimulated BMMCs (Figure 4D, lower panel).
Phospho-Ser582 site-specific antibodies (see Figure S4) revealed
p110c Ser852 phosphorylation in PMA-, thapsigargin-, and IgE/
antigen-stimulated BMMCs, but not in mast cells exposed to
adenosine or IgE alone (Figure 5A). Consistent with the
requirement of Ca2+ mobilization, IgE/DNP-induced phosphor-
ylation of p110c on Ser582 was blocked by extracellular (EDTA,
EGTA) and intracellular (BAPTA/AM) Ca2+ chelation
(Figure 5B).
Although the extended peptide around Ser582 scores as a PKC
substrate site, the core Arg-X-X-Ser582 sequence is a putative
recognition site for several protein kinases (scores are PKC.pro-
tein kinase A.calcium/calmodulin-dependent kinases [CAMK]).
As mast cell activation is accompanied by a massive influx of
extracellular Ca2+, we assessed if CAMK could phosphorylate
p110c directly. In the presence of 32P-c-ATP, recombinant
CAMKII (CAMK2) incorporated equal amounts of phosphate
into free and p84-bound p110c. In the same experiment, PKCb
preferentially phosphorylated free p110c, illustrating a preference
A Molecular Switch on PI3Kc
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of PKCb for p110c surfaces obscured in the p84-p110c complex.
CAMK also substantially phosphorylated p84, which was border-
line in in vitro assays with PKC (12 versus 3 mol %) (Figure S5A).
Probing the phosphorylation of Ser582 in vitro demonstrated that
access to this site is blocked when p84 is bound to p110c (Figure
S5B).
In cellular assays stimulating BMMCs with thapsigargin,
CAMK activation could be monitored using anti-phospho-
CAMKII antibodies. While PKC inhibitors left CAMKII phos-
phorylation .50% intact, Ser582 and PKB/Akt phosphorylation
were both reduced to background levels (Figure S6), even in a
context favoring Ca2+-triggered responses. The above, and the fact
that PKCb2/2 BMMCs showed a major reduction in phospho-
Ser582 after PMA or IgE/antigen stimulation (Figure 5C and 5D),
illustrate that phosphorylation of p110c is mainly mediated by
PKCb, and that other PKC isoforms (see also Figure S2) and
Ca2+-dependent kinases attribute to less than 18% of the observed
overall signal.
Phosphorylation of Ser582 Positively Regulates p110c’s
Activity and Displaces p84
To evaluate if the Ser582 phosphorylation affected the intrinsic
activity of p110c, a phosphorylation-mimicking mutant (Ser582-
Glu) was produced. The activity of the p110c Ser582Glu mutant
∆
γ
Figure 2. Thapsigargin-triggered PI3Kc activation requires influx of extracellular Ca2+. (A) Where indicated, IL-3 starved BMMCs were
incubated with EDTA (5 mM) for 5 min, before cells were stimulated with thapsigargin (1 mM) or ionomycin (1 mM). Cells were lysed 5 min after
stimulation, and phosphorylation of PKB/Akt on Ser473 was analyzed. (B) BMMCs as in (A) were pretreated for 10 min with the cell-permeable Ca2+-
chelator BAPTA/AM (10 mM) and stimulated either with IL-3 (10 ng/ml), adenosine (1 mM), or thapsigargin (1 mM). (C, D) BMMCs were loaded with the
ratiometric low affinity Ca2+ probe Fura-4F/AM for 10 min in physiologic HEPES buffer at 1 mM Ca2+ (for details see Text S1). After the loading,
washed cells were resuspended in the presence of increasing Ca2+ concentrations (extracellular Ca2+, [Ca2+]e) to modulate maximal stimulation-
induced intracellular Ca2+ levels ([Ca2+]i). Cells were then stimulated with 0.5 mM thapsigargin, and maximal [Ca
2+]i increase and phosphorylation of
PKB/Akt were measured. pPKB S473 levels are displayed as a function of the individually determined [Ca2+]i. Data points come from two
independently performed experiments. (E) Representative anti-phospho-PKB/Akt immunoblot as used to determine pPKB/Akt levels in (D). (F)
Intracellular Ca2+ concentrations were measured in wild type BMMCs following stimulation with the adenosine 3A receptor-selective agonist N6-(3-
iodobenzyl)-adenosine-59-N-methylcarbox-amide (IB-MECA) (10 nM) or thapsigargin (1 mM). B. Pertussis toxin (100 ng/ml) was added 4 h before
stimulation where marked.
doi:10.1371/journal.pbio.1001587.g002
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was enhanced approximately 2-fold independently of the substrate
used (PtdIns(4,5)P2, PtdIns, or auto-phosphorylation) (Figure 6A–
6C). Ser582 is localized in the helical domain of p110c, and it is
interesting to note that helical domain mutants of p110a found in
tumors display a similar increase in enzyme activity [21–25].
As mutations in the helical domain of p110a attenuate contacts
with the p85 regulatory subunit [21], we examined binding of
p110c mutants to the PI3Kc adaptor subunit p84: the substitution
of Ser582 with Glu and Asp, abrogated p110c-p84 interactions in
HEK293 cells and BMMCs, while the Ser582Ala replacement
favored p110c-p84 complex formation (Figure 6D–6F). In line
with this, PMA-induced phosphorylation of Ser582 in BMMCs
was suppressed by the overexpression of p84 (Figure 6G), which
fits the very limited access of PKCbII to in vitro phosphorylate
Ser582 in the p110c-p84 complex (reduced to 20% of phosphor-
ylation of free p110c) (Figure S5B).
Most importantly, the correlation of phosphorylation of Ser582
on p110c and the release of p84 could also be established in wild
type BMMCs: when stimulated with PMA, the amount of p84 that
could be co-precipitated with p110c was reduced significantly, and
was linked to Ser582 phosphorylation of p110c. In the inverse co-
immunoprecipitation, anti-p84-associated p110c was reduced, and
phosphorylation was below detection levels in the remaining p84-
associated p110c (Figure S7). The collected results are in
agreement with a mechanism in which PKCbII-mediated
phosphorylation of Ser582 and the interaction of p84 and p110c
are exclusive events, and in which PKCb action displaces p84
from p110c.
The Helical Domain of p110c Binds and Is Stabilized by
p84
In order to understand how p84 could mask Ser582 phosphor-
ylation, and to map the p110c-p84 contact interface, hydrogen
deuterium exchange mass spectrometry (HDX-MS) was used.
HDX-MS elucidated contacts of class IA p110d with its p85
regulatory subunit, and the mechanism of action of cancer-linked
mutations in p110a [25,26]. HDX-MS relies on amide hydrogen
exchange with solvent at a rate dependent on their involvement in
secondary structure and solvent accessibility. Following proteoly-
sis, location and extent of deuterium uptake are analyzed by
peptide mass determination. The primary sequence of p110c was
covered .90% by 202 peptide fragments (Figure S8; Table S1).
Deuterium (2H) incorporation into free and p84-complexed
p110c was analyzed at seven time points (3 to 3,000 s). Differences
in 2H-exchange of free and complexed p110c were mapped onto
the crystal structure of p110c lacking the N-terminal domain (PDB
ID:2CHX, residues 144–1,093), to visualize conformational
changes induced by p84 (Figures 7A, S9, and S10). Peptides with
highest decrease in 2H incorporation (.1.0 Da) clustered to the
RBD-C2 linker, the C2-helical domain linker, and the helical
domain. The 2H-incorporation in the presence of p84 is visualized
as integrated average difference in exchange at all seven time
points in Figure 7B, illustrating that the helical domain provides
the dominant interface with p84. Due to difficulties in producing
free p84, the contacts on p84 with p110c could not be mapped.
Interestingly, in the absence of the p84 subunit, the majority of
peptides in the helical domain exhibited broad isotopic profiles
(HDX of peptide 623–630, which is representative of peptides in
the helical domain, is shown in Figures 7C and S11). This type of
profile known as type 1 exchange (EX1) kinetics is indicative of
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Figure 3. PKCb relays thapsigargin-induced PI3Kc activation.
(A) Effect of PKC inhibitors on thapsigargin-induced PKB phosphoryla-
tion on Ser473 (S473). IL-3 starved BMMCs were preincubated with the
indicated compounds for 20 min before stimulation (pan-PKC:
Ro318425, Go¨6983; classical PKC: PKC412 (CPG41251); classical and
atypical PKC: Go¨6976; Rotterlin: broad band inhibitor; see Text S1; &
refers to comparison with untreated control; p-values see Figure 1). (B)
PKB/Akt activation in response to 100 nM PMA or 1 mM thapsigargin
was analyzed in wild type and PKCb2/2 BMMCs. Cells were IL-3
deprived as in (A), and were pretreated with wortmannin (Wm, 100 nM)
for 15 min before stimulation where indicated. Cells were lysed 2 min
after stimulation, and analyzed for phosphorylation of PKB/Akt (T308
and S473) and MAPK (T183/Y185). (C) Wild type and PKCb2/2 BMMCs
were stimulated with 1 mM adenosine, 10 ng/ml IL3, or 10 ng/ml SCF,
and processed as in (B). (D–F) PtdIns(3,4,5)P3 (PIP3) levels were
determined in untreated (Ctrl) and classical PKC-inhibitor (PKC412)-
treated wild type BMMCs and PKCb2/2 BMMCs after stimulation with
0.5 mM thapsigargin, 200 ng/ml PMA, or 5 mM adenosine (30 s). BMMCs
were metabolically labeled with [32P]-orthophosphate, lipids were
extracted, deacylated, and applied to high-pressure liquid chromatog-
raphy (HPLC). (D) shows representative elution peaks of PIP3 of the
HPLC chromatograms. (E) Levels of PIP3 in relation to PtdIns(4,5)P2 (PIP2)
were quantified by integration of the peak areas of PIP3 and PIP2
and expressed as ratio of PIP3/PIP2 (data shown as mean 6 standard
error of the mean [SEM], n$4–6). (F) Cellular PIP3 production was
measured over time in wild type BMMCs in response to PMA (200 nM)
stimulation in the presence or absence of the classical PKC inhibitor
PKC412 (mean 6 SEM, n=3). (G) Granule release and PKB activation
(S473) in response to thapsigargin (1 mM) or IgE/antigen (100 ng/ml IgE
overnight, 10 ng/ml DNP) was measured in the presence of increasing
concentrations of the classical PKC inhibitor PKC412. Cells starved as in
(A) were stimulated with IgE/antigen (IgE/Ag) or thapsigargin (Tg), and
PKB phosphorylation and b-hexosaminidase release assays were
performed in parallel (mean 6 SEM, n= 3). (H) b-hexosaminidase
release determined in wild type, PKCb2/2, and p110c2/2 BMMCs
incubated with IgE, and stimulated with the indicated antigen (Ag)
concentrations (mean 6 SEM, n=5; * refer to comparison with wild
type control. Only the higher p-values of the overlapping data points
are indicated).
doi:10.1371/journal.pbio.1001587.g003
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concerted dynamic motions of a substructure in a protein, rather
than the local fluctuations characteristic of EX2 kinetics [27].
The N-terminus of p110c was shown to stabilize the p110c-
p101 heterodimer [28]. Expression of p110c mutants lacking the
first 130 amino acids (D130–p110c) seemed to support this view, as
association with p84 was lost (Figure 7D). However, when
truncated p110c was N-terminally tagged with GST (GST-
D130-p110c), binding of p84 was restored. Although we detected
a small decrease in the 2H-incorporation in two N-terminal p110c
peptides (59–70 and 107–113) in the presence of p84, this
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Figure 4. PKCb interacts with and phosphorylates the catalytic subunit of PI3Kc. (A) Schematic representation of the PKCb-p110c
interaction: full-length (fl) PKCb is in a closed conformation due to the interaction of the pseudo-substrate domain with the catalytic pocket of PKCb,
while the truncated catalytic domain (cat; amino acids 302–673) and pseudo-substrate deletion mutant (Dps; deletion of aa 19–31) give access to
p110c. (B) HEK293 cells were co-transfected with p110c and HA-tagged PKCb2 constructs. Protein complexes were immunoprecipitated with anti-
p110c or anti-HA antibodies, before HA-PKCb2 and p110c was detected by immunoblotting. Ig: immunoglobulin heavy chain signals of mouse anti-
p110c and anti-HA antibodies. (C) Recombinant GST-p110c wild type (wt) or a catalytically inactive p110c mutant (KR, Lys833Arg mutant) were
incubated with recombinant PKCb2 and [c32P]-ATP in kinase buffer for 30 min, before proteins were denatured and separated by SDS-PAGE.
Phosphatidylserine (PS) lipid vesicles containing 1-oleoyl-2-acetyl-sn-glycerol (OAG) were present during the reaction where marked. Protein-bound
32P was determined by radioisotope imaging, and recombinant proteins were stained with Coomassie blue (mean 6 standard error of the mean
[SEM], n= 3; * point to comparison with respective sample without PKC). (D) In vitro and in vivo phosphorylation of PI3Kc on S582, analyzed by LC-
MRM. S582 non-phospho- and phospho-peptides were detected in the MRM mode, quantifying the transition 501.1 to 709.3 for the non-modified
peptide (blue) and 541.3 to 492.1 for the phospho-peptide (red). Data were normalized to the transition of the non-modified peptide, which was set
to 1. Upper part: recombinant catalytically inactive human GST-PI3Kc (2 mg) was incubated alone, together with PKCb2 or with PKCb2 and PKC-
inhibitor (Ro318425, 2 mM) as in (C). After SDS-PAGE and Coomassie staining, PI3Kc was excised from the gel and prepared for LC-MRM. Lower part:
wild type BMMCs (300 M cells/stimulation) were starved for 4 h in IL-3 free medium/2% FCS, and were left unstimulated or were treated for 2 min
with 50 nM PMA or for 4 min with 10 ng/ml antigen (cells preloaded with 100 ng/ml IgE overnight). Endogenous PI3Kc was immunoprecipitated
from cell lysates, resolved by SDS-PAGE and analyzed with LC-MRM.
doi:10.1371/journal.pbio.1001587.g004
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interaction seems to be dispensable. The N-terminus of p110c
instead has a role in stabilizing the intact catalytic subunit. The
helical domain is the main location of interaction with p84; however,
it appears that this interaction is vulnerable and easily broken, as a
single phosphorylation at Ser582 is able to disrupt the contact.
Discussion
The activation of PI3Kc has been tightly linked to GPCRs-
triggered dissociation of trimeric Gai proteins, and has been
shown to require the interaction of Gbc subunits with p110c and
the PI3Kc adaptor subunits p101 and p84 [1,2,4,16,29,30].
Moreover, GPCRs generate PI3K signals typically through PI3Kc,
thereby controlling extravasation of hematopoietic cells [31,32],
cardiovascular parameters [33,34], and metabolic output [35,36].
Non-GPCR-mediated activation of PI3Kc has not been
reported so far, but it has been shown that phorbol esters and
Ca2+ ionophores can modulate phosphoinositide levels in a variety
of cells, including platelets [37], adipocites [38], fibroblasts [39],
and hematopoietic cells [40]. The proposed mechanisms have
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Figure 5. Phosphorylation of PI3Kc requires Ca2+ and is PKCb-dependent. (A) Stimulus-induced phosphorylation of endogenous p110c on
Ser582 in wild type BMMCs. IL-3 deprived cells were stimulated with 100 nM PMA, 1 mM thapsigargin, 1 mM adenosine, or 20 ng/ml DNP for 2 min.
Where indicated (IgE), BMMCs were loaded with IgE (100 ng/ml) overnight. PI3Kc was immunoprecipitated from cell lysates with an anti-PI3Kc
antibody, before precipitated protein was probed for phosphorylated p110c (pp110c) with a phospho-specific anti-pSer582 antibody (validation of
antibody see Figure S4). PI3Kc phosphorylation is shown normalized to total PI3Kc levels (mean 6 standard error of the mean [SEM], n=3; * depict
analysis using unstimulated control. & reference point is IgE only). (B) IgE/antigen-induced Ser582 phosphorylation of p110c requires Ca2+ influx. Cells
were stimulated as in (A), but exposed to EDTA, EGTA, or loaded with BAPTA/AM where indicated (see Figure 2). Phosphorylated p110c was detected
as in (A); mean6 SEM, n=3; * comparison with unstimulated control; &analysis of stimulated versus chelator treated). (C) Phosphorylation of p110c in
wild type and PKCb2/2 BMMCs. Experimental settings were as in (A), and (D) depicts quantification of pp110c in relation to total p110c protein (mean
6 SEM; PMA n= 4, antigen n= 3). Cells devoid of p110c were included as negative control.
doi:10.1371/journal.pbio.1001587.g005
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Figure 6. Ser582 phosphorylation increases p110c activity and displaces p84. (A–C) Lipid and protein kinase activities of recombinant
p110c wild type (wt) and phosphorylation site mutants (Ser582Ala, [A]; Ser582Glu, [E]). (A) Mixed phospholipid vesicles containing PtdIns(4,5)P2 were
used to measure PtdIns(3,4,5)P3 (PIP3) production, while in (B) PtdIns was used as a substrate. Protein kinase activity of p110c was determined by
auto-phosphorylation in (C). Bars display quantifications of incorporated 32P as mean6 standard error of the mean [SEM] (n= 3; * comparison with wt
protein), and representative thin layer chromatograms [32P] and loaded p110c protein (Coomassie blue) are shown below. (D, E) Wild type p110c and
Ser582 mutants (Ser582Asp, [D]) were expressed together with HA-tagged p84 in HEK293 cells. In (D), the PI3Kc complex was immunoprecipitated
with anti-HA antibodies directed against HA-p84 (n=4). In (E) PI3Kc was immunoprecipitated using anti-p110c antibodies (n=2). (F) Wild type p110c
and Ser582 mutants were co-expressed with p84 in p110c2/2 BMMCs. PI3Kc was immunoprecipitated from cell lysates as in E (mean 6 SEM, n= 3).
(G) The p84 adapter competes with PKCb for access to p110c. Increasing amounts of HA-p84 expression plasmid were transfected into p110c2/2
BMMCs, before the cells were stimulated with PMA for 30 s. PI3Kc was subsequently immunoprecipitated with an anti-p110c antibody, and bound
p84 and Ser582 phosphorylation were quantified. The values are normalized to total p110c protein (mean 6 SEM, n= 2).
doi:10.1371/journal.pbio.1001587.g006
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Figure 7. p84 Interacts with the helical domain of p110c. (A) Changes in deuteration levels between free and p84-bound PI3Kc are mapped
onto the crystal structure of PI3Kc (PDB ID: 2CHX). Regions that are covered by peptides of PI3Kc (labeled A–R) that showed greater than 0.5 or 1.0 Da
changes in deuteration are colored light or dark blue, respectively. The greatest difference in exchange observed at any time was used for the
mapping. S582 is labeled red. The ATP competitive inhibitor PIK-90 in the crystal structure is shown in green as a reference point for the kinase
domain. The linker regions between the RBD and the C2 domain and the C2 and the helical domain are shown as dotted lines (right part). (B) The
percent deuterium exchange differences between free and p84-bound PI3Kc were summed up over all seven time points for every identified peptide
(y-axis), which were graphed according to their central residue number (x-axis). (C) A selected peptide (623–630) from the helical domain is shown at
four time points of H/D on-exchange +/2 the p84 subunit. In the absence of the p84 adaptor the majority of peptides in the helical domain showed
broadening of the isotopic profiles indicative of EX1 kinetics (see 30, or 300 s in free p110c). The helix A3 (624–631) selected is located at the interface
of the helical domain with the C-lobe. Ser582 and Thr1024 have been highlighted as a reference. (D) p84 was coexpressed with GST-tagged or
untagged PI3Kc constructs in HEK293 cells. N-terminal deletions of 37 or 130 amino acids are denoted D37 or D130, respectively. HA-p84 (left) or
PI3Kc (right) was immunoprecipitated from cell lysates with anti-HA or anti-PI3Kc antibodies and protein G beads. PI3Kc-p84 interactions were
analyzed by Western blotting, quantified with Odyssey Imager software and expressed as fold of untagged, full-length p110c-p84 association (mean
6 standard error of the mean [SEM], left: n=4, 6, 6, 6; right: n= 2, 4, 4, 4).
doi:10.1371/journal.pbio.1001587.g007
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been diverse and involved protein tyrosine kinases and GPCR
signaling. A recent finding that protein kinase D (PKD) can
phosphorylate two distinct sites on the p85 regulatory subunit to
control class IA PI3K activity [41] is an indication that PI3K
control is more complex than anticipated.
PI3Kc has been shown to be a key element in enhancing IgE/
antigen output by the release of adenosine. This process involves
signaling downstream of Gai-coupled A3AR, and is sensitive to
PTx and ADA [9]. The resistance of thapsigargin-induced
degranulation to ADA shown here, and the fact that PTx did
not diminish the PI3Kc-dependent, thapsigargin-induced phos-
phorylation of PKB/Akt, points to a novel mechanism of PI3Kc
activation, which is clearly distinct from GPCR action. This Ca2+-
mediated PI3Kc activation requires SOCE and [Ca2+]i
.600 nM. In contrast, GPCRs yield phosphorylation of PKB/
Akt in mast cells even in the absence of a change in [Ca2+]i.
Furthermore, increases in [Ca2+]i triggered via GPCRs remain at
levels incapable of engaging a Ca2+-dependent activation of
PI3Kc.
Thapsigargin bypasses the signaling chain from IgE/antigen-
clustered FceRI to the activation of phospholipase Cc (PLCc) and
inositol(1,4,5)-trisphosphate (Ins(1,4,5)P3) production, and triggers
SOCE by the depletion of Ca2+ stores. That thapsigargin requires
functional PI3K activity to induce mast cell degranulation was first
demonstrated using the PI3K inhibitors wortmannin and
LY294002 [14], but no link between [Ca2+]i rise and PI3Kc
activity was established previously. The fact that inhibitors for
classical PKCs only prevented the thapsigargin- and PMA-
induced phosphorylation of PKB/Akt, while the GPCR-mediated
phosphorylation of PKB/Akt remained intact, points to a link
between classical PKCs and PI3Kc. Experiments on BMMCs
lacking PKCa, PKCb, and PKCc, showed that only the PKCb
null cells lost the ability to activate PKB/Akt in response to
thapsigargin or PMA stimulation. As the PMA- and thapsigargin-
induced phosphorylation of PKB/Akt on Ser473 showed a partial
resistance to wortmannin, and as it has been reported that PKCb
can directly phosphorylate Ser473 in the hydrophobic motif of
PKB/Akt [18], the effect of genetic and pharmacological targeting
of PKCb was also validated measuring PtdIns(3,4,5)P3 production
directly. The lack of PtdIns(3,4,5)P3 production in thapsigargin or
PMA-stimulated BMMCs treated with the PKC inhibitor
PKC412, and in cells devoid of PKCb, is in agreement with a
requirement of PKCb upstream of PI3Kc. That signaling from
PKC to PI3K plays a role in mast cell degranulation is further
supported by the close correlation of PKC inhibitor sensitivity of
phosphorylated PKB/Akt and degranulation responses. More-
over, the loss of PKCb or PI3Kc results in a similar reduction of
degranulation over a wide range of IgE/antigen concentrations.
The results obtained here are in agreement with previous findings
that mast cells and mice devoid of p85a/p55a/p50a [42,43] and
p85b [44] remain fully responsive to IgE/antigen complexes. A
previous report showed a biphasic activation of PI3K with PI3Kc
having an early role and PI3Kd a later role downstream of FceRI
in murine mast cells [45,46].
A mechanistic link between PKCb and the catalytic subunit of
PI3Kc was initially difficult to establish, as the direct
PtdIns(3,4,5)P3 response to PMA-stimulation was transient (main
peak half life ,1 min), and the two full-length enzymes interacted
only weakly. The observation that truncated, activated forms of
PKCb formed stable complexes with p110c, suggested that PKCb
must attain an open conformation to interact with p110c, and that
PKCb binds to p110c via its catalytic domain. This contact
resulted in phosphorylation of Ser582 on p110c, which could be
detected both in vitro and in PMA or IgE/antigen-stimulated
BMMCs by mass spectrometry. The PKCb-mediated phosphor-
ylation of p110c was confirmed using site-specific anti-phospho-
Ser582 antibodies. Stimuli like PMA, thapsigargin, and IgE/
antigen complexes all required PKC to signal to PKB/Akt, which
correlated with the phosphorylation of Ser582 on p110c.
Moreover, the phosphorylation of Ser582 on p110c was sensitive
to removal of extracellular Ca2+, buffering of [Ca2+]i, and the
genetic deletion of PKCb. Adenosine stimulates PI3Kc via
GPCRs and PTx-sensitive trimeric G proteins [9] in a Ca2+-
independent process, and did not yield a detectable phosphory-
lation of Ser582.
The increased turnover of PtdIns and PtdIns(4,5)P2, and the
increased rate of auto-phosphorylation displayed by p110c with a
phosphate-mimicking mutation (Ser582Glu), suggests that a
structural change in the helical domain of p110c is sufficient to
increase the catalytic activity independent of the presence of the
p84 subunit. Previous work examining the activation of the class
IA p110a, p110b, and p110d catalytic subunits has shown that
part of the activation mechanism occurs through a conformational
change from a closed cytosolic form to an open form on
membranes [25,26]. The helical domain of p110c is exquisitely
well placed to propagate conformational changes due to the fact
that it is in contact with every other domain in p110c. In the
crystal structure of N-terminally truncated (D144) p110c, the side
chain of Ser582 points inward [47,48], and has to rotate to
accommodate a phosphate. Our HDX-MS results showed a
dynamic ‘‘breathing’’ motion in the helical domain in the free
p110c catalytic subunit that may allow for temporary exposure of
Ser582, enabling modification by PKC. HDX results showed that
the p84 subunit slowed or prevented this dynamic motion, and this
correlated with a decreased efficiency of phosphorylation by PKC
in cells in the presence of p84.
Although Ser582 is not in a direct contact with the kinase
domain, it is structurally linked to it: the heat repeat HA1/HB1
housing Ser582, and the connecting intra-helical loop (residues
560 to 570), along with helix A3 (624–631) are in contact with
helices ka9 and ka10 in the C-lobe of the kinase domain (known as
the regulatory arch [49,50]) and could transduce a conformational
change to the catalytic center of p110c (Figure 7C). The
phosphorylated Ser582 and phosphorylation-mimicking mutants
may activate lipid kinase activity by causing a conformational shift
at this interface. It has been shown recently that this region of the
p110c kinase domain is critical in regulating lipid kinase activity,
as phosphorylation of Thr1024 in the ka9 by protein kinase A
(PKA) negatively regulates p110c activity in vitro and in
cardiomyocytes (Figure 7C) [51].
In contrast to the p110a-p85 heterodimer, stabilized by the N-
terminal adaptor-binding domain (ABD)/inter SH2 domain
interaction, the association of the p110c subunit with its adaptor
subunit is quite vulnerable, and the Ser582Glu mutant, but not
Ser582Ala, abrogated the formation of a p110c-p84 complex.
HDX-MS revealed that the helical domain of p110c was stabilized
by p84. Ser582 is located in the center of the p110c-p84 contact
surface, which explains how a change in charge (Ser582Glu)
breaks the interaction with p84, either by direct contact or by
destabilization of the helical domain. Overexpression of p84
shields p110c from a PMA-induced phosphorylation, and suggests
that binding of p84 to p110c, and Ser582 phosphorylation by
PKCb are mutually exclusive. This implies that the two activation
modes of PI3Kc—by GPCRs or PKCb—are completely separat-
ed. At low [Ca2+]i, PI3Kc is exclusively activated by Gbc subunits.
It has been demonstrated that a PI3Kc adapter protein is
absolutely needed for functional GPCR inputs to p110c [6]. If the
interaction of p84 with p110c is blocked by the phosphorylation of
A Molecular Switch on PI3Kc
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Ser582, p110c is decoupled from its GPCR input (for a schematic
view of the process see Figure 8). The PKCb-mediated activation
and phosphorylation of p110c constitutes therefore an unprece-
dented PI3K molecular switch, which enables the operation of
p110c downstream of FceRI signaling, and will elucidate cell type-
specific activation processes in allergy and chronic inflammation.
Materials and Methods
Cells and Mice
BMMCs were derived from bone marrow of 8–12-wk-old
C57BL/6J wild type, p110c2/2, PKCa2/2, PKCb2/2, and
PKCc2/2 mice, and cultured and characterized as described in
[9]. Animal experiments were carried out in accordance with
institutional guidelines and national legislation. Human embryonic
kidney 293 (HEK293) cells were grown in DMEM supplemented
with 10% HI-FCS, 2 mM L-glutamine, 100 units/ml penicillin,
100 mg/ml streptomycin. Sf9 cells were cultivated in IPL-41
medium (Genaxxon Bioscience) supplemented with 10% HI-FCS,
2% yeastolate, 1% lipid concentrate, 50 mg/ml gentamicin
(Invitrogen), and 2.5 mg/ml amphotericin B (Genaxxon Biosci-
ence). Detailed descriptions and references are available in Text
S1.
Cellular PdtIns(3,4,5)P3 Measurements
PtdIns(3,4,5)P3 levels have been measured as described in [9]
with some modifications. BMMCs were cultured for 2 h in
phosphate-free RPMI medium/2% FCS at 37uC and 5% CO2,
followed by labelling with 1 mCi/ml [32P]-orthophosphate for 4 h.
Cells were washed, stimulated, and lysed by the addition of
chloroform/methanol (1:2, v/v, with butylated hydroxytoluene
and carrier phosphoinositides). Lipids were extracted, deacylated,
and separated by high-pressure liquid chromatography (HPLC).
In Vitro Lipid Kinase Assay
PI3Kc-His6 was incubated with PtdIns(4,5)P2-containing lipid
vesicles (PE/PS/PC/SM/PIP2=30/20/10/4.5/1.2; PIP2 final
5 mM), 10 mM ATP, and 4 mCi of [c32P]-ATP in lipid kinase
buffer (40 mM HEPES [pH 7.4], 150 mM NaCl, 4 mM MgCl2,
1 mM DTT [1,4-Dithio-DL-threitol], 0.1 mg/ml fatty-acid free
BSA) for 10 min at 30uC. Alternatively, PtdIns/PS vesicles
(,200 mM each) were used. Reactions were terminated by
addition of 1 M HCl and CHCl3/MeOH. Lipids were isolated
by chloroform extraction, separated by TLC and quantified on a
Typhoon 9400.
Statistical Analysis
Numeric results were tested for significance using a two-tailed
Student’s t test, (paired or unpaired, as imposed by datasets). * or
&, ** or &&, and *** or &&& refer to p-values p,0.05, p,0.005, and
p,0.0005. * and & were used for comparison of different
genotypes, stimuli an conditions as indicated. Calculations were
carried out using Graph Pad Prism, Microsoft Excel, or
Kaleidagraph software.
Deuterium Exchange Reactions
Protein stock solutions (5 ml; Hsp110c-C-His6: 30 mM;
Hsp110c-C-His6/Mmp84-C-His6: 35 mM) were prepared in
20 mM Tris [pH 7.5], 100 mM NaCl, 1 mM ammonium sulfate,
γ
γ
βα
γ
β
γ
γ
Figure 8. Phosphorylation of Ser582—loss of GPCR coupling of p110c. In a resting mast cell, the PI3Kc complex is responsive to GPCR-
mediated dissociation of trimeric G proteins. An adapter protein (here p84) is required for a productive relay of the GPCR signal to PI3Kc. When FceRI
receptors are clustered via IgE/antigen complexes, a signaling cascade is initiated, which triggers the depletion of intracellular Ca2+ stores and the
opening of store-operated Ca2+ channels. The resulting increase in [Ca2+]i and PLCc-derived diacylglycerol activate PKCb, which binds to p110c and
subsequently phosphorylates Ser582 (Rpp110c). Phosphorylated p110c cannot interact with p84, and is therefore unresponsive to GPCR inputs.
GPCR input to PI3Kc coincides with migration and adhesion, while Ca2+/PKCb activation of p110c occurs when mast cells degranulate. The
phosphorylation of PKB/Akt occurs downstream of PtdIns(3,4,5)P3, which originates from G protein-activated p84-p110c complex or PKCb-activated
pp110c. The phosphorylated residues Thr308 and Ser473 of PKB/Akt are used to monitor PI3K activation. More detailed effector signaling event
schemes can be found in [52].
doi:10.1371/journal.pbio.1001587.g008
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and 5 mM DTT. Exchange reactions were initiated by addition of
25 ml of a 98% D2O solution containing 10 mM HEPES (pH 7.2),
50 mM NaCl, and 2 mM DTT, giving a final concentration of
82% D2O. Deuterium exchange reactions were allowed to carry
on for seven time periods, 3, 10, 30, 100, 300, 1,000, and 3,000 s
of on-exchange at 23uC, before addition of quench buffer. On-
exchange was stopped by the addition of 40 ml of a quench buffer
containing 1.2% formic acid and 0.833 M guanidine-HCl, which
lowered the pH to 2.6. Samples were then immediately frozen in
liquid nitrogen until mass analysis. The full HDX-MS protocol
can be found in Text S1.
Supporting Information
Figure S1 PAF-mediated signaling does not activate
PI3K, and does not synergize with FceRI co-stimulation
(related to Figure 1). IgE-sensitized (100 ng/ml IgE, overnight)
or non-sensitized wild type BMMCs were IL-3 depleted for 3 h
and stimulated with either 1 mM adenosine (Ade), 1 mM PAF, or
5 ng/ml antigen (post IgE-sensitization) 6 PAF for 2 min.
Subsequently, cell lysates were subjected to SDS-PAGE. Phos-
phorylation of Ser473 in PKB/Akt (A), (B) Ser133 in cyclic AMP-
responsive element-binding protein (CREB) and Ser660 in
PKCbII was monitored by immunodetection with phosphosite-
specific antibodies (n=3, *: p,0.05; * refers to unstimulated
control).
(EPS)
Figure S2 Effect of PKC-inhibitors on PMA- or adeno-
sine-induced PKB phosphorylation (S473) (related to
Figure 3). (A/B) Wild type BMMCs were starved for 3 h in IL-3
free medium supplemented with 2% FCS, and preincubated with
the inhibitors for 20 min before stimulation (pan-PKC: Ro318425,
Go¨6983; classical PKC: PKC412 [CPG41251]; classical and
atypical PKC: Go¨6976; Rotterlin: broad band inhibitor; all 1 mM;
& refers to comparison with untreated, stimulated control). (C)
PKB activation in response to 100 nM PMA or 1 mM Thapsi-
gargin (2 min) was analyzed in wild type, PKCa2/2 and PKCc2/
2 BMMCs. Cells were deprived of IL-3 as in (A/B). PKB (S473)
and MAPK (T183/Y185) phosphorylation was determined by
Western blotting. (D) Wild type, PKCb2/2 and PI3Kc2/2
BMMCs were stimulated with different concentrations of
thapsigargin, before degranulation was quantified by the mea-
surement of b-hexosaminidase release into cell supernatants (data
are the average of three independent experiments 6 standard
error of the mean [SEM]; * comparison to wild type (both
genotypes); & only the p110c2/2 dataset reached significance).
(EPS)
Figure S3 Identification of PI3Kc phosphorylation sites
by MS (related to Figure 4). (A/B) Recombinant, catalytically
inactive GST-PI3Kc (K833R mutant; GST fused to p110c amino
acids 38–1,102) was phosphorylated in vitro by recombinant
PKCb in the presence of 100 mM ATP/[c32P]-ATP. Proteins
were separated by SDS-PAGE and trypsin-digested PI3Kc was
analyzed by LC-MSMS. (A) Enhanced product ion spectra of the
tryptic phospho-S582-peptide of PI3Kc. The y- and b-fragments
detected are indicated in the sequence. Fragments showing a
H3PO4 loss are marked with an asterisk. The b2, y6, and y7
fragments allow assignment of the phosphorylation to serine 3 in
the peptide. (B) Enhanced product ion spectra of the non-
phosphorylated form of this peptide. (C) Relevant information for
the MRM analysis of the peptides containing Ser582. The amino
acid numbering is as in Swiss-Prot entry P48736. (D) Sequence
alignment of the beginning of the helical domain of class I PI3Ks.
Alignments were done by inspection of the crystal structures of
PI3Kc (1E8Y), PI3Ka (3HHM), PI3Kb (2Y3A), and PI3Kd
(2WXR). Secondary structure elements are labeled as indicated in
the legend. S582 is colored red, while cancer-associated PI3Ka
mutations are marked as blue.
(TIF)
Figure S4 Anti-phospho-Ser582 antibody validation (re-
lated to Figure 5). (A) Wild type BMMCs were transfected with
empty vector, expression plasmid for GFP-PI3Kc wild type or the
GFP-PI3Kc S582A mutant. On the next day, cells were
stimulated with 200 nM PMA for 45 s, and PI3Kc was
immunoprecipitated from cell lysates. Specificity of the anti-S582
antibodies was validated by Western blotting.
(EPS)
Figure S5 Global and site-specific in vitro phosphory-
lation of monomeric p110c and p110c-p84 complexes by
PKCb and CamKII (related to Figure 5). (A) Equal amounts
of purified recombinant p110c-His6 (2.5 pmole) or p110c-His6/
EE-p84 complexes were incubated with 20 pmole wortmannin to
eliminate auto-phosphorylation signals. Free or complexed p110c
(with p84 protein) was incubated with 10 mM ATP and 5 mCi of
[32P]-c-ATP, and equal specific activity of recombinant PKCbII
and CamKII (Life Technologies assays: 30 pmol phosphate
incorporation/min.) for 30 min at 30uC. Subsequently, proteins
were denatured and separated by SDS-PAGE followed by
Coomassie staining (lower panel). 32P-incorporation was visualized
by autoradiography and quantified on a phospho-imager (Ty-
phoon 9400, middle panel). Band intensities were quantified with
ImageQuant TL Software (Amersham Biosciences, top panel;
n=4, * p,0.05). Insert: quantification of p84 phosphorylation
from the reactions shown in (A), (open bars, n=4, * p,0.05).
Phospho-PKCbII levels were subtracted from phospho-p84 signals
(due to identical apparent Mr on SDS-PAGE). The filled bar
represents phosphorylated p84-His6 after Ni
2+-NTA pull-down to
minimize contaminating PKCbII autophosphorylation signals
(n=3). (B) Equal amounts of purified recombinant p110c-His6
(2.5 pmole) or p110c-His6/EE-p84 complexes were incubated as
indicated with ATP (100 mM), recombinant PKCbII and CamKII
for 30 min at 30uC. Proteins were denatured, separated by SDS-
PAGE followed by immunological detection of p110c and p84
protein, as well as site-specific phosphorylation of residue Ser582
(pp110c S582) in p110c. PKCbII and CamKII input was adjusted
to equal protein kinase activity (30 pmol of transferred phosphate/
min). For quantification, Ser582 phosphorylation levels were
normalized (n=4, *: p,0.05, ***: p,0.0005).
(EPS)
Figure S6 Phosphorylation of p110c requires active
PKCb (related to Figure 5). (A) Effect of PKC inhibitors on
thapsigargin induced p110c Ser582 phosphorylation. IL-3 de-
prived BMMCs were preincubated with PKC inhibitors (1 mM
Ro318425 or 1 mM AEB071) for 20 min before stimulation with
1 mM thapsigargin for 2 min. PI3Kc was immunoprecipitated
from cell lysates with anti-p110c antibody (see Methods).
Precipitated protein was then probed for phosphorylated p110c
(pp110c) using phospho-specific anti-pSer582 antibodies. PI3Kc
phosphorylation is shown normalized to total p110c levels (mean
6 standard error of the mean [SEM], n=3; * depict comparison
with stimulated control). (B) Cells were stimulated as in (A). PKB
(T308) and CamKII (T286) phosphorylation was determined by
Western blotting. Data are the average of three independent
experiments 6 SEM.
(EPS)
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Figure S7 Ser582 phosphorylation releases p84 from
p110c (related to Figure 6). IL-3 deprived BMMCs were
stimulated with 100 nM PMA for 2 min. PI3Kc complex was co-
immunoprecipitated from cell lysates using either (A) anti-p110c
or (B) anti-p84 antibodies. The amount of p84 co-immunoprecip-
itated with p110c (A) or p110c co-immunoprecipitated with p84
(B) was normalized to the total amount of p110c or p84,
respectively. Data are the average of five independent experiments
6 standard error of the mean [SEM].
(EPS)
Figure S8 PI3Kc domain order and peptide coverage
after pepsin digestion (related to Figure 7). Identified and
analyzed peptides are shown under the primary sequence of
PI3Kc, which has been colored according to the domain
boundaries shown above.
(EPS)
Figure S9 Changes in deuteration levels of PI3Kc in the
presence of p84 (related to Figure 7). Peptides spanning
PI3Kc (labeled A–Q) that showed greater than 0.5 Da changes in
deuteration in the presence and absence of p84 were mapped onto
the PI3Kc structure (PDB ID: 2CHX, residues 144–1,093). The
greatest difference in exchange observed at any time was used for
the mapping. S582 is shown as red balls. The ATP competitive
inhibitor PIK-90 is shown in green as a reference point for the
kinase domain. The linker regions between the RBD and the C2
domain and the C2 and helical domain are shown as dotted lines.
(EPS)
Figure S10 Changes in deuteration levels of PI3Kc
peptides in the presence of p84 (related to Figure 7).
The graphs showing the number of incorporated deuterium atoms
in the presence (o) and absence (N) of p84 at seven time points in
peptides that showed a greater than 0.5 Da H/D exchange
difference. Data represent mean 6 standard deviation (SD) of two
independent experiments.
(EPS)
Figure S11 Deuteration levels in free and p84-bound
p110c (related to Figure 7). Changes in deuteration levels
were mapped onto the crystal structure of PI3Kc (PDB ID:
2CHX) as in Figure 7.The isotopic profiles of two selected peptides
(579–592, 623–630) from the helical domain are shown at three or
four time points of H/D on exchange +/2 the p84 subunit. In the
absence of the p84 adaptor the majority of peptides in the helical
domain showed broadening of the isotopic profiles indicative of
EX1 kinetics (see 30 s of HDX in free p110c). The helices HB1,
HA2 (579–592), and HA3 (624–631) selected are all structurally
linked, with HA3 located at the interface of the helical domain
with the C-lobe. Ser582 (red) and Thr1024 (yellow) have been
highlighted as a reference.
(TIF)
Table S1 Deuterium exchange data of all analyzed
peptides of PI3Kc in the absence or presence of p84
are summarized in tabular form (related to Figure 7).
Percent hydrogen deuterium exchange was calculated for each of
the seven time points and colored according to the legend. Data
show the mean of two independent experiments. The charge state
(Z), maximal number of exchangeable amides (#D), starting
residue number (S), and ending residue number (E) are displayed
for every peptide.
(XLSX)
Text S1 Extended experimental procedures, reference
to animals and plasmids. Detailed description of experimen-
tal procedures, materials, and further reference to the origin of
genetically modified mice used here, and a primer to the
determination of deuterium incorporation (HDX_MS).
(DOCX)
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EXTENDED EXPERIMENTAL PROCEDURES 
 
Materials 
 Where not indicated otherwise, materials and chemicals were purchased from Sigma-Aldrich. 
 
Mice 
 C57BL6/J wild type (Jackson Laboratories), p110γ-/- [1], PKCα-/- [2,3], PKCβ-/- [4], and PKCγ-/- [5] mice were 
used for the preparation of BMMCs. 
 
Cell Culture 
 Mouse bone marrow-derived mast cells (BMMCs) were developed from progenitor cells of femurs of 8-12 
week old mice on a pure C57BL/6J genetic background [6]. Femurs were cut off at both ends and the marrow 
collected by centrifugation. Cells were resuspended in complete growth medium: Iscove’s modified Dulbecco’s 
medium (IMDM) supplemented with 10% heat-inactivated fetal calf serum (HI-FCS), 2 mM L-glutamine, 100 units/ml 
penicillin, 100 µg/ml streptomycin, 50 µM β-mercaptoethanol, 2 ng/ml recombinant murine IL-3 (Peprotech) and 
initially 1x 5 ng/ml SCF, and cultured at 37°C, 5% CO2. IL-3 was re-added every third day. Non-adherent cells were 
transferred to new flasks and diluted weekly to 0.5 M cells/ml using 80% of fresh and 20% of conditioned medium. 
Differentiation of BMMCs was confirmed by measuring expressing of c-Kit and IgE receptors by flow cytometry. All 
mast cell experiments were carried out with BMMCs cultured for 4 to max. 16 weeks. 
 The human embryonic kidney 293 (HEK293) cell line was grown in Dulbecco’s modified essential medium 
(DMEM) supplemented with 10% HI-FCS, 2 mM L-glutamine , 100 units/ml penicillin, 100 µg/ml streptomycin at 
37°C, 5% CO2.  
 Spodoptera frugiperda (Sf9) cells were grown in IPL-41 medium (Genaxxon Bioscience) supplemented with 
10% HI-FCS (Sigma-Aldrich), 2% yeastolate, 1% lipid concentrate, 50 µg/ml gentamicin (all Invitrogen) and 2.5 
µg/ml amphotericin B (Genaxxon Bioscience). Sf9 cells were cultured as adherent or suspension culture at 27°C. 
Suspension cells were grown in Erlenmeyer flasks in a shaking incubator at 75-90 rpm.  
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Plasmids 
 Full-length, untagged human PI3Kγ was expressed from pcDNA3 (Invitrogen) [7]. Point mutations were 
introduced by polymerase chain reaction (PCR) using the overlap extension technique [8]. The mouse PKCβ2 cDNA 
was kindly obtained from Jae-Won Soh (PKClab.org) and inserted BamHI-BstEII-XhoI into pcDNA3 containing a 
Kozak translation initiation sequence and the human influenza hemagglutinin (HA)-tag between HindIII and BamHI 
(pcDNA3-kzHA). The catalytic part of PKCβ2 (PKCβ2-CAT) including amino acids 302-673, was amplified from full-
length PKCβ2 with the forward primer 5’-ccgcaGGATCCcagaagtttgagagagccaagattg and the reverse primer 5’-
ggcgTCTAGAttagctcttgacttcaggttttaaaaattc and inserted BamHI-XbaI into pcDNA3-kzHA. The pseudosubstrate 
deletion mutant of PKCβ2 was produced by the overlap extension technique with primers lacking the coding 
sequence for amino acids 19-31 of PKCβ2 (forward: 5’-gagcacagtgcacgaggtgaagaaccacaaattcac, reverse: 5’-
cacctcgtgcactgtgctctcctcgccc) and two helper primers. The baculovirus transfer plasmid encoding GST-PI3Kγ 
(pAcG2T-PI3Kγ, codons 38-1102) has been described [9]. The transfer plasmid for baculovirus-mediated expression 
of C-terminal His-tagged full-length human PI3Kγ has been derived from pVL1393 (Invitrogen) containing codons 
144-1102 of human PI3Kγ [10]) by inclusion of codons 1-143 by PCR. Serine 582 mutations were introduced into this 
construct by insertion of a PciI-EcoRI or BstEII-EcoRI fragment from mutant PI3Kγ in pcDNA3, respectively. All 
constructs were confirmed by sequencing. 
 
Transfections 
HEK293 cells were seeded into 6 cm dishes and were transfected with JetPEITM (Polyplus-transfection) 
using 2.5 µg of total plasmid DNA. BMMCs were transfected by nucleofection (Amaxa) using solution T, 1-3 µg of 
PI3Kγ and, if indicated, 0.2-2 µg of p84 expression plasmid. Total DNA concentration was adjusted to 10 µg with 
pcDNA3 vector. 
 
Stimulation of BMMCs 
 BMMCs were incubated overnight with 100 ng/ml anti-dinitrophenyl (DNP)-specific immunoglobulin E (clone 
SPE-7) in complete growth medium (see cell culture, above). Next day, cells were centrifuged for 5 min at 146 g and 
resuspended in IL-3 free growth medium containing 2% (signaling experiments) or 10% FCS (degranulation assay). 
Degranulation was induced by the addition of DNP coupled to human serum albumin (DNP-HSA) at the indicated 
concentrations. Other stimuli used to trigger BMMC activation were thapsigargin, phorbol 12-myristate 13-actetate 
(PMA; 100nM, Alexis), adenosine (1 µM), N6-(3-iodobenzyl)-adenosine-5’-N-methylcarbox-amide (IB-MECA; 10 nM), 
stem cell factor (SCF; 10 ng/ml, Peprotech), interleukin-3 (IL-3; 10 ng/ml, Peprotech), and platelet activating factor 
(PAF [1 uM], β-Acetyl-γ-O-alkyl-L-α-phosphatidylcholine). Stimulations were done at 37°C. Preincubation with B. 
Pertussis Toxin (PTx; 100 ng/ml) was done for 4 hours, and adenosine deaminase (ADA; 10 units/ml) was added 1 
min before stimulation. Inhibitor pretreatment time was 15 min for wortmannin (100 nM), and 20 min for the PKC 
inhibitors (Ro318425 (1 µM), Gö9683 (0.5 µM), Gö6976 (0.5 µM), and Rottlerin (10 µM), a brad-band kinase inhibitor 
[11] [all from Calbiochem]; PKC412/CPG41251 (1 µM, LC Laboratories), Sotrastaurin (AEB071; 1µM, Selleckchem). 
For Western blot analysis of PKB and MAPK phosphorylation, stimulations were stopped on ice, and cells were 
collected by centrifugation for 1 min at 2000 g (4°C) and immediately lysed in 1x Laemmli sample buffer [62.5 mM 
Tris/HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, bromophenolblue]. 
 
(Co-)Immunoprecipitation 
Transfected HEK293 cells were washed with phosphate buffered saline (PBS) and lysed with NP-40 lysis 
buffer [50 mM Tris/HCl pH 7.4, 138 mM NaCl, 2.7 mM KCl, 5% glycerol, 1% NP-40] supplemented with protease 
inhibitors [20 µM leupeptin, 18 µM pepstatin, 5 µg/ml aprotinin, phenylmethylsulfonylfluorid (PMSF)], phosphatase 
inhibitors [40 mM NaF, 2 mM Na3VO4], 0.5 mM EDTA and 0.5 mM EGTA for 15 min on ice. Insoluble material was 
pelleted by centrifugation and one-tenth of clarified lysate was mixed with Laemmli sample buffer to examine overall 
protein expression. The remainder of lysate was incubated with anti-p110γ (ascites fluid, 641, corresponds to Jena 
Bioscience ABD-027) or anti-HA.11 (Covance) antibodies for 1 hour at 4°C on a rotating wheel, followed by 
incubation with 25 µl of a 50% slurry of GammaBind Plus Sepharose (Amersham Biosciences) or protein G agarose 
(Millipore) for additional 2 hours. Immune complexes were washed 3x with NP-40 lysis buffer, 1x with 0.1 M Tris/HCl 
pH 7.4, 0.5 M LiCl, 0.2% NP-40, 1x again with NP-40 lysis buffer, and eluted by the addition of Laemmli sample 
buffer. 
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BMMCs were collected by centrifugation and lysed in NP-40 lysis buffer supplemented with protease 
inhibitors, phosphatase inhibitors [40 mM NaF, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate], 2 mM 
EDTA and 2 mM EGTA for 15 min on ice. Cell debris were removed by centrifugation, and endogenous or 
transfected PI3Kγ was immunoprecipitated from the cleared lysate with anti-PI3Kγ (ascites fluid, clone 641) 
antibodies (1-2 hours) and protein A or G-agarose beads (2-5 hours). Immune complexes were washed as describe 
above before resuspension in 1x Laemmli sample buffer.  
For co-immunoprecipitations from BMMCs, cells were suspended in hypotonic lysis buffer (20 mM Tris/HCl 
pH 7.4, 20 mM NaCl, 2.7mM KCl, 5% glycerol, 0.5% CHAPS) supplemented with protease inhibitors [20 µM 
leupeptin, 18 µM pepstatin, 5 µg/ml aprotinin, 1mM phenylmethylsulfonylfluorid (PMSF), 0.5mM diisopropyl 
fluorophosphate], phosphatase inhibitors [40 mM NaF, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate], 2 
mM EDTA and 2 mM EGTA. PI3Kγ complex was immunoprecipitated from cleared cell lysates with either anti-p110γ 
(ascites fluid, clone 641) or anti-p84 (goat antisera, for epitopes see [12]) antibodies for 1 h, before protein G-
agarose beads were added for another hour. Beads were washed three times with lysis buffer and resuspended in 
1x Laemmli sample buffer. Lysates and immunoprecipitations were analysed by Western blotting. 
 
Western Blotting 
 Protein samples were heated to 95°C for 5 min, centrifuged for 2 min at 16’000g, separated by SDS-
polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene fluorid (PVDF)-membranes (Millipore) 
by semi-dry transfer. Membranes were blocked with 5% (w/v) milk powder (Migros, Schweiz) in TBS-T buffer [20 mM 
Tris/HCl, pH 7.6, 137 mM NaCl, 0.1% (v/v) Tween 20 (Fluka)]. Blots were incubated overnight at 4°C with the 
primary antibody, followed by incubation with horseradish peroxidase (HRP)-coupled secondary goat anti-mouse or 
anti-rabbit antibodies. Protein bands were visualized by enhanced chemiluminescence (ECL) (Millipore). Phospho-
specific antibodies were kept in TBS-T/1% BSA [pPKB S473, pPKB T308, pCamKII T286, pCREB S133 and pan-
phospho PKC (S660 in PKCβII; all from Cell Signaling); pMAPK (Sigma M8159 or Promega V8031); phospho-p110γ 
S582 antibodies were raised against Cys-conjugated peptides C+KELLWHFRYE-[phosphoSer]-LKHPKAYPKLFSS 
and C+WHFRYE-[phosphoSer]-LKHPK, and affinity purified]. All other antibodies were diluted in TBS-T/1% (w/v) dry 
milk powder [PI3Kγ (raised against amino acids 97-335); PKCβ2 (Santa Cruz, sc-210), PKCα (sc-208), PKCγ (sc-
211), β-Tubulin (Boehringer Mannheim), α-Tubulin (Sigma, T9026), HA (Covance, MMS-101R), p84 (rabbit antisera, 
[12]), total PKB (a kind gift from B. Hemmings)]. Quantifications of Western blots have been done with ImageJ 
software (NIH). 
 
β-Hexosaminidase Release Assay 
Mast cell degranulation was assessed by the release of β-hexosaminidase into cell supernatants [13,14]. 
BMMCs were cultured at 0.8-1 Mio cells/ml in complete growth medium, and were, pre-loaded with 100 ng/ml IgE 
(for IgE/Ag experiments). Cells were wash once and resuspended in PIPES-buffered solution [25 mM PIPES pH 7.4, 
119 mM NaCl, 5 mM KCl, 5.6 mM glucose, 1 mM CaCl2, 0.4 mM MgCl2, 0.1 % fatty-acid free, low endotoxin bovine 
serum albumin (LE-BSA, Sigma)]. Cells (0.5 M) were stimulated with IgE/DNP-HSA or thapsigargin in a total volume 
of 500 µl PIPES-buffered solution in 24 well plates. Following incubation at 37°C for 20 min, plates were centrifuged 
at 4°C at 330 g for 5 min. Then, 100 µl aliquots of supernatant were transferred to 96 well plates. To determine total 
β-hexosaminidase, unstimulated cells were lysed by the addition of PIPES-buffered solution with 0.1% Triton X-100 
for 10 min, and 100 µl aliquots were transferred to 96 well plates. Activity of β-hexosaminidase was assessed by 
incubation with 100 µl of substrate solution [100 mM p-nitrophenyl-N-acetyl-β-D-glucosaminidine (p-NAG) in 0.1 M 
sodium acetate pH 4] for 1 h at 37°C. The reaction was stopped with 100 µl of 0.15 M Na2CO3/NaHCO3, and the 
amount of produced p-nitrophenol was assessed by the absorbance at 410 nm. Background values were obtained 
from lysates of unstimulated cells incubated without p-NAG. The amount of β-hexosamidinase released was 
calculated by using the formula: Release (R) [%] = (AStimulated – AUnstimulated)/(ATotal unstimulated – ATotal background)*100 
 
Cytosolic Ca2+ concentration measurements 
 BMMCs were suspended in physiologic HEPES buffer (10 mM HEPES/NaOH pH 7.5, 137 mM NaCl, 2.7 
mM KCl, 5 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 0.1 % fatty acid free BSA]. Cells were loaded with 4 µM Fura-
4F/AM [KD for Ca2+ in vitro is 770 nM; intracellular KD for Ca2+ is ca. 1 µM [15,16]) for 10 min, washed twice, and 
resuspended in HEPES buffer containing different Ca2+ concentrations ([Ca2+]e (extracellular) = 0 - 1 mM). Cells were 
subsequently stimulated in final volume of 3 ml (0.5 M cells/ml) in a continuously stirred cuvette at 37° in a 
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fluorescence spectrometer (Perkin Elmer LS50B). The excitation wavelength was alternated between 340 and 380 
nm and fluorescence emission was measured at 510 nm every 200 ms. After recording a base line cells were 
stimulated (e.g. with 0.5 µM thapsigargin). To calculate [Ca2+]i maximal Fura fluorescence (Fmax) was determined 
after cell permeabilisation with 0.1% Triton X-100 after addition of 2 mM Ca2+. Minimal fluorescence (Fmin) values 
were obtained after the addition of 4 mM EGTA. Autofluorescence was subtracted before [Ca2+]i was calculated 
using the equation of [17]:  
  [Ca2+]i = Kd[(R - Rmin)/(Rmax - R)](F380 EGTA/F380 Triton), R = F340/F380 
 
 To correlate intracellular Ca2+ concentrations with PKB phosphorylation, [Ca2+]i levels were plotted against 
relative levels of phosphorylated PKB (S473). Phospho-PKB levels were obtained from cells (1.5 ml) taken out of the 
measurement cuvette 2 min after stimulation. Lysed cells were analyzed by Western blotting and PKB 
phosphorylation was quantified by intensity measurements with ImageJ software. 
 
Production of recombinant PI3Kγ 
Recombinant human PI3Kγ was expressed as N-terminal GST- or C-terminal His6-tagged-fusion protein in 
Sf9 cells by infection with recombinant baculovirus. Plasmid (pAcG2T-PI3Kγ, codons 38-1102) and baculovirus for 
GST-PI3Kγ have been described [9]. Full-length PI3Kγ-His6 and S582 point mutants were expressed in pVL1393 
(BD Biosciences) after co-transfection of Sf9 cells with BaculoGold DNA (BD Biosciences). Proteins were harvested 
as described in [18]. Baculovirus-infected Sf9 cells were harvested 2-2.5 days postinfection, were washed with PBS 
und lysed with either GST- or His-lysis buffer [GST: 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM NaF, 
1 mM DTT, 1% Triton-X100; His: 50 mM NaH2PO4·2H2O/NaOH, 300 mM NaCl, 20 mM imidazol, 5% glycerol, 1% 
NP-40] containing protease inhibitors. GST-PI3Kγ was purified on glutathione sepharose 4B (Amersham 
Biosciences) and eluted with 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 5% glycerol, 20 mM 
glutathione after extensive washing. PI3Kγ-His6 was purified over Ni2+-NTA agarose (Qiagen) and eluted with 50 mM 
NaH2PO4·2H2O/NaOH pH 8, 300 mM NaCl, 250 mM imidazol. Proteins were mixed 1:1 with 2x storage buffer [80 
mM HEPES/NaOH, 4 mM EDTA, 2 mM DTT, 20 mM benzamidine, ~90% ethylenglycol] and kept at -20°C. Protein 
concentrations were quantified by Coomassie-staining in SDS-PAGE gels using the Odyssey infrared imaging 
system (LI-COR Biosciences). Bovine serum albumin served as standard. 
 
In vitro kinase assay 
Recombinant GST-PI3Kγ wild type (wt) or kinase inactive mutant (KR, Lys833 mutated to Arg) was 
incubated at an equal molar ratio (if not stated differently) with recombinant PKCβ2 (40 ng, Invitrogen) in 1x PKC 
kinase buffer (50 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 1 mM DTT, 0.03% Triton X-100) in the presence 
of 10 µM adenosine 5’-triphosphate (ATP) and 5 µCi of [γ32P]-ATP [Perkin Elmer, 6000 Ci/mmol] per sample in a 
final volume of 40 µl. Ca2+/calmodulin-dependent protein kinase II (CamKII, Life Technologies)-mediated 
phosphorylation was performed in 1x CamKII kinase buffer (10 mM HEPES, 10 mM MgCl2, 1 mM Na3VO4, 10 ug/ml 
calmodulin, 0.5 mM CaCl2, 5 mM DTT). Kinase reactions were pre-warmed for 2 min at 30°C, started by the addition 
of 4 µl of ATP-mix (in H2O), and incubated at 30°C for 30 min. Reactions were terminated by the addition of 5x 
sample buffer and the proteins were resolved by SDS-PAGE. Gels were stained with Coomassie brilliant blue (Serva 
blue G); 32P-incorporation was visualized by autoradiography or quantified on a phosphoimager (Typhoon 9400). 
Band intensities were quantified with ImageQuant TL Software (Amersham Biosciences). A dilution series of the 
ATP/[γ32P]-γ-ATP-mix served as a standard to calculate absolute 32Pi-incorporation rates. 
Where indicated, phosphatidylserine (PS) lipid vesicles (0.1 mg/ml) containing 1-oleoyl-2-acetyl-sn-glycerol 
(OAG, 0.01 mg/ml, Cayman Chemical) were added. PS in CHCl3/MeOH 2:1 was mixed with OAG in acetonitril in an 
Eppendorf tube, dried by a stream of nitrogen gas and resuspended in kinase buffer by sonication.  
 
In vitro lipid kinase assay 
Assays were performed in a final volume of 50 µl in 1.5 ml Eppendorf tubes in lipid kinase buffer [40 mM 
HEPES, pH 7.4, 150 mM NaCl, 4 mM MgCl2, 1 mM DTT, 0.1 mg/ml fatty-acid free BSA] in the presence of 
PtdIns(4.5)P2-containing lipid vesicles, 10 µM adenosine 5’-triphosphate (ATP) and 4 µCi of [γ32P]-ATP [Perkin 
Elmer, 6000 Ci/mmol] per sample. Phospholipid composition of the lipid vesicles has been chosen to mimic relative 
mole ratios found in the inner leaflet of the plasma membrane (PE/PS/PC/SM/PIP2 = 30/20/10/4.5/1.2-4.6). Lipids 
dissolved in CHCl3/MeOH (2:1) were combined in a glass tube [f. c. in assay: 130 µM PE, 87 µM PS, 43 µM PC, 20 
µM SM, 5-20 µM PIP2], dried under a stream of nitrogen gas and resuspended in lipid kinase buffer without BSA by 
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sonication (3x 15 seconds at an amplitude of 30%) on ice with a tip sonicator (U200S, IKA Labortechnik). 
Recombinant wild type or mutant PI3Kγ-His6 (200 ng/reaction) were diluted in lipid kinase buffer and added (8 µl) to 
4 µl of mastermix [lipid kinase buffer, but with 1.05 mg/ml BSA] followed by the addition of 30 µl of lipid mix. Samples 
were mixed and kept on ice for additional 20 min, were then warmed up to 30°C for 2 min on a heat block before 
starting the reaction by the addition of 8 µl of ATP-mix in lipid kinase buffer without BSA. Samples were incubated for 
10 min at 30°C with shaking (1200 min-1) on a heat block. The reaction was stopped by the addition of 100 µl 1 N 
HCl and the lipids were extracted by the addition of 200 µl CHCl3/MeOH 1:1 and vortexing. Phases were separated 
by centrifugation for 2 min at 9300 g, the lower organic phase was transferred to a new tube and the lipids dried 
under a low heat vacuum in a Speed-Vac (Univapo 150H). Lipids were re-dissolved in CHCl3/MeOH 4:1 and loaded 
onto a potassium oxalate-pretreated silica gel 60 W F254S TLC plates (Merck) for separation by thin layer 
chromatography (TLC) in a horizontal tank using CHCl3/acetone/MeOH/acetic acid/H2O (80/30/26/24/14 v/v) as 
mobile phase. Dried plates were exposed to Fuij Super RX x-ray films or Kodak Storage Phosphor Screens to 
quantified by phospho-imaging. 
 L-α-phosphatidylcholine from chicken egg (PC), sphingomyelin from porcine brain (SM) and L-α-
phosphatidylinositol(4,5)bisphosphate from porcine brain, triammonium salt (PIP2) were purchased from Avanti Polar 
Lipids, while L-α-phosphatidylserine (PS) from bovine brain and L-α-phosphatidylethanolamine from egg yolk, type 
III (PE) was obtained from Sigma-Aldrich. 
 
Mass spectrometry 
The PI3Kγ protein band was excised from the gel, reduced with 10 mM DTT, alkylated with 55 mM 
iodoacetamide and cleaved with porcine trypsin (Promega, Madison, USA) in 50 mM ammonium bicarbonate (pH 
8.0) at 37°C overnight [19]. The extracted peptides were analyzed by capillary liquid chromatography tandem mass 
spectrometry (LC-MSMS) using a Magic C18 100 µm x 10 cm HPLC column (SwissBioanalytics, Switzerland) 
connected on line to a 4000 Q Trap (MDS Sciex, Concord, Ontario, Canada) as described earlier [20]. Data analysis 
was done with Mascot [21] searching the protein sequence database UNIPROT_15.6. from Feb 2010 (9421896 
sequences; 1248797668 residues). Relative quantification of the peptides was done with multiple reaction 
monitoring (MRM) using the same instruments and identical chromatographic conditions. The approach was 
described earlier [22]. The Ser582 site in YESP[582]LKHPK corresponds well to consensus substrate motifs for 
PKCβ as determined by peptide library screens [23]. 
 
Protein expression and purification for deuterium exchange studies 
 The PI3Kγ alone and PI3Kγ/p84 complex were expressed in Sf9 cells using the pFastBac system 
(Invitrogen). Cells were resuspended in sonication buffer (50 mM Tris/HCl pH 8, 100 mM NaCl, 1 mM PEFA, 25 mM 
imidazole) and lysed by sonication on ice for 10 minutes. The lysates were ultracentrifuged at 35’000 rpm for 45 
minutes at 4 °C in a Ti45 rotor. The soluble cell lysate was filtered through a 0.45 µM filter. Subsequently, the lysate 
was passed over a Ni-NTA 5 ml Fast Flow column (GE Healthcare) and eluted with an imidazole concentration 
gradient from 25 to 200 mM. The protein was further purified by ion-exchange HiTrap Q (5ml), Heparin agarose 
(5ml) and Superdex 200 (16/60) gel-filtration chromatography. The protein was eluted from the gel filtration column 
in 20 mM Tris pH 7.5, 100 mM NaCl, 5 mM DTT and 1 mM (NH4)2SO4.  
 
Deuterium exchange sample preparation 
 5 µl of stock protein solutions (Hs_PI3Kγ-His6: 30 µM; Hs_PI3Kγ-His6/Mm_p84-His6: 35μM) were prepared 
in 20 mM Tris pH 7.5, 100 mM NaCl, 5 mM DTT and 1 mM ammonium sulfate. Exchange reactions were initiated by 
addition of 25 µl of a 98% D2O solution containing 10 mM HEPES pH 7.2, 50 mM NaCl, and 2 mM DTT, giving a 
final concentration of 82% D2O. Deuterium exchange reactions were allowed to carry on for seven time periods, 3, 
10, 30, 100, 300, 1000 and 3000 seconds at 23 ºC. On-exchange was stopped by the addition of 40 µl of quench 
buffer containing 1.2% formic acid and 0.833 M guanidine-HCl, which lowered the pH to 2.6. Samples were then 
immediately frozen in liquid nitrogen until mass analysis. 
 
Protein digestion and peptide identification for DXMS analysis 
 Different digestion conditions were employed to optimize the peptide digestion map. These optimizations 
included changing denaturant concentration, flow rate over pepsin, and denaturation time. Peptide identification was 
performed by running tandem MS/MS experiments using a Sciex QStar Pulsar hybrid QqTOF (Applied Biosystems). 
Data was analyzed using Mascot software v. 2.2 (Matrix Science) to identify all peptides based on fragmentation and 
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peptide mass, and these identifications were then manually validated using DXMS software (Sierra Analytics) to test 
for correct m/z state, and the presence of overlapping peptides. 
 
Measurement of deuterium incorporation 
Samples were thawed rapidly on ice and then injected onto an online HPLC system that was immersed in 
ice. The protein was run over an immobilized pepsin column (Applied Biosystems, Poroszyme®, 2-3131-00) at 50 
µl/min, and collected over a 1.7 µm particle C18 peptide trap (2.1 mm x 8 mm, Waters Van-guard) for five minutes. 
The trap was then switched in line with a 1.7 µm particle, 1 mm x100 mm C18 column (Waters Acquity UPLC) with a 
vanguard pre-column and peptides were eluted by a 5-45% gradient of buffer A (0.1% formic acid) and buffer B 
(80% acetonitrile, 20% H2O, 0.02% formic acid) over 22 minutes and injected onto a Sciex QStar Pulsar hybrid 
QqTOF (Applied Biosystems) which collected mass spectra from a range of 350 to 1300 m/z. 
Mass analysis of the peptide centroids was performed as described previously using the software DXMS 
(Sierra Analytics) [24,25]. Briefly, all selected peptides passed the quality control threshold of the software, and were 
then manually examined for accurate identification and deuterium incorporation. Results are shown as relative levels 
of deuteration with no correction for back exchange as described previously [26]. The real level of deuteration will be 
~25-35% higher than what is shown, based on tests performed with fully deuterated standard peptides. All 
experiments were repeated in duplicate, and we found that the average error was less than 0.2 Da, and for this 
reason we consider all changes between conditions greater than 0.5 Da that occur at more than one time point as 
significant. The resulting deuterium incorporation was graphed versus the on-exchange time. All deuterium 
exchange data for all peptides analyzed (~202 peptides) is shown in tabular form (Table S1). 
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